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Abstract 
It is well established that changes in insulin secretion play an important role in the 
pathogenesis of type 2 diabetes. However, the underlying mechanisms of secretory changes 
occurring at the pancreatic beta-cell level are not fully elucidated. Therefore, this thesis focuses on 
the modulation of beta-cell function, particularly insulin granule exocytosis, during the progression 
of type 2 diabetes using the BKS.Cg-Dock7m+/+Lepr
db
/J (Lepr
db
 mice) as a model of disease.  
I applied a variety of in vivo and in vitro methods to this project and further refined a live-
cell two-photon assay which I used to measure the numbers and kinetics of granule fusion events 
within intact islets. 
Using this latter technique, in the first part of the project I aimed to test a prevalent 
hypothesis that granule fusion behaviour changes in disease. Three indices of the post-fusion 
granule behaviour were compared between islets from animals with overt diabetes (db/db) and wild 
type. There was no difference in two indices of the fusion-granule behaviour; lifetime of granule 
fusion and post-fusion fluorescence intensity. The only change was a small increase in the 
percentage of recaptured granules (or “kiss-and-run” exocytosis) in db/db islets. In contrast to this 
minor change in granule fusion kinetics, further work showed that the main secretory deficit of 
frank diabetes, in db/db islets, is due to the loss of responding beta-cells and a reduction in the 
numbers of exocytic fusing granules in the remaining responsive cells. 
In the second part of the project I studied disease progression in the Lepr
db
 model. Based on 
the area under the curve of the glucose tolerance tests, each db/db mouse was classified into one of 
four stages of disease, ranging from pre-diabetes (stage 1) to severe diabetes (stage 4). The results 
indicated that changes in islet size and insulin content occurred across all stages of disease severity. 
At stage 1, there was an increase in islet insulin content due to both an increased number of beta-
cells and increased insulin content in each cell, whereas at stages 2-4, there was a progressive loss 
of islet insulin content that is a reflection of loss of content from individual beta-cells.  
Finally, in terms of beta-cell function, the data revealed that modulation of function 
characterised all stages of disease severity in db/db mice. In stage 1 there was an upregulation in the 
number of fusion of insulin-containing granules as well as the prevalence of compound exocytosis. 
At later disease stages there was a loss of glucose-induced insulin-granule fusion which my data 
indicated was due to impairment in glucose sensing. This work demonstrates that beta-cell function 
is intimately associated with pre-diabetes and progression to diabetes and adds weight to clinical 
strategies for therapeutic intervention as early as possible. 
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In summary, the results show that the major factors in the disease phenotype are changes in 
the numbers of responding beta-cells and the numbers of fusing granules rather than the kinetics of 
the fusion granules. Moreover, my work provides further evidence for the importance of modulation 
in beta-cell function at all stages of disease. 
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1.1. Type 2 diabetes 
1.1.1. Definition, diagnosis and classification of diabetes 
The term “diabetes mellitus” comes from the Greek word “diabetes”, which means to pass 
through the kidney an excessive amount of urine, and the Latin word “mellitus” meaning honeyed 
to describe the sweet taste of diabetic urine that would attract ants (Poretsky 2009). People have 
been aware of this ailment for thousands of years with the first known mention of diabetes 
symptoms (excessive urination, constant thirst and loss of weight) in 1552 B.C (Ahmed 2002).  
Diabetes mellitus, however, appears to be a death sentence at this ancient era. It was not until the 
early 19
th
 century that any major breakthrough in the diagnosis and treatment of diabetes has 
occurred including the identifying of glucose as the sugar present (1838), the extraction of insulin 
(1921) and the introducing of the first glucose meter (1970) (Clarke and Foster 2012).   
The passage of time has led to a better understanding of the disease which is now considered 
as a group of metabolic disorders of carbohydrate metabolism characterised by hyperglycemia 
resulting from defects in insulin secretion, insulin action, or both (American Diabetes Association 
2014). A diagnosis of diabetes is made when fasting blood glucose (FBG) level above 126 mg/dl (7 
mM) on two separate times or a random blood glucose level over 200 mg/dl (11.1 mM) with classic 
symptoms of diabetes or blood glucose after loading 75g glucose for 2 hours exceeding 200 mg/dl 
(11.1 mM) or hemoglobin A1C which reflects average blood glucose level over 2-3 months 
exceeding 6.5% (Figure 1.1) (American Diabetes Association 2014). 
Moreover, between normal glucose homeostasis and diabetes, there exist 2 intermediate 
states of abnormal glucose metabolism: impaired fasting glucose (IFG) and impaired glucose 
tolerance (IGT). The former is characterised by an elevated FBG which does not yet reach the 
diabetes criteria (≥ 100 mg/dl and <126 mg/dl) (American Diabetes Association 2014). Whereas, 
the latter is defined by an elevated 2-hour plasma glucose after loading 75g glucose that is again 
lower than the diabetes criteria (≥140 mg/dl and <200 mg/dl) (Figure 1.1) (American Diabetes 
Association 2014). As the majority of people with IFG or IGT will develop diabetes after years or 
decades, these two conditions are known as the pre-diabetes states (Shaw, Zimmet et al. 1999; de 
Vegt, Dekker et al. 2001). Despite overlapping, IFG and IGT do not identify the same “at risk” 
population due to different pathophysiology abnormalities (Nathan, Davidson et al. 2007).  
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 Figure 1.1: Diagnosis criteria for diabetes and prediabetes. 
(adapted from American Diabetes Association) (American Diabetes Association 2014) 
There are many types of diabetes including type 1, type 2, gestational diabetes, diseases of 
the exocrine pancreas, drug- or chemical-induced diabetes (American Diabetes Association 2014). 
Nevertheless, type 2 diabetes (T2D) which was previously referred to as non-insulin-dependent 
diabetes is the most common form, accounting for at least 90% of all cases of diabetes (American 
Diabetes Association 2014). 
1.1.2. Magnitude and impact of type 2 diabetes worldwide 
Type 2 diabetes is one of the most common non-communicable diseases globally which is 
on the increase in every country. According to the International Diabetes Federation 2014, there are 
more than 387 million people worldwide have T2D which is responsible for 4.9 million deaths each 
year, or one death every seven seconds (International Diabetes Federation 2014). If no urgent action 
is taken, this figure will escalate to 592 million by 2035 which approximates three new cases every 
ten seconds or almost ten million per year (International Diabetes Federation 2014). 
This is a major healthcare problem since diabetes is associated with a wide range of 
complications, including micro-vascular complications such as peripheral neuropathy, retinopathy 
and loss of vision, nephropathy and end stage renal disease as well as macro-vascular complications 
like stroke, cardiovascular diseases, peripheral arterial disease and lower extremity amputations 
(Fowler 2008; Van Dieren, Beulens et al. 2010). 
On the other hand, prediabetes, a condition preceding diabetes, is less well documented. 
Current estimates revealed that about 16.4% of Australian adults and about 36% of the U.S. adults 
are classified as prediabetes (Twigg, Kamp et al. 2007; Bullard, Saydah et al. 2013). More 
importantly, approximately half of prediabetes people (IGT/IFG) will develop diabetes with a rate 
of 3-10% annually or a sixfold increased risk compared with normal glucose tolerance (NGT) 
Page | 4  
 
population (Twigg, Kamp et al. 2007). 
1.1.3. Type 2 diabetes in Australia 
According to the Australian Diabetes, Obesity and Lifestyle Study, nearly one million 
Australians are currently diagnosed with diabetes (Diabetes Australia 2011). For every person 
diagnosed, it is estimated that there is another who is not yet diagnosed; a total of about 1.7 million 
people (Diabetes Australia 2011). The prevalence of T2D in Australia has doubled over the past 20 
years with more than 7% of Australian adults now have diabetes. By 2031, it is estimated that 3.3 
million Australians will have T2D. With an estimated 275 Australians develop diabetes everyday, 
diabetes is Australia’s fastest growing chronic disease (Diabetes Australia 2011).  
In terms of economic burden, as the sixth leading cause of death in Australia, T2D costs 
Australia $3 billion per year. Average cost for a person with T2D who has no complications is 
$9,625 a year and $15,850 when there are complications (Diabetes Australia 2009). 
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1.2. Islet of Langerhans 
1.2.1. Islet distribution 
The islets of Langerhans, discovered by a German medical student nearly 150 years ago 
play a pivotal role in the endocrine regulation of fuel metabolism (Langerhans 1869). The endocrine 
pancreas in humans consists of approximately one million islets, embedded throughout the exocrine 
parenchyma, most numerous in the tail of the pancreas (Weir and Bonner-Weir 1990). Although the 
endocrine part comprises only 1-2% of the entire pancreas, it is supplied with approximately 10% 
of the pancreatic blood flow and is more densely innervated by cholinergic, adrenergic and 
peptidergic nerve endings than the exocrine compartment (Jansson and Hellerstrom 1983). 
1.2.2. Islet as a micro-organ 
Not simply the gathering of cells, the pancreatic islet is considered as a complex micro-
organ composing of endocrine cells, endothelial cells and extracellular matrix that promptly 
releases a balanced mixture of islet hormones into the blood stream in response to changes in 
plasma nutrient levels (Weir and Bonner-Weir 1990; Brissova and Powers 2008; In’t Veld and 
Marichal 2010). Five different hormone-producing cell types are present in an islet including 
insulin-producing beta-cells, glucagon-producing α-cells (both first described in 1907 by Lane), 
somatostatin-producing δ-cells (first recognized by Bloom, 1931), pancreatic polypeptide-
producing PP cells (1975), and ghrelin-producing ε-cells (2002) (Lane 1907; Bloom 1931; Kimmel, 
Hayden et al. 1975; Wierup, Svensson et al. 2002). Among which, beta-cells are the most abundant, 
making up 50 to 80% of the total islet cell population depending on the species, the morphometric 
techniques, the type of samples, and the extent of the analysis (Brissova, Fowler et al. 2005; In’t 
Veld and Marichal 2010). The physical relationship between different cell types within an islet has 
physiologic significance which happens through cell-cell interactions, paracrine mechanisms and 
influences of hormone and products secreted by one endocrine cell to other downstream cells 
(Brissova and Powers 2008; In’t Veld and Marichal 2010). 
1.2.3. Islet size and structure 
Typically an islet consist of about 1000-2000 cells, although some may be clusters of a few 
cells and others may made up of up to 12,000 cells (Weir and Bonner-Weir 1990). Despite 
differences in body weight and pancreas size among species, the distribution of their islet sizes 
nearly overlaps with a mean diameter about 140 μm (Hellman B and Hellerström C 1969). Instead 
of enlarging the islets, larger animals such as humans share similar islets size distributions with 
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mice and compensate for it by increasing the number of islets which suggests an optimal functional 
size of the islet (Kim, Miller et al. 2009).  
In contrast, islet cyto-architecture varies among species or even within the same species 
under different pathophysiological conditions such as obesity, pregnancy and diabetes (Brissova, 
Fowler et al. 2005; Kim, Miller et al. 2009). In rodent islets, the beta-cells are located mainly in the 
central core with non beta-cells resided at the periphery forming a mantle while in human and other 
primate islets, the non-beta-cells are not localized in the periphery but are rather dispersed 
throughout the islet as illustrated in Figure 1.2 (Brissova, Fowler et al. 2005). 
 
 Figure 1.2: Optical sections of rodent and human islets 
There was an absence of non-beta-cells in the rodent islet interior (left figure) while there is an 
intermingling of beta-cells with α- and δ-cells in human islet (right figure). beta-cells: green, α cells: red 
and δ cells: blue (Brissova, Fowler et al. 2005).  
The cyto-structure of the islet is very important for its optimal function. It has been shown 
that beta-cells behaviour in intact islets is more uniform than dispersed beta-cells (Pipeleers 1987; 
Bennett, Jetton et al. 1996; Nunemaker and Satin 2004).  The chief possibility for better 
synchronization of beta-cells within intact islets is gap junction communication, which exists not 
only between cells of the same type but also between different types of islet cells (Meda, Santos et 
al. 1986; Charollais, Gjinovci et al. 2000).  
To date, with the advanced technologies, many clonal beta-cell models have been generated 
for research in this area (Hohmeier, Mulder et al. 2000; Skelin, Rupnik et al. 2010). Although they 
do secrete insulin in response to stimulus and provide some valuable information of physiological 
process, they generally cannot fully replicate the kinetics of biphasic insulin release seen in the real 
islets (Skelin, Rupnik et al. 2010). 
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1.3. Glucose homeostasis and mechanisms of glucose induced insulin 
secretion 
1.3.1. Glucose homeostasis 
Glucose is the most important carbohydrate that is metabolized by nearly all known 
organisms including humans. More importantly, the brain relies almost exclusively on glucose for 
fuel. Under normal circumstances, plasma glucose level is kept in a narrow range of about 3.9 to 8.0 
mM (70 to 144 mg/dl). This is the result of a fine balance between glucose influx (exogenous 
glucose delivery, endogenous glucose production) and glucose efflux (chiefly utilization) (Aronoff, 
Berkowitz et al. 2004).  
After a meal, glucose is derived from intestinal absorption of dietary carbohydrate which 
raises the blood glucose concentration and immediately stimulates the secretion of insulin from the 
pancreatic beta-cells. Insulin, a small peptide hormone, exerts its anabolic actions through binding 
to specific receptors on the target tissues, mainly muscle, liver and adipose cells. It facilitates the 
uptake of glucose into skeletal muscle as well as stimulates glycogen synthesis to replace glycogen 
used by muscle activity. It also acts on the liver to promote glycogenesis and inhibit glycogenolysis 
or gluconeogenesis. In addition, insulin enhances the storage of triglyceride in adipose cells and 
promotes protein synthesis in both liver and muscle tissue (Aronoff, Berkowitz et al. 2004; Sprague 
and Arbeláez 2011). Altogether, insulin helps to lower postprandial blood glucose. 
In the post-absorptive state, beginning 4-6 hours after a meal when nutrients absorption 
from a recent meal has sub-seeded, insulin secretion is inhibited and glucagon, a main counter-
regulatory hormone of insulin is secreted (Sprague and Arbeláez 2011).  Just as the metabolic 
effects of glucagon opposes those of insulin, it favors the glycogenolysis and gluconeogenesis in the 
liver, the glycogenolysis in the skeletal cells as well as the lipolysis in the adipose tissue (Gromada, 
Franklin et al. 2007; Sprague and Arbeláez 2011). If fasting period is prolonged, the glycogen 
storage is depleted, epinephrine, growth hormone and cortisol are secreted which leads to the 
increase of gluconeogenesis, lipolysis and ketogenesis (Sprague and Arbeláez 2011). 
1.3.2. Mechanism of glucose induced insulin secretion (GIIS) 
The biphasic pattern of GIIS was first demonstrated in the 1960s with a rapid first phase 
followed by a sustained second phase during which insulin is secreted at a lower rate but still higher 
than the pre-stimulatory stage (Curry, Bennett et al. 1968). While potassium chloride and other non-
nutrient secretagogues can induce first-phase release, only fuel secretagogues such as glucose can 
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yield a sustained second-phase of insulin secretion (Gembal, Gilon et al. 1992). 
Extensive work has been done on the cellular mechanisms underlying biphasic insulin 
secretion which could be classified into three main findings. First, the glucose molecule has to be 
metabolized by the beta-cells to induce insulin secretion. This is based on the fact that agents which 
interfere with cellular metabolism of carbohydrate could inhibit GIIS (Grodsky, Batts et al. 1963; 
Coore and Randle 1964). Second, Ca
2+
 plays a crucial role in insulin secretion which was proved by 
the deficit of GIIS in the absence of extracellular Ca
2+ 
(Milner and Hales 1967; Curry, Bennett et al. 
1968). Third, pancreatic beta-cells are electrically excitable which was demonstrated by changes of 
the islet cell membrane potentials in response to stimulus measuring by a microelectrode inserted 
into a beta-cell of an intact islet (Dean and Matthews 1968).  
Two classes of ion channel that play essential roles in the regulation of insulin secretion are 
voltage-dependent Ca
2+
channels (VDCCs) and the ATP-regulated K
+
 (KATP) channels which is later 
shown to be the target for the therapeutic action of the hypoglycemic sulfonylureas (Cook and 
Hales 1984; Sturgess, Ashford et al. 1985; Ashcroft and Rorsman 1989). In the absence of glucose, 
the cytoplasmic ATP/ADP ratio is low and the KATP channels are open which leads to the constant 
outflow of K
+
 and the negative membrane potential of the beta-cell. When the extracellular glucose 
levels rise, glucose enters the beta-cell via the cell-surface-localized glucose transporter-2 
(GLUT2). The metabolic degradation of glucose leads to an elevated ATP/ADP ratio in the beta-
cell which then depolarizes the cells by closing KATP channels (Cook and Hales 1984; Malaisse and 
Sener 1987). This membrane depolarization results in the opening of VDCCs, the entering of Ca
2+
, 
the fusion of insulin-containing granules and the releasing of insulin into the blood stream 
(Figure 1.3) (Ashcroft and Rorsman 1989)  .  
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Figure 1.3: The stimulus-secretion coupling pathway of GIIS. 
Glucose enters the cells via the GLUT2 (1) and undergoes metabolism (2), which induces an increase of 
ATP/ADP ratio (3).This results in the closure of KATP channels (4) and membrane depolarization (5), 
which triggers the opening of VDCCs, the influx of Ca
2+
 (6), the fusion of insulin-containing granules with 
the plasma membrane and the releasing of insulin (7).  
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1.4. Insulin granule dynamics & the clinical implications for diabetes 
1.4.1. Insulin biosynthesis 
Insulin was the first protein whose primary structure was elucidated by Fred Sanger and 
colleagues in the 1950’s which led to a Nobel price (Sanger 1959). Insulin is synthesized in the 
pancreatic beta-cell through a series of single-chain precursors, including pre-proinsulin, proinsulin 
and several intermediate cleavage products (Steiner 1969; Halban 1991). The initial translation 
product of insulin mRNA is pre-proinsulin which contains a 24-residue signal peptide. The pre-
prohormone is then translocated into the lumen of the rough endoplasmic reticulum where the 
signal sequence is cleaved and proinsulin is produced (Patzelt, Labrecque et al. 1978). Within the 
endoplasmic reticulum, the proinsulin undergoes meticulous protein folding to obtain the native 
structure stabilized by three disulfide-bonds (Huang and Arvan 1995). Properly folded proinsulin is 
then delivered to the Golgi apparatus and packaged into secretory granules. The conversion of 
proinsulin to insulin and the residual C-pepide takes place in the secretory granules (Steiner 2008).  
Insulin and the C-peptide are stored together in the secretion granules along with small 
amounts (3-5%) of intact proinsulin, its intermediate cleavage forms, and islet amyloid polypeptide 
(Steiner 2008; Hou, Min et al. 2009). A large fraction of the mature granules distributes throughout 
the beta-cell cytoplasm as a repository storage which is available for secretion in response to 
appropriate stimulus up to several days (Dean 1973; Rorsman, Eliasson et al. 2000; Olofsson, Gopel 
et al. 2002; Hou, Min et al. 2009). Excess granules will be taken up and degraded by autophagy, 
especially if demand for insulin decreases, for example during extended fasting (Halban 1991).  
1.4.2. Insulin granules dynamics 
Although the mechanism of impaired GIIS in diabetes is not fully understood, some 
evidence implicates defects in the distal step of the secretion, ie. fusion of insulin granules with the 
beta-cell membrane (Nagamatsu, Nakamichi et al. 1999; Tsuboi, Ravier et al. 2006). Thus, an 
understanding of how individual insulin-vesicles fuse with the beta-cell membrane, release their 
content, and are then recaptured is valuable for better characterizing and exploring new therapy for 
the disease. Many steps involve in the secretory cascade including the packaging of insulin in small 
secretory granules (diameter ~300 nm), the trafficking of these granules to the plasma membrane, 
the docking at the plasma membrane, the preparation for release (priming), the fusion of the 
granules with the plasma membrane and the retrieval of the secreted membranes (Eliasson, 
Renstrom et al. 1997; Barg, Huang et al. 2001; Bratanova-Tochkova, Cheng et al. 2002; Olofsson, 
Gopel et al. 2002; Rorsman and Renström 2003). 
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It is estimated that the total number of insulin-containing granules of a mouse beta-cell is 
about 9,000- 13,000 and the insulin secreted in response to a glucose stimulus is very small 
compared to the total insulin content of the beta-cell (Figure 1.4) (Dean 1973; Barg, Eliasson et al. 
2002; Olofsson, Gopel et al. 2002). Hyperglycemic clamp and experiment on isolated pancreatic 
islets have shown that GIIS occurs in a biphasic manner with a transient first phase and a sustained 
second phase as shown in figure 1.4 (Anello, Gilon et al. 1999; Bratanova-Tochkova, Cheng et al. 
2002). With the assumption that beta-cells contain the same number of granules and insulin content, 
the graph can be expressed in terms of the number of granules released by an “average” beta-cell 
per minute. Presented in this manner, it reveals that the pancreatic beta-cell releases about one 
granule every 3 seconds at the peak of the first phase of insulin secretion and one every 10 second 
during the second phase (Figure 1.4) (Bratanova-Tochkova, Cheng et al. 2002).  
 
Figure 1.4: Biphasic insulin release in mouse islets 
The biphasic insulin secretion in response to 16.7mM glucose which is expressed as percent of total insulin 
content or the number of granules released/cell/minute (Anello, Gilon et al. 1999; Bratanova-Tochkova, 
Cheng et al. 2002). 
Although the complexity of the granule population in the beta-cell is not yet fully explored, 
extensive work has been carried out and several models have been put forward to explain the 
dynamics of the insulin vesicles in response to stimuli (Rorsman and Renström 2003; Ohara-
Imaizumi, Fujiwara et al. 2007; Shibasaki, Takahashi et al. 2007; Pedersen, Corradin et al. 2008). In 
the classical model, insulin-containing granules were classified into three distinct pools depending 
on their proximity to the plasma membrane and their ability to undergo exocytosis: a non-releasable 
reserve pool, a morphologically docked pool, and a readily releasable pool (Dean 1973; Rorsman, 
Eliasson et al. 2000; Barg, Eliasson et al. 2002; Bratanova-Tochkova, Cheng et al. 2002) (Figure 
1.5). Quantitative morphometric studies of electron micrographs of mouse beta-cells and mouse-
derived beta-cell line (β-HC9 cells) revealed that about <10% of the granules were docked to the 
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plasma membrane (the morphologically docked pool) (Bratanova-Tochkova, Cheng et al. 2002; 
Olofsson, Gopel et al. 2002). Moreover, capacitance studies estimated that only a fraction of the 
granules, about 40-100 granules or 0.3-0.7% of the total can undergo exocytosis following elevation 
of the [Ca
2+
]i without any further modification (the readily releasable pool) (Eliasson, Renstrom et 
al. 1997; Barg, Eliasson et al. 2002; Olofsson, Gopel et al. 2002). The remaining granules (~90% of 
the total) are kept in a non-releasable reserve pool, which must undergo physical translocation to 
the plasma membrane as well as a series of ATP-, Ca
2+
-, time and temperature-dependent reactions 
(referred to as “priming”) to gain release competence (Figure 1.5) (Parsons, Coorssen et al. 1995; 
Eliasson, Renstrom et al. 1997; Barg, Huang et al. 2001; Olofsson, Gopel et al. 2002). 
 
Figure 1.5: Distinct insulin-granule pools of the pancreatic beta-cells. 
This figure represents the reserve, morphologically docked, and readily releasable pools of granules in a 
mouse beta-cell (Dean 1973; Rorsman, Eliasson et al. 2000; Bratanova-Tochkova, Cheng et al. 2002). 
With this model, the prevailing hypothesis is that the readily releasable pool  is responsible 
for the first phase of secretion and the replenishment of this pool is more important for sustaining a 
second phase secretion (Bratanova-Tochkova, Cheng et al. 2002; Ohara-Imaizumi, Nakamichi et al. 
2002; Olofsson, Gopel et al. 2002). Therefore, if the 1,300 morphologically docked granules (10% 
of the total) are the ones that supply for the second phase, then with the rate of six granules per cell 
per minute, these granules could sustain the second phase for over 3.5 hours (Barg, Eliasson et al. 
2002; Bratanova-Tochkova, Cheng et al. 2002). Moreover, as the rate of granule mobilization 
estimated by the capacitance measurement (10-15 granules/second) is far exceed what is required 
for second phase secretion (0.1-0.7 granules/second), other factors such as the priming process may 
serve as the rate-limiting step for the second phase of secretion (Eliasson, Renstrom et al. 1997; 
Barg, Eliasson et al. 2002; Bratanova-Tochkova, Cheng et al. 2002).  
To make it even more complicated, it has been shown by ultra-structural analysis that 
stimulation with high potassium alone depletes the pool of docked granules whereas glucose has the 
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capacity to maintain the size of the docked granule pool through new granule recruitment (Ohara-
Imaizumi, Nakamichi et al. 2002; Olofsson, Gopel et al. 2002). This could be explained by the fact 
that while potassium stimulated insulin secretion was induced only by the calcium signal, glucose 
stimulated insulin secretion is induced by various signals including metabolites as well as calcium 
(Gembal, Gilon et al. 1992). 
However, using the total internal reflection fluorescence microscope (TIRFM), the above 
model has been revisited recently with the introducing of a new model where the insulin-containing 
granules were not distinguished based on their physical location in the beta-cell but rather by their 
modes of exocytosis (Shibasaki, Takahashi et al. 2007; Seino, Takahashi et al. 2009; Seino, 
Shibasaki et al. 2011; Xie, Zhu et al. 2013; Zhu, Koo et al. 2013). The first mode of exocytosis, also 
called old face, characterises by the immediate fusion of the pre-docked granules with the plasma 
membrane upon stimulation. The second mode of exocytosis, named newcomer, describes those 
granules that are newly recruited to the plasma membrane by stimulation but immediately fuse to 
the plasma membrane with very short or no docking step detected by TIRFM. The third mode of 
exocytosis, referred to as resting newcomer, represents those granules that are also newly recruited 
by stimulation but first dock and then fuse to the plasma membrane (Figure 1.6) (Shibasaki, 
Takahashi et al. 2007; Seino, Shibasaki et al. 2011). 
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Figure 1.6: Three modes of insulin-granule exocytosis (Shibasaki, Takahashi et al. 2007). 
(A) Old face: pre-docked granule fuses to the plasma membrane by stimulation.  
(B) Restless newcomer: newly recruited granule immediately fuses to the plasma membrane by 
stimulation.  
(C) Resting newcomer: newly recruited granule first docks and then fuses to the plasma membrane.  
Sequential images (1 μm × 1 μm) acquired every 300 ms. The flash indicates fusion events of insulin 
granules. 
 Interestingly, TIRFM recordings indicated that both phases of GIIS are caused 
predominantly by restless newcomer, some from a distance away from the plasma membrane (>50 
nm) but readily releasable (Shibasaki, Takahashi et al. 2007; Seino, Takahashi et al. 2009; Seino, 
Shibasaki et al. 2011; Zhu, Koo et al. 2013). Old face mode of fusion (pre-docked granules), on the 
other hand, contributes mainly to the insulin secretion in response to high potassium (~60%) but not 
to glucose stimulation (Seino, Takahashi et al. 2009). The underlying reason for this observation 
remains obscure. One of the explanations is that in this model docking is considered as a braking 
step that prevents immediate fusion of insulin granules to the plasma membrane and that a supra-
physiologic level of [Ca
2+
]i following high potassium stimulation can overwhelm this braking step 
to force the pre-docked insulin granule (old face) to fuse with the plasma membrane whereas 
stimulation with glucose results in an insufficient rise in [Ca
2+
]i to overcome this braking state to 
induce the fusion of these old face granules (Seino, Shibasaki et al. 2011).  
1.4.3. SNARE proteins 
As mentioned previously, the secretion process includes the recruitment of the vesicles to 
the plasma membrane, the docking of these vesicles with the membrane and the fusion between the 
two membranes (Rorsman, Eliasson et al. 2000; Hou, Min et al. 2009). This exocytic process 
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requires the soluble N-ethylmaleimide–sensitive factor attachment proteins (SNAREs) (Weber, 
Zemelman et al. 1998; McNew, Parlati et al. 2000).  
Since their discovery more than 20 years ago by Rothman and colleagues, the SNARE 
superfamily has become the most robustly studied factor of the protein machinery involved in 
intracellular membrane fusion (Block, Glick et al. 1988; Clary, Griff et al. 1990; Chen and Scheller 
2001; Ungar and Hughson 2003). Briefly, fusion among membranes requires that SNARE proteins 
associated with the vesicle membrane (v-SNAREs) to bind to the ones associated with the target 
membrane (t-SNAREs), which results in the formation of stable SNARE complexes and the merger 
of the two layers ((Weber, Zemelman et al. 1998; McNew, Parlati et al. 2000; Chen and Scheller 
2001; Ungar and Hughson 2003).  
However, this functional nomenclature (v and t SNAREs) is confusing for other fusion 
reaction that are not asymmetric (such as between vacuoles) where the structural naming scheme is 
more suitable: R-SNAREs (arginine containing SNAREs) and Q-SNAREs (glutamine containing 
SNAREs) (Fasshauer, Sutton et al. 1998). Generally, a fusion-competent SNAREs complex 
includes four-helix bundles composed of one R-SNARE and three Q-SNAREs. Most of the cases, 
the three Q-SNAREs are contributed from the target organelle while the single R-SNARE is from 
the vesicle (Fasshauer, Sutton et al. 1998). In fact, more than a hundred of SNARE proteins from 
diverse organisms have been identified (Jahn and Sudhof 1999). Based on the sequence homology 
and domain structure, the mammalian SNAREs have been grouped into the syntaxin, SNAP-25 
(synaptosomal-associated protein, 25kDa) and VAMP (vesicle-associated membrane protein) 
families (Jahn and Sudhof 1999; Chen and Scheller 2001). 
 The syntaxin family and SNAP-25 have been identified in plasma membrane and the 
synaptobrevin/ VAMP family on secretory vesicles (Bennett and Scheller 1994; Sudhof 1995). Not 
long after their discovery, these SNARE proteins (syntaxin-1, SNAP-25 and VAMP2) were shown 
to expressed in the pancreatic beta-cells and involved in insulin exocytic machinery (Regazzi, 
Wollheim et al. 1995; Sadoul, Lang et al. 1995; Nagamatsu, Fujiwara et al. 1996; Wheeler, Sheu et 
al. 1996). Syntaxin binds to two molecules of SNAP-25, which in turn forms a high-affinity binding 
site for VAMP (Sutton, Fasshauer et al. 1998; Duman and Forte 2003). This tight protein-
association results in the assembled SNARE complexes that bridge two membranes (trans-SNARE) 
which is then converted to a kinetic and thermodynamic stable complex (cis-complex) (Figure 1.7) 
(Sutton, Fasshauer et al. 1998; Chen and Scheller 2001). 
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Figure 1.7: SNARE-mediated fusion reaction (Sutton, Fasshauer et al. 1998; Chen and Scheller 
2001).  
(A.) VAMP (blue) on the vesicle interacts with syntaxin (red) & SNAP-25 (green) on the plasma membrane. 
(B.) SNARE proteins form a four-helical bundle complex that drives membrane fusion. 
  Nevertheless, the actual physiological process of membrane fusion is much more 
complicated and remains to be fully elucidated. Although SNAREs play a pivotal role in the 
cellular fusion machinery, there are roles for other collaborating proteins which could involve in the 
fusion process such as facilitating linkage of SNAREs or promoting the assembly of SNAREs 
(Chen and Scheller 2001; Duman and Forte 2003). 
1.4.4. Fusion pore dynamics of insulin-containing granules 
Exocytosis of insulin granules or other peptide-containing vesicles requires the fusion of the 
vesicle membrane with the plasma membrane and the formation of the aqueous pore, through which 
the contents are discharged. Studies of exocytosis in other endocrine cells and neurons (most 
notably the chromaffin cells) have shed light on the area of insulin-granule dynamics (Ceccarelli, 
Hurlbut et al. 1973; Albillos A, Dernick G et al. 1997). In the classical model of exocytosis, the 
release of neurotransmitters or peptide-hormones involves the full fusion of secretory granules with 
the plasma membrane and then the retrieval of membrane at other sites to maintain the cell 
membrane area (Heuser and Reese 1973; Orci, Amherdt et al. 1973). However, evidence for a more 
complex model of the exocytosis has been first proposed by the Ceccarelli group and was further 
developed by Meldolesi and colleagues (Ceccarelli, Hurlbut et al. 1973; Meldolesi 1998). Different 
from the classical model, the vesicle maintains its integrity without collapsing into the plasma 
membrane during exocytosis in this alternative model (referred to as “kiss-and-run” or transient 
fusion) which according to Meldolesi will facilitate the rapid recycling of the vesicles (Ceccarelli, 
Hurlbut et al. 1973; Meldolesi and Ceccarelli 1981).  
Evidence for the “kiss-and-run” model remained indirect until the introducing of 
capacitance measurement technique which enables the qualitative and quantitative monitor of 
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vesicle turnover (Zupancic, Kocmur et al. 1994; Henkel and Almers 1996). Since then, studies from 
many research groups have confirmed the presence of “kiss-and-run” exocytosis in different cell 
types (Albillos A, Dernick G et al. 1997; Ales, Tabares et al. 1999; Rutter and Tsuboi 2004; 
Obermuller, Lindqvist et al. 2005; Larina, Bhat et al. 2007).  
Given the existence of both the classical fully collapse and the alternative “kiss-and-run” 
exocytosis, investigators started to question the role of fusion pore closure on the loss of granule 
content. Work from the Corey Smith group has shown that in the chromaffin cells, the activity-
dependent dilation of the fusion pore could screen the granule contents according to molecular 
weight and regulate the release of different transmitters through a size-exclusion mechanism: 
releasing catecholamine under basal condition but releasing both neuropeptide and catecholamine in 
acute stress situation (Fulop, Radabaugh et al. 2005). In the pancreatic beta-cell area, recent 
findings suggested that “kiss-and-run” fusion pores allow only the release of small transmitters such 
as ATP and GABA but retain the bulky insulin peptide cargo, presumably due to its large diameter 
compared to the narrow fusion pore (Rutter and Tsuboi 2004; Obermuller, Lindqvist et al. 2005; 
MacDonald, Braun et al. 2006) (Figure 1.8). Interfering with the fusion pore dilation is, therefore, 
very important in insulin secretion and may play a role in diabetes. Indeed, a recent study has 
shown that rat pancreatic beta-cells cultured for 2 days in high-glucose media (30 mM) resulted in a 
significant increase in the fraction of “kiss-and-run” exocytosis at the expense of the full fusion 
(Tsuboi, Ravier et al. 2006).  
 
Figure 1.8: Different modes of exocytosis. 
(A) Complete exocytosis where both the insulin crystal (yellow) and the small transmitters (blue) are 
released. 
(B)“Kiss-and-run” exocytosis where the granule transiently fuses with the plasma membrane, maintains 
its integrity and prematurely closes the fusion pore which traps the insulin crystal inside. 
Although “kiss-and-run” exocytosis is well characterised in adrenal chromaffin cells, it is 
still controversial in the beta-cell area, where the mechanism is unclear and the definition as well as 
the frequency vary according to the method employed (MacDonald and Rorsman 2007). 
Examination of diffusible extracellular markers revealed a low frequency (~7%) of “kiss-and-run” 
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(Ma, Bindokas et al. 2004; Takahashi, Hatakeyama et al. 2004), studies using electro-physiological 
measurements reported a higher rate (~25%) (MacDonald, Braun et al. 2006) and others utilizing 
fluorescent dense core vesicle cargo or membrane markers suggested a very high proportion of 
“kiss-and-run” exocytic events (~70%) (Obermuller, Lindqvist et al. 2005). If the relative frequency 
of “kiss-and-run” exocytic events in the beta-cells is not well-established, the molecular mechanism 
underling it is even less so. Recent studies demonstrated the recruitment of dynamin to sites of 
“kiss-and-run” in insulin-secreting cells, suggesting a mechanism whereby dynamin prevents the 
expansion, stabilizes and finally closes the fusion pore (Tsuboi, McMahon et al. 2004). Evidence 
from other studies suggested a role for the Ca
2+
-sensing exocytotic protein synaptotagmin I, since 
genetic knockdown of this protein inhibited fast exocytosis which is often taken to represent “kiss-
and-run” (Xiong, Zhou et al. 2006). 
1.4.5. Compound exocytosis of the pancreatic beta-cells 
Secretory cells can release their content to the extracellular space either by fusion of 
individual vesicles to the plasma membrane or by a phenomenon of chain release in which two or 
more granules are discharged through a single exocytic opening with the plasma membrane. The 
later has been known of as compound exocytosis which occurs in many secretory cell types such as 
mast cells, pancreatic acinar cells, pituitary lactotrop cells or islet beta-cells (Ichikawa 1965; 
Rohlich, Anderson et al. 1971; Orci and Malaisse 1980; Cochilla, Angleson et al. 2000). The term 
compound exocytosis encompasses two distinct phenomena, sequential and mutigranular exocytosis 
(Alvarez de Toledo and Fernandez 1990; Cochilla, Angleson et al. 2000; Thorn, Fogarty et al. 
2004). In sequential exocytosis, granules fuse selectively with other granules that already fused with 
the plasma membrane, whereas in multigranular exocytosis granules can prefuse within the cell 
before undergoing exocytosis as one unit (Figure 1.9) (Alvarez de Toledo and Fernandez 1990; 
Cochilla, Angleson et al. 2000; Takahashi, Hatakeyama et al. 2004; Thorn, Fogarty et al. 2004). 
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Figure 1.9: Schematic representation of sequential versus multigranular modes of 
exocytosis. 
In sequential exocytosis, the granule first fuse with the plasma membrane and other granules subsequently 
fuse with this granule while in multigranular exocytosis several granules first fuse within the cell before 
undergoing exocytosis. 
Compound exocytosis especially sequential exocytosis has been shown to present in the 
pancreatic beta-cells of intact islets (Orci and Malaisse 1980; Takahashi, Hatakeyama et al. 2004; 
Hoppa, Jones et al. 2012). However, unlike other cell types (mast cells, eosinophils, pancreatic 
acinar cells or pituitary lactotrops), compound exocytosis contributes marginally (<5-10%) to the 
glucose stimulated insulin secretion in pancreatic beta-cells (Takahashi, Hatakeyama et al. 2004; 
Hoppa, Jones et al. 2012). The rarity of sequential/ mutigranular exocytosis in pancreatic beta-cells 
under normal condition is believed to play an important physiological role in prolonged regulation 
of blood glucose concentration whereby massive secretion is prevented. However, when stimulated 
with muscarinic agonist carbachol or glucagon like peptide 1 (GLP-1) in addition to glucose, 
compound exocytosis of the insulin-containing granules becomes quantitatively significant (3-4 
times increase) which suggests an important role of this type of exocytosis in essential conditions 
where insulin demand is very high (Kwan and Gaisano 2005; Hoppa, Jones et al. 2012). 
Nevertheless, there is much less information about the molecular machinery driving 
compound exocytosis. Several proteins of the SNARE complex have been proposed to mediate the 
insulin granule-granule fusions in pancreatic beta-cells which may include but not limited to 
SNAP25, synataxin-3, Munc18b and VAMP8  (Takahashi, Hatakeyama et al. 2004; Lam, Ohno et 
al. 2013).  
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1.5. Pathogenesis of type 2 diabetes and the role of beta-cell 
dysfunction 
1.5.1. Pathogenesis of type 2 diabetes 
Although controversy remains around the pathogenesis of T2D, it is generally accepted that 
the disease has strong genetic and environmental components that act harmoniously and in concert 
to stress the glucose homeostasis system (Gerich 1998; D’Adamo and Caprio 2011; Cornelis and 
Hu 2012). The genetic factors underlying susceptibility to T2D were demonstrated by many studies 
in genetically predisposed individuals including first-degree relatives of T2D patients and identical 
twins (Barnett, Spiliopoulos et al. 1981; Vaag, Henriksen et al. 1995; Vauhkonen, Niskanen et al. 
1998). It is estimated that between 43 and 45% of siblings, parents and children of T2D patients 
would develop the disease if they live to the age of 80 which means that the lifetime risk for T2D is 
5-10 times higher for a person with a first-degree relative of T2D than that of age-matched subjects 
without a family history of the disease (Kobberling and Tillil 1982; O'Rahilly, Wainscoat et al. 
1988). Stronger evidence came from study in monozygotic twin which revealed that 48 out of 53 
non-insulin dependent diabetic twin pairs were concordant for the disease (Barnett, Eff et al. 1981). 
In other words, if one twin was diagnosed with T2D, approximately 90% of the unaffected twins 
eventually develop the disease. Though a few single-gene defects have been identified in T2D, most 
of the genetic influences are polymorphic which is understandable given the polygenic nature of the 
disease (O'Rahilly, Wainscoat et al. 1988; Gerich 1998). 
In addition to a strong genetic predisposition, the risk for T2D is greatly increased when 
associated with environmental factors such as obesity, physical inactivity, smoking, poor diet 
quality with high intake of trans/ saturated fat, sugar-sweetened beverages, and nutritional 
environment during pre- and postnatal life (Romao and Roth 2008; Burdge and Lillycrop 2010). 
Even among groups with increase genetic risk for T2D like the Pima Indians, there is evidence for 
the important role of environmental factors on the disease development. As an example, the 
prevalence of T2D among Pima Indians living in Mexico is less than one-fifth that in the U.S. Pima 
Indians with the same genetic background (6.9% vs. 38%) (Schulz, Bennett et al. 2006). 
Extensive work has been carried on during recent decades and considerable progress has 
been made in the knowledge of the disease development. It is now recognized that the disturbances 
both in insulin resistance and insulin secretion represent the core pathophysiologic defects of T2D 
(Vauhkonen, Niskanen et al. 1998; van Haeften 2002; DeFronzo 2004). Briefly, individuals 
destined to develop T2D inherit a set of genes that make their tissue less sensitive to insulin 
Page | 21  
 
including hepatic glucose overproduction during the basal state and impaired muscle glucose uptake 
and inadequate suppression of hepatic glucose production after meals (Eriksson, Franssila-Kallunki 
et al. 1989; Groop, Bonadonna et al. 1989; Rothman, Magnusson et al. 1995). This insulin 
resistance state presents years before the diagnosis of T2D which puts pressure on the beta-cells to 
augment insulin secretion (Eriksson, Franssila-Kallunki et al. 1989; Rothman, Magnusson et al. 
1995; DeFronzo 2009). As long as the beta-cells can maintain sufficient insulin secretion to 
compensate for the insulin resistance, blood glucose remains normal (Zimmet, Whitehouse et al. 
1978; Saad, Knowler et al. 1989; Diamond, Thornton et al. 1995). In predisposed T2D people, 
however, with time the beta-cells begin to fail and initially the post-prandial blood glucose and 
subsequently the FBG will rise, resulting in the onset of diabetes (Zimmet, Whitehouse et al. 1978; 
Saad, Knowler et al. 1989; DeFronzo 2004) (Figure 1.10). 
 
Figure 1.10: Representative depiction of the natural history of T2D 
Initially, in response to insulin resistance, the beta-cell increases in insulin secretion. However, in 
susceptible people, beta-cell function starts to decline- in face of stable insulin resistance which results in 
first postprandial hyperglycemia and then fasting hyperglycemia (Kendall, Cuddihy et al. 2009). 
1.5.2. The role of beta-cell dysfunction in T2D 
The relative contribution of insulin resistance and beta-cell failure in T2D has been the topic 
of intense investigation for several decades (Gerich 1998; DeFronzo 2009; Ashcroft and Rorsman 
2012). Although understanding about the dynamic interaction between insulin sensitivity and 
insulin secretion in the etiology of T2D is far from complete, the essential role of reduced beta-cell 
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function in T2D has been confirmed with the following supportive evidence (Gerich 1998; Florez 
2008; Seino and Bel 2008; Ashcroft and Rorsman 2012). 
Firstly, investigations conducted on African American T2D patients living around the New 
York city revealed that up to 50% of these patients has normal insulin sensitivity but defective 
insulin secretion which suggested that full-blown T2D can happen even in the absence of insulin 
resistance (Banerji and Lebovitz 1992). Also, there is evidence for defective insulin secretion in 
NGT individuals with a first degree T2D relative (Rojas, Soeldner et al. 1969; Pimenta, 
Korytkowski et al. 1995; Gerich 1998). Moreover, studies in identical twins discordant for T2D 
provided more convinced evidence for the dominant role of beta-cell dysfunction in the disease 
development. As illustrated in table 1.1, four out of the five studies revealed that the NGT 
discordant twin had impaired insulin secretion and the only report investigating both insulin 
secretion and insulin sensitivity found defective insulin secretion without insulin resistance (Vaag, 
Henriksen et al. 1995; Gerich 1998).  
Table 1.1:  Beta-cell function and insulin sensitivity in monozygotic twins discordant for 
T2D (Gerich 1998). 
References Subjects 
Beta-cell 
function 
Insulin sensitivity 
1. (Cerasi and Luft 1967) 85C, 5M Reduced  Not studied 
2  (Gottlieb, Soeldner et al. 1974) 24C, 12M Normal  Not studied 
3  (Pyke and Taylor 1967) 24C, 9M Reduced  Not studied 
4. (Barnett, Spiliopoulos et al. 1981) 5C, 5M Reduced  Not studied 
5. (Vaag, Henriksen et al. 1995) 13C, 5M Reduced  Normal  
C: control subject; M: monozygotic discordant twin 
Additionally, as women with a history of gestational diabetes are at high risk of developing 
T2D, this forerunner condition serves as another invaluable tool for investigating the disease’s 
pathogenesis. As depicted in table 2.2, seven out of eight studies conducted in NGT women with 
prior gestational diabetes indicated reduced beta-cell function and four out of five revealed a normal 
insulin sensitivity (Gerich 1998). Taken together, these lines of evidence indicated that the main 
genetic factor predisposing to T2D is beta-cell dysfunction.   
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Table 1.2: Βeta-cell function and insulin sensitivity in NGT women with prior gestational 
diabetes (Gerich 1998). 
References Subjects Beta-cell function Insulin sensitivity 
1. (Dornhorst, Chan et al. 1992) 44C, 44PGD Reduced  Not studied 
2. (Ward, Johnston et al. 1985) 19C, 19PGD Reduced  Normal  
3. (Chan, Gelding et al. 1992) 15C, 15PGD Reduced  Not studied 
4. (Damm, Kuhl et al. 1995) 30C, 23PGD Reduced  Not studied 
5. (Ryan, Imes et al. 1995) 14C, 14PGD Reduced  Reduced  
6. (Persson, Hanson et al. 1991) 39C, 108PGD Normal  Not studied 
7. (Efendic, Hanson et al. 1987) 10C, 17PGD Reduced  Normal  
8. (Catalano, Bernstein et al. 1986) 5C, 5PGD Not studied Normal  
9. (Dornhorst, Edwards et al. 1991) 7C, 7PGD Reduced  Normal  
C: control subject; PGD: previous gestational diabetes. 
Secondly, though insulin resistance is present in about 24% of the US., half of these 
individuals have normal blood glucose due to the increment of insulin secretion appropriately to the 
severity of insulin resistance (Ford, Giles et al. 2002). This dynamic interaction between insulin 
resistance and secretion has been clearly demonstrated in a study of non-obese NGT women with a 
significant reciprocal relationship between insulin sensitivity and insulin secretion: women in the 
lowest quartile of insulin sensitivity had the highest insulin response during the hyper-glycemic 
clamp and vice versa (Diamond, Thornton et al. 1995). In other words, because of the feedback 
between blood glucose concentration and islet insulin secretion, it is virtually impossible to develop 
diabetes due to the severity of insulin resistance alone unless the compensatory capacity of the beta-
cells is impaired (Zimmet, Whitehouse et al. 1978; Polonsky, Given et al. 1988; Saad, Knowler et 
al. 1989; DeFronzo 2004). 
Thirdly, under normal conditions, the beta-cell population exceeds what is required to 
maintain normoglycemia in most species (Seino and Bel 2008). In dogs, 60% pancreatectomy did 
not induce hyperglycemia and in healthy rats and mice, over 90% pancreatectomy is required to 
induce frank diabetes (Srinivasan and Ramarao 2007). Moreover, a 50% donation of islets from a 
healthy human pancreas has been reported to normalize blood glucose in the previously unstable 
diabetic recipient but not to induce hyperglycemia in the donor (Matsumoto, Okitsu et al. 2005). 
Furthermore, work on human islets reported that, different from normal islets, an equivalent number 
of T2D islets cannot reverse hyperglycemia when transplanted to immune-deficient diabetic mice 
which suggests abnormalities in T2D islets (Deng, Vatamaniuk et al. 2004). Collectively, these 
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findings implicated a large reserve capacity for insulin production that a moderate reduction in beta-
cell mass would not cause diabetes unless function in terms of GIIS was also affected. 
Last but not least, as T2D has a strong hereditary component, dissecting its genetic 
architecture would give insight into the disease biology. Unlike monogenic disorders, investigating 
the genetic structure of this polygenic disease is a slow, limited and cumbersome process. With the 
introduction of whole genome-wide association studies in 2007, the number of confirmed genetic 
variants that increase the risk of T2D has remarkably increased from three to eighteen in the first 
three years and to over sixty to date (Groop and Lyssenko 2009; Wheeler and Barroso 2011; 
Morris, Voight et al. 2012; Basile, Johnson et al. 2014). Interestingly, the majority of the discovered 
gene variants increase the risk of T2D through reducing beta-cell function rather than increasing 
insulin resistance (Florez 2008; Lyssenko and Groop 2009; Ridderstrale and Groop 2009; De Silva 
and Frayling 2010; Basile, Johnson et al. 2014). Furthermore, TCF7L2, the strongest T2D-
susceptibility loci discovered to date, was shown to associate with impaired insulin secretion with 
no evidence of insulin resistance (Gloyn, Braun et al. 2009). Such evidence by no means rules out 
the genetic contribution of insulin resistance to T2D, but rather highlights the important role of 
genetic background of the beta-cell that determines its compensated capacity to the situation of 
insulin resistance (De Silva and Frayling 2010). 
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1.6. Mechanism of beta-cell dysfunction in type 2 diabetes 
1.6.1. Detrimental effects of hyperglycemia on beta-cell function 
Type 2 diabetes is not a stable disease, it is progressive in nature. In the context of diabetes, 
several elements have been identified as contributors to the progressive loss of beta-cell mass or 
beta-cell function, including but not limited to endoplasmic reticulum stress, oxidative stress, 
mitochondria dysfunction, islet amyloid deposition and inflammation processes (Fonseca 2009; 
Cernea and Dobreanu 2013). Whatever the nature of the initial defects and pathogenetic 
mechanisms, once the hyperglycemia occurs, it will further damage the beta-cell function and lead 
to a vicious circle of metabolic disorders (Scheen 2003; Fonseca 2009). 
Normally the pancreatic beta-cells function in a narrow range of blood glucose and thus 
even slightly increased blood glucose concentration generate an unnatural environment, which 
induces structural and functional changes especially the loss of acute insulin response to glucose. 
Substantial evidence has supported the adverse effect of hyperglycemia on beta-cell function 
(Leahy, Cooper et al. 1986; Poitout and Robertson 1996; Jonas, Sharma et al. 1999). Although the 
mechanisms underlying beta-cell dysfunction in hyperglycemic environment is not yet clear, there 
is evidence for changes in critical islet transcription factors that involved in GIIS, beta-cell 
development and differentiation (Jonas, Sharma et al. 1999). Another evidence came from the 
restoration of GIIS after normalization of plasma glucose level for short periods of time in human 
T2D (Turner, McCarthy et al. 1976; Vague and Moulin 1982). Furthermore, study in partial 
pancreatetomised rats fed with either tap water or 10% sucrose indicated that reduce in beta-cell 
mass that did not cause hyperglycemia had no adverse effect on the remaining beta-cells. However, 
if associated with even mild hyperglycemia, beta-cell function became impaired leading to an 
inappropriate low level of GIIS (Leahy, Bonner-Weir et al. 1988). 
The unfavorable effect of chronic hyperglycemia on the pancreatic beta-cells can be 
classified into three distinct phenomena: glucose desensitization, beta-cell exhaustion and 
glucotoxicity (Poitout and Robertson 2002; Robertson, Harmon et al. 2003; Cernea and Dobreanu 
2013). Glucose desensitization, sometimes considered as  an adaptive mechanism, refers to the 
temporal state of cellular refractoriness to glucose stimulation after being exposured to 
hyperglycemia for a short period of time (Poitout and Robertson 2002; Robertson, Harmon et al. 
2003). Whereas, beta-cell exhaustion characterises by the physical depletion of the intracellular 
insulin stores secondary to prolonged stimulation which is sometime reversible with islet rest 
(Leahy, Bumbalo et al. 1994; Poitout and Robertson 2002). Glucotoxicity, on the other hand, 
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decribes the slow but progressive irreversible damage to cellular components of insulin production 
and secretion after long-term exposure to hyperglycemia (Robertson, Harmon et al. 2003).  
The question is which of these phenomena plays dominant role in the disease progression. In 
order to address this issue, Sako and Grill compared the level of insulin secretion from the rat 
pancreas after 2 days infusion with glucose with or without diazoxide, an inhibitor of insulin 
release. The result was the preservation of insulin secretion in the presence of diazoxide which 
suggests that beta-cell exhaustion due to excessive stimulation rather than the hyperglycemic 
environment underlies the impairment of GIIS (Sako and Grill 1990). Conversely, other study 
reported that 2 days exposure to high glucose reduced GIIS but retained normal arginine-induced 
insulin secretion in human islets and this defect can be partially reversed by an additional culture in 
normal glucose medium which suggests a glucose desensitization effect (Davalli, Ricordi et al. 
1991). On the other hand, study in 85-95% pancreatectomised rats showed that chronic 
hyperglycemia altered expression of several important islet transcription factors which supported 
the role of glucotoxicity (Jonas, Sharma et al. 1999). Despite intensive work in this area, no single 
defect (glucose desensitization, beta-cell exhaustion or glucotoxicity) can fully explains the beta-
cell dysfunction in all common forms of T2D, which is consistent with the heterogeneous nature of 
the disease (Poitout and Robertson 1996). It is also possible that in response to chronic 
hyperglycemia beta-cells within an islet are in various damaging states and thus after normalizing 
blood glucose some beta-cells can recover their insulin secretion (Cernea and Dobreanu 2013). 
1.6.2.  Dedifferentiation of the pancreatic beta-cells 
It is conceivable that the impairment of beta-cell function in diabetes is much greater than 
could be explained by the rate of beta-cell apoptosis which makes beta-cell death unlikely to be the 
main contributor to the disease progression (Ashcroft and Rorsman 2012; Dalbøge, Almholt et al. 
2013). An alternative mechanism for the loss of functional beta-cell mass which has received 
considerable attention recently is the beta-cell dedifferentiation (Weinberg, Ouziel-Yahalom et al. 
2007; Talchai, Xuan et al. 2012; Blum, Roose et al. 2014; Wang, York et al. 2014). Briefly, 
dedifferentiation refers to a process that the cells gradually lose their mature identity and move to a 
more primitive state with the loss of crucial components responsible for normal cellular function 
(Talchai, Xuan et al. 2012; Weir, Aguayo-Mazzucato et al. 2013; Blum, Roose et al. 2014). In fact, 
dedifferentiation has been demonstrated in the pancreatic beta-cells of rodent models of genetic 
disruption of the crucial transcription factor FoxO1 or NeuroD where the beta-cell gradually loses 
its specific transcription factors (MafA, Nkx6.1, Pdx1) and adapts the progenitor makers 
(Neugenin3, Oct4, C-myc, Nanog)  (Gu, Stein et al. 2010; Talchai, Xuan et al. 2012). The major 
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cause for these changes is believed to be the hyperglycemic environment that forces the already 
stress beta-cells to secrete more insulin, leading to the metabolic overload and dedifferentiation. It 
is unclear in which stages of the disease that the dedifferentiation process occurs. However, a recent 
report from the Melton group suggested that Urocortin 3, a marker for mature beta-cells was 
reduced early in T2D mice whose blood glucose was just slightly above normal and even before the 
reduction in insulin gene expression (Blum, Roose et al. 2014). 
Although there are many uncertain issues surrounding the dedifferentiation process  such as 
in which stages of diabetes that it occurs and to which primitive states that these dedifferentiated 
beta-cells rest, there is ample evidence for a subset of beta-cells that no longer contribute to the 
production and secretion of insulin in diabetic islets and that the progressive loss of beta-cell 
phenotype antedates their physical termination (Ferrannini 2010; Olsson and Carlsson 2011; 
Talchai, Xuan et al. 2012; Weir, Aguayo-Mazzucato et al. 2013). Notably, instead of a degenerative 
progress, these diseased beta-cells regress to a more progenitor-like stage which is considered as a 
protective behaviour to facilitate their survival (Talchai, Xuan et al. 2012). This finding is of 
paramount importance for both scientists and clinicians in that there is a sufficient time window 
between beta-cell dysfunction and beta-cell death for regenerative therapy by re-differentiating 
these endocrine progenitor-like cells back to the functional beta-cells (Ferrannini 2010; Talchai, 
Xuan et al. 2012; Weir, Aguayo-Mazzucato et al. 2013; Blum, Roose et al. 2014). Indeed, a recent 
study using KATP -gain of function diabetic model has shown that insulin therapy can rescue the 
dedifferentiated beta-cells of the diabetic islets (Wang, York et al. 2014). 
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1.7. Progression of type 2 diabetes 
The transition from normal to pre-diabetes and diabetes in adults is usually a gradual 
process, occurring over many years or even decades (Weyer, Bogardus et al. 1999; Weiss, Taksali 
et al. 2005). The clinical presentation of T2D varies widely from asymptomatic to life-threatening 
symptoms of ketoacidosis or hyperosmolar hyperglycemic state and correspondingly, plasma 
glucose concentration may range from slightly elevated to severe hyperglycemia (American 
Diabetes Association 2014). Even though glucose is a continuous variable and thus diabetes is 
considered as a continuum, the progression of diabetes can be classified into different stages from 
fully compensation to severe decompensation with each has its own important characteristics (Weir, 
Laybutt et al. 2001; Weyer, Tataranni et al. 2001; Weir and Bonner-Weir 2004; Prentki and Nolan 
2006; Fonseca 2009). Delineation of these stages especially the underlying pathophysiological 
difference between them is of great importance for both physicians and researchers in order to 
target the disease efficiently. 
In humans, diabetes especially T2D has been categorized into five stages based on the FBG: 
compensation, adaptation, early decompensation, late and severe decompensation (Figure 1.11) 
(Weir, Laybutt et al. 2001; Weir and Bonner-Weir 2004). This proposed classification scheme has 
served as a widely accepted framework to categorize the disease phenotype. 
 
Figure 1.11: Schema of five stages of progression of diabetes  
      (Weir and Bonner-Weir 2004). FPG: fasting plasma glucose.  
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1.7.1. Stage 1- compensation 
In stage 1, the pancreatic beta-cells have the capacity to increase their secretion output to 
keep up with the extra demand of insulin resistance which is usually manifested by elevated fasting 
and post-prandial insulin concentrations (Saad, Knowler et al. 1989; DeFronzo, Bonadonna et al. 
1992). The FBG is marginally increased which is clinically unnoticeable as not yet satisfying the 
criteria of IFG (≥ 5.6 mmol/l) (Weir and Bonner-Weir 2004). At this very beginning phase, there is 
evidence for an intact or even increased GIIS which could happen through either compensated beta-
cell mass or beta-cell function (Karam, Grodsky et al. 1963; Polonsky, Given et al. 1988; Saad, 
Knowler et al. 1989; Gonzalez, Merino et al. 2013).  
For the beta-cell mass component, there is substantial evidence for the proliferative ability 
of the pancreatic islets in response to the body’s increased insulin demand in both human (obesity, 
pregnancy) and animal models (genetic or diet induced obesity) (Hull, Kodama et al. 2005; 
Sachdeva and Stoffers 2009; Dalbøge, Almholt et al. 2013; Saisho, Butler et al. 2013). For example, 
short-term glucose infusion (96 hours) can stimulate 50% increase in beta-cell mass in rats which 
confirmed the plasticity of postnatal beta-cell mass (Bonner-Weir, Deery et al. 1989). Although the 
underlying mechanism for the expansion of beta-cell mass is not yet fully understood, recent studies 
employing insulin-promoter-based lineage tracing suggested that new adult beta-cells arise mainly 
from replication of existing beta-cells, with minor role of differentiation from specialized 
progenitors or stem cells (Dor, Brown et al. 2004; Teta, Rankin et al. 2007). The ability to re-
duplicate of adult beta-cell is limited by replication-refractory periods that prevent beta-cells from 
immediately re-dividing (Teta, Rankin et al. 2007). Moreover, a recent report by Olsson and 
Carlsson revealed an exciting result about a low-oxygenated subpopulation of islets (~20-25%) that 
is less active normally but is called into action by demand (Olsson and Carlsson 2011). These 
sleeping islets, therefore, serve as a functional reserve of insulin-producing cells in addition to the 
expansion in beta-cell mass (Weir and Bonner-Weir 2011).  
Despite abundant evidence surrounding the increased beta-cell mass in the context of insulin 
resistance, the compensatory role of beta-cell function receives less attention and remains 
controversial. Experiments on spontaneously hypertensive rats or partially pancreatectomised rats  
suggested a lower glucose set-point for insulin secretion which results in more insulin secreted at a 
given level of glucose (Chen, Hosokawa et al. 1994; Hosokawa, Hosokawa et al. 1995). Moreover, 
study in the genetic obesity ob/ob mice indicated a significant plasticity in individual beta-cell 
function to maintain normal FBG in face of insulin resistance (Irles, Neco et al. 2015). Contrarily, 
evidence exists for lower beta-cell function in women with former gestational diabetes mellitus or 
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NGT people who are first degree relatives of T2D patients, which implied earlier disturbances in 
the beta-cell function of predisposed people than often appreciated (Pimenta, Korytkowski et al. 
1995; van Haeften 2002). In addition, high fat feeding mice showed an increase in beta-cell 
population proportionally to the increase in body weight but the insulin release normalized to 
fractional beta-cell area tended to decrease which argued for an inadequate functional adaptation of 
the beta-cell (Hull, Kodama et al. 2005). Therefore, the issue remains obscure regarding the role of 
beta-cell function in the early stage of diabetes even before the appearance of hyperglycemia. 
All things considered, the compensated stage of T2D is characterised by an unnoticeable 
change in blood glucose due to higher plasma insulin (Saad, Knowler et al. 1989). The intact or 
increased insulin response in this very beginning stage of T2D is a function of enlarged beta-cell 
mass with the role of beta-cell function remains to be determined.  
1.7.2. Stage 2- adaptation 
It is not possible to define an exact range of blood glucose for this adaptation stage. 
However, the glycemia is no longer kept in the truly normal range, but rises to a noticeable level 
(Weir and Bonner-Weir 2004). Besides moderate hyperglycemia, changes in beta-cell phenotype 
are also observed during this adaptation state, with up or down regulated key islet gene and protein 
expressions as reported in the male Zucker pre-diabetes fatty rats or partially pancreatectomised rats 
(Tokuyama, Sturis et al. 1995; Jonas, Sharma et al. 1999; Laybutt, Kaneto et al. 2002). 
Another important feature of this stage is the loss of acute glucose-stimulated insulin 
secretion (Mitrakou, Kelley et al. 1992; van Haeften 2002). It has been shown that the early phase 
of GIIS was maintained as long as FBG was kept below 100 mg/dl (5.6 mM). It dropped, however, 
significantly when FBG exceeded this level and disappeared with FBG ≥ 115 mg/dl (6.4 mmol/l) 
(Brunzell, Robertson et al. 1976). Even though there is more evidence for impaired first phase 
insulin secretion during this early state of disease, using the hyperglycemic clamp on IGT people, 
Van Haeften indicated that both first and second phase of secretion were affected (reduced by 35% 
and 28% respectively) (van Haeften, Pimenta et al. 2000). 
The adaption stage clinically corresponds to IFG and/or IGT (Mitrakou, Kelley et al. 1992). 
Individuals at this stage can progress to over diabetes, remain pre-diabetes or revert to NGT, 
depending on the adaptation ability of the beta-cells (Wong, Gu et al. 2003). It is considered as a 
stable state as study showed that people in the upper end of stage 2 with IGT progress to diabetes at 
a rate of 11% per year with no intervention and 4.8% per year with lifestyle intervention (Knowler 
WC, Barrett-Connor E et al. 2002). Interestingly, a longitudinal study in Pima Indians- a population 
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with very high incidence of T2D- revealed that the progression from NGT to IGT to T2D is 
primarily determined by the acute insulin response to intravenous glucose (AIR) with a 27% 
decrease in AIR occurring during the transition from NGT to IGT and a further decrease of 51% 
during the transition from IGT to DM (Weyer, Bogardus et al. 1999). Whereas this AIR index is 
either unchanged or increased by 30% in the non-progressors (Figure 1.12) (Weyer, Bogardus et al. 
1999). 
 
Figure 1.12: Insulin secretion (AIR) and insulin resistance (M-low) in the pathogenesis of 
T2D (Weyer, Bogardus et al. 1999). 
The graph illustrates changes in acute insulin response (AIR) and insulin sensitivity (M-low, the rate of 
insulin-stimulated glucose disposal) in 11 Pima Indian progressors who progressed from NGT to IGT to 
diabetes (DIA) and 23 non-progressors who retained NGT. The lines represent the prediction line ± 95% 
confidence interval of the regression between AIR and M-low derived from a reference population of 277 
Pima Indians with NGT. 
1.7.3. Stage 3- early decompensation 
Over time the compensatory ability of the beta-cell deteriorates resulting in the development 
of overt diabetes with the FBG ≥126 mg/dl (7 mM). As the symptoms of hyperglycemia (polyuria, 
polydipsia, polyphagia, and unexplained weight loss) may or may not be present at this state, a large 
proportion of diabetes patients remains undiagnosed (American Diabetes Association 2014).  
Although it is not yet clear to what extent, if any, that the insufficient beta-cell mass 
contributes to the transition to diabetes, a postmortem observation from the European population of 
T2D suggested a slight reduction (by 24%) of the beta-cell mass at the early onset of T2D (< 5 year 
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of diagnosis), with large overlapping values compared to control subjects, which according to the 
authors hardly caused overt diabetes in the absence of impaired beta-cell function (Rahier, Guiot et 
al. 2008).  
It is noteworthy that, despite impairment in cellular GIIS, the beta-cell’s insulin storage 
seems to be unaffected at this stage which favors the defect in cellular secretory mechanisms rather 
than the insulin biosynthesis (Hull, Kodama et al. 2005). However, since stage 3, the glucose 
homeostasis system of the body is clearly disturbed and without treatment that hyperglycemic 
environment will place more stress on the beta-cell to push it further downstream of the 
pathological pathway (Poitout and Robertson 1996).  
1.7.4. Stage 4- late decompensation 
Once present, hyperglycemia itself can damage the beta-cell function and worsen the insulin 
resistance state leading to a vicious circle of metabolic disorders (Kjørholt, Åkerfeldt et al. 2005; 
Leahy 2005; Cernea and Dobreanu 2013). The plasma glucose, therefore, continues to rise to a 
considerably higher level which was categorized as late decompensation phase (Weir and Bonner-
Weir 2004). It is hard to assign a range of blood glucose for this state as it is an intermediate step 
between early onset of diabetes and the eventual stage of the disease.  
At this stage, the beta-cell mass and function are severely impaired and the insulin 
biosynthesis is also reduced which serves as a rate-limiting step for secretion (Ward, Bolgiano et al. 
1984; Leibowitz, Uckaya et al. 2002; Butler, Janson et al. 2003; Rahier, Guiot et al. 2008). Despite 
being damaged, the residual level of functional beta-cell mass can manage to secrete enough insulin 
for a certain period of time to prevent immediate transition to the final severe hyperglycemic stage 
(Weir and Bonner-Weir 2004).  
1.7.5. Stage 5- severe decompensation 
End-stage diabetes is characterised by very high plasma glucose level due to remarkably 
loss of functional beta-cell mass and a blunt or almost disappeared GIIS that is no longer enough to 
prevent severe diabetic ketoacidosis or hyperosmolar hyperglycemic state (Weir and Bonner-Weir 
2004; Yamazaki, Kato et al. 2009). Despite differences in the pathogenesis, these two life-
threatening complications share the same underlying disorders of extreme deficit in insulin 
secretion and elevated counter-regulated hormone, which requires insulin treatment for survival 
(Umpierrez, Murphy et al. 2002). In addition to the functional failure, there are serious degenerative 
features observed in the final-stage pancreatic islets including irregular shape, degranulation and 
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transparent appearance, intra-islet amyloid/ fat deposition or even collapsing islets (Nugent, Smith 
et al. 2008; Dalbøge, Almholt et al. 2013). 
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1.8. Lepr
db 
mouse model 
1.8.1. Leprdb as a model of type 2 diabetes 
In order to explore the potential long-term effects of elevated glucose levels on the beta-cell 
function, diabetic animal models have been introduced. There is a wide range of animal models for 
T2D which can be obtained either spontaneously or induced by dietary or chemicals or surgical 
manipulations or by combination of them (Srinivasan and Ramarao 2007; Leiter 2009). Among 
these available models, Lepr
db
 is one of the most intensively studied models for T2D.  
The db/db (diabetic) mice (relabeled as Lepr
db
) which were first described in 1966 were 
derived from an autosomal recessive mutation on chromosome 4 in mice of C57BL/KsJ strain 
originating from Bar Harbor (Hummel, Dickie et al. 1966). The spontaneous GT point mutation 
in this diabetic animal was traced back to the db gene, which encodes for the leptin receptors (Chen, 
Charlat et al. 1996). 
Defects in leptin signaling pathway lead to typical metabolic changes such as hyperphagia, 
obesity, hyperinsulinemia and disturbances of glucose metabolism (Hummel, Dickie et al. 1966). 
Unlike ob/ob model (leptin deficiency), leptin treatment has no effect on the db/db mice due to 
leptin receptor deficiency (Halaas, Gajiwala et al. 1995; Pelleymounter, Cullen et al. 1995). The 
db/db mice are spontaneously hyperphagic, hyperinsulinaemic, obese, insulin resistant within the 
first month of age and develop hypoinsulinaemia, hyperglycaemia later with a peak between 12-18 
weeks of age (Hummel, Dickie et al. 1966; Coleman 1978). They then exhibit ketosis, progressive 
body weight loss, diabetic complications (nephropathy) and usually cannot survive beyond 8–10 
months without treatment (Hummel, Dickie et al. 1966; Yamazaki, Kato et al. 2009). In view of 
this, the pathophysiological sequence of events in this model appears to mimic human T2D 
(Yamazaki, Kato et al. 2009).  
However, it is worth noting that the course of the disease is largely influenced by the genetic 
background, on which the mutation is bred (Champy, Selloum et al. 2008). While diabetes resistant 
strains C57BL/6 (B6) remain near normal-glycemia and hyperinsulinemia, susceptible backgrounds 
C57BLKS/J (BKS) develop overt hyperglycemia (Puff, Dames et al. 2011). 
1.8.2. The role of leptin in glucose metabolism and type 2 diabetes   
Leptin, a 16 kDa protein, is secreted from white adipocytes and levels correlate with adipose 
tissue mass (Halaas, Gajiwala et al. 1995; Considine, Sinha et al. 1996; Zheng, Jones et al. 1996). 
Leptin was first described to play an essential role in the regulation of energy balance, satiety, and 
Page | 35  
 
body composition (Friedman and Halaas 1998; Elmquist, Elias et al. 1999). Via leptin receptors 
(ObR) in the hypothalamic arcuate nucleus, leptin restricts food intake and increases energy 
expenditure in normal individuals (Elmquist, Elias et al. 1999). 
There is growing evidence that in addition to the hypothalamus, leptin also works at the 
level of the pancreatic beta-cells (Fehmann, Peiser et al. 1997; Seufert 2004; Marroqui, Gonzalez et 
al. 2012). Recent studies supported a bidirectional feedback loop between adipose tissue and the 
beta-cells via leptin and insulin, (Kieffer and Habener 2000; Seufert 2004). The leptin- insulin 
interrelationship, nevertheless, is complex and remains controversial (Ceddia, Koistinen et al. 2002; 
Thomas-Geevarghese and Ratner 2007). Briefly, insulin is an adipogenic hormone that enhances 
the storage of fat tissue and stimulates leptin secretion from adipocytes (Zheng, Jones et al. 1996). 
In turn, leptin is a potent inhibitor of both pancreatic insulin secretion and biosynthesis to adapt 
insulin secretion to the amount of body fat storage (Fehmann, Peiser et al. 1997; Seufert 2004). 
Therefore, leptin together with insulin are considered as key metabolic hormones of the “adipo-
insular axis” (Kieffer and Habener 2000; Seufert 2004). 
Whether leptin is an important factor that links obesity and diabetes is unknown. Obesity is 
associated with diabetes and the majority of obese people have high plasma concentration of leptin, 
suggestive of a “leptin resistance” state (Considine, Sinha et al. 1996). Indeed, diet induced weight 
loss is followed closely by a reduction in plasma leptin level and a coincidental increase in insulin 
sensitivity (Considine, Sinha et al. 1996). However, the relationship between leptin and insulin is 
not straightforward (Ceddia, Koistinen et al. 2002; Thomas-Geevarghese and Ratner 2007). A 
physiological concentration of leptin (1-10 nM) significantly suppressed insulin secretion, whereas 
high concentration (100 nM) was ineffective (Pallett, Morton et al. 1997). Therefore, it is 
reasonable to propose that under conditions of obesity and chronic hyperleptinemia, the pancreatic 
beta-cells become insensitive to the inhibitory effect of leptin, resulting in the disturbance of the 
“adipo-insular axis” which promotes hyperinsulinemia, insulin resistance and impaired glucose 
homeostasis (Kieffer and Habener 2000; Marroqui, Gonzalez et al. 2012). 
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1.9. Two-photon microscopy and its role in live-cell imaging of 
pancreatic islets 
1.9.1. Methods for examining single vesicle exocytosis    
In the field of exocytosis, measurement of secretory products released into the extracellular 
space (such as using radioimmunoassay) has been the most popular approach. Although this method 
helps to demonstrate a defect in the secretory output, it cannot pinpoint where in the pathway this 
defect occurs. Therefore, other methods have been employed to study specific steps in the secretory 
cascade especially the distal step of single granule exocytosis which requires high spatial and 
temporal resolution approaches. 
Total internal reflection fluorescence microscopy (TIRFM) uses evanescent wave of a 
totally internally reflecting laser beam to excite only those fluorescent molecules within one-light 
wavelength of the substrate surface which has shown to be useful for tracking the dynamics of 
secretory granules in the beta-cells (Axelrod 1981). However, the main disadvantage of this 
technique is its thin depth of focus, within 100 nm of the inner leaflet of the plasma membrane 
(Axelrod 1981; Ohara-Imaizumi, Nakamichi et al. 2002). 
Capacitance measurement electrically monitors the changes in cell-surface area that occur 
when secretory granules fuse with the plasma membrane (Neher and Marty 1982). This method 
bases mainly on the fact that cell capacitance measured by electrophysiological techniques is 
proportionally related to the cell surface area. Although the benefit of this approach in studying 
stimulus-secretion coupling at the cellular level cannot be denied, the crucial drawback is the 
interpretation is not straightforward. As changes in capacitance represent the sum of endocytosis 
and exocytosis, this technique cannot differentiate exocytosis from endocytosis (Zupancic, Kocmur 
et al. 1994). Also, it is better performed with single beta-cells rather than the whole intact islets.  
Another approach of the exocytosis field is amperometry (electrochemical measurement of 
monoamines by carbon fiber electrodes), originally developed by Wightman et al, which has also 
been used widely to characterise exocytic events of many secretory cells that secrete oxidative 
substances (Wightman, Jankowski et al. 1991; Haller, Heinemann et al. 1998; Mosharov and Sulzer 
2005). The transfer of electrons after monoamine oxidation results in an electrochemical current 
which is represented as an amperometric “spike” (Wightman, Jankowski et al. 1991; Haller, 
Heinemann et al. 1998). Analysis the shape of these “spikes” provides information about molecular 
steps involved in the exocytosis (Mosharov and Sulzer 2005). However, this method is affected by 
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the distance between the detector electrode and the release sites and its time course is not simply 
represent the real time course of exocytosis (Haller, Heinemann et al. 1998).  
Though the conventional confocal microscopes (single photon), originally developed by 
Marvin Minski, is a good method for imaging thin objects such as isolated cells due to its shorter 
excitation wavelengths, its performance is not appreciated in thick sample such as intact islets 
(Minsky 1988; Helmchen and Denk 2005). Besides, if it was used for quantification the fusion 
granules, the sufficient laser power to detect these small vesicles would damage the tissues 
(Paddock and Eliceiri 2014). Moreover, when imaging multiple fluorophores, one needs to switch 
between light sources in order to perform multicolor imaging. 
Lastly, electron microscope, which was first built by the German engineer Ernst Ruska in 
1931, provides additional option for investigating vesicle exocytosis. Unlike light microscopes 
which are limited by the wavelength of the light source, transmission electron microscope operates 
based on electrons rather than light which improves the resolution by thousand times (Clarke 1973). 
This high resolution is very beneficial for investigating small objects such as the secretory granules. 
However, it usually requires extensive sample preparation and tissue fixation which makes the 
technique a relative time-consuming process with a low throughput sample. Although electron 
microscopy is not highly appreciated as a stand-alone method for live-cell recordings, it is very 
useful as a supplemental approach for visualizing ultrastructure of intracellular organelles due to its 
powerful magnification (Polishchuk, Polishchuk et al. 2012).  
All things considered, direct measurement of individual steps including pre- and post-
exocytosis is still not satisfactory with the above methods (Rorsman and Renström, 2003). An ideal 
methodology should be able to track sizes of the vesicles, to reveal dynamics of hemi-fusion of two 
biological membranes, to detect the fates of fused vesicles and can be used in light-scattering 
tissues like an islet (MacDonald and Rorsman 2007). Two photon imaging fulfills many of these 
goals.  
1.9.2. Two-photon microscopy and its role in live-cell imaging of intact pancreatic islets 
Two-photon microscopy was invented more than two decades ago by Winfried Denk in the 
laboratory of Cornell University by combining the idea of two-photon absorption with the use of a 
laser scanner (Denk, Strickler et al. 1990). Unlike traditional methods including confocal 
microscopy which generate contrast from light-matter interaction and thus depend linearly on the 
incident light intensity, two-photon microscopy employs the nonlinear optical approach which uses 
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higher-order light-matter interactions with multi photon for contrast generation (Helmchen and 
Denk 2005).  
By restricting fluorophore excitation (and thus emission) to the focal plane, two-photon 
microscopy offers several advantages over the traditional methods. Firstly, the longer wavelengths 
used for two-photon microscopy are scattered significantly less than the shorter wavelength of 
confocal microscopy, leading to a deeper penetration capacity of the focused laser beam (Denk 
1996). Secondly, as out-of focus fluorescence is not generated, no pinhole is required in the 
detection path of the microscope which greatly increases the fluorescence collection efficiency and 
contrast at any given tissue depth (Denk 1996). Thirdly, with lower-energy photons this technique 
is less likely to damage the tissue outside the focal volume, and thus enables long-term imaging of 
biological specimens (Denk 1996; Svoboda and Yasuda 2006). Also, with a broad excitation-
spectrum (679-1070nm), two-photon microscopy is applicable to many fluorophores used in 
biology. Moreover, multicolor excitation capacity of the two-photon microscopy enables 
simultaneous quantification of different fluorescence events (Helmchen and Denk 2005; Takahashi 
and Kasai 2007; Nemoto 2008). In short, the major advantage of two-photon as well as other non-
linear microscopy is the ability to maintain high resolution and contrast imaging within scattering 
tissue which is of paramount importance for direct visualization of normal cellular behaviour in 
their natural environment.  
Shortly after its invention, two-photon microscope was extensively used in a wide variety of 
research fields, including the release of neurotransmitters by neurons and the secretion of digestive 
enzymes of the pancreatic exocrine cells (Denk, Strickler et al. 1990; Svoboda, Denk et al. 1997; 
Nemoto, Kimura et al. 2001; Thorn, Fogarty et al. 2004). It also inspired extensive applications in 
the field of pancreatic beta-cells to assess the exocytosis response of insulin-containing granules 
(Takahashi, Nemoto et al. 2002; Takahashi, Hatakeyama et al. 2004; Lam, Ohno et al. 2013; Low, 
Mitchell et al. 2013). 
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1.10. Hypothesis and aims 
It is known that insulin secretion changes over the course of T2D but the basis of these changes is 
unknown. I hypothesized that structural and functional modulations, particularly insulin granule 
exocytosis, occurring within the pancreatic beta-cells during disease characterise the secretory 
changes in the progression of T2D. To test this hypothesis, I used the Lepr
db
 model of type 2 
diabetes (BKS.Cg-Dock7m+/+Lepr
db
/J), with the following aims: 
1) Test whether the insulin granule fusion and exocytosis behaviours are different in pancreatic 
beta-cells of overt diabetic db/db mice compared with the wild type. 
2) Identify structural and morphological alterations in pancreatic islets and beta-cells across 
different stages of disease progression in Lepr
db
 mice. 
3) Characterise the changes in the secretory capacity of pancreatic beta-cells from prediabetes to 
early disease in the Lepr
db
 mice.  
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1.11. Thesis overview 
Extensive work over the past century has brought valuable insights into the pathogenesis 
and pathophysiology of T2D and led to treatments that make it no longer a death sentence. To date, 
the role of beta-cell dysfunction in the development of T2D is recognized but not well understood. 
Therefore, understanding the nature of insufficient insulin secretion in T2D islets is of great 
importance for curing or preventing disease. In my thesis I focus on three aspects of beta-cell 
structure and function in disease. 
Firstly, advanced imaging techniques have shed light on the area of granule fusion kinetics 
with different types of granule exocytosis identified in insulin-secreting cells such as complete 
fusion or “kiss-and-run” exocytosis (Tsuboi and Rutter 2003; MacDonald, Braun et al. 2006; 
Hanna, Pigeau et al. 2009). However, to what extent if any that these fusion-granule behaviours 
contribute to the pathology of T2D especially in the context of an intact islet is not yet clear. 
Therefore, in chapter 3, using the live-cell two-photon assay to visualize the fusion of individual 
granules, I investigated the changes in granule fusion kinetics in intact islets of overt diabetes db/db 
mice. 
Secondly, diabetes especially T2D is a progressive disease (Weir, Laybutt et al. 2001; Weir 
and Bonner-Weir 2004; Prentki and Nolan 2006; Fonseca 2009). Performing the glucose tolerance 
test on single db/db mice, each mouse was classified into one of four stages of disease from 
prediabetes (stage 1) to severe diabetes (stage 4). Even though there is evidence for increased beta-
cell mass in early disease of db/db mice (Dalbøge, Almholt et al. 2013), the underlying 
morphological changes of the pancreatic islet and beta-cell over the disease course are unclear 
which will be addressed in chapter 4.  
Finally, current studies investigate mainly the pathology of established diabetes which is 
useful but not enough to decelerate the disease epidemic. Understanding primary alterations at the 
very beginning stage of the disease will be imperatively required given that this knowledge could 
translate into better preventative therapy for T2D or at least prolong the pre-diabetes stage of 
genetically predisposed individuals. Currently, it remains ambiguous whether the increased 
glucose-induced overall insulin secretion of insulin resistant subjects is due solely to larger beta-cell 
mass or also the secretion of individual beta-cells (Polonsky, Given et al. 1988; Weir and Bonner-
Weir 2004). Therefore, chapter 5 focuses on functional changes of pancreatic beta-cell in 
prediabetes as well as the transition from prediabetes to early disease in the Lepr
db
 model.  
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CHAPTER 2 
MATERIALS AND METHODS 
 
 
 
 
 
 
Part of this chapter (2.3 and 2.7) was adapted and modified from the following paper: 
 
Do, H.O., Low, J.T., Thorn, P. 2015. Lepr
db 
Mouse Model of Type 2 Diabetes: Pancreatic Islet 
Isolation and Live-Cell two-photon Imaging Of Intact Islets. J. Vis. Exp.e52632, 
doi:10.3791/52632. 
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2.1. Lepr
db
 colony and glucose tolerance test 
2.1.1 Leprdb colony 
The leptin receptor-deficient (db/db) mice were used as a model for T2D. Homozygous 
(db/db), wild type (WT, +/+) and heterozygous (HET, db/ +) mice were generated from breeding 
pairs of BKS.Cg-Dock7m WT Lepr
db
/J heterozygous mice purchased from Jackson Laboratory (Bar 
Harbor, Maine, USA). Mice were supplied with a normal diet under standard animal house 
conditions and kept at the Australian Institute for Bioengineering and Nanotechnology building of 
the University of Queensland. All mice were identified by polymerase chain reaction (PCR) tissue 
type analysis for the leptin-receptor upon weaning. Mice of both sexes, 13-18 weeks of age were 
used, except where indicated. 
2.1.2  Glucose tolerance test 
Glucose 25% was prepared in Milli-Q water, autoclaved in a glass bottle, aliquoted into 
sterile eppendorf tubes and stored at -20
o
C. 
After the overnight fast (5pm to 9am), mice were weighted and the dose of glucose was 
calculated based on the mouse’s body weight (1g/kg body weight; ie. 100μl of glucose 25% for a 
25g mouse). Glucose solution was warm up to room temperature and loaded into a 1 ml insulin 
syringe ready for injection. The mouse’s tail was dipped into bupivicaine (0.25%) for local 
anaesthesia before snipping (~1 mm). FBG was obtained by the Accu-check Active (Roche) 
glucometer with a small drop of blood (~5 μl) from the tail tip. Then, glucose 25% was slowly 
injected intraperitoneally and blood samples from the tail tip were taken at 15, 30, 60, 90 and 120 
minutes after the injection for measuring blood glucose. At the end of the test, mice were provided 
with food as normal and returned to the animal house. 
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2.2. Islet isolation and culturing   
2.2.1. Reagent preparation 
Mixture of enzymes: For the pancreatic digestion, a mixture of liberase and collagenase type 
IV was used. Liberase TL (thermolysin low) (Roche) was dissolved in DMEM (Dulbecco’s 
Modified Eagle Medium) at a concentration of 0.192 mg/ml (1 vial of 5 mg in 26 ml of DMEM). 
Collagenase type IV was prepared in Hank’s buffer (Sigma Aldrich, Australia) at a concentration of 
0.5 mg/ml, supplemented with 5 mM HEPES, 0.5 mM CaCl2, 0.1 mg/ml DNAse and 1 mg/ml 
bovine serum albumin (BSA). Liberase TL and collagenase solutions were mixed in a ratio of 4:1 
(by volume). The enzyme mixture was divided into aliquots of 2.5 ml and store at -20
0
C. 
RPMI isolation media: One vial of RPMI 1640 powder (Sigma Aldrich, Australia) was 
dissolved in 1 litre of MilliQ water in a large conical flask, supplemented with 2 g NaHCO3, 4.02 g 
HEPES, adjusted to pH 7.4 with NaOH, filter sterilized and stored at 4
0
C. 
RPMI culture media: RPMI culture media (Gibco, Life Technologies, Vic, Australia), 
supplemented with 10% fetal bovine serum (Gibco, Life Technologies, Vic, Australia) and 1% 
antibiotics (i.e. penicillin 100 U/ml, streptomycin 100 μg/ml) (Gibco, Life Technologies, Vic, 
Australia). The culture media was divided into several 50 ml conical tubes and stored at 4
o
C. 
2.2.2. Islet isolation 
Mice (13-18 week-old) were sacrificed by carbon dioxide asphyxiation according to the 
animal ethics procedures of the University of Queensland (approved by the University of 
Queensland, Anatomical Biosciences Ethics Committee). The mouse body was sprayed thoroughly 
with 70% ethanol.  
Two long cuts were applied laterally through the abdominal skin and peritoneum to make a 
V-shaped flap. The flap of the skin was pulled up to uncover the entire abdominal cavity, the bowel 
was put aside and the liver was kept in place by a folded tissue paper to reveal the common bile 
duct. The animal was put so that the head toward the surgeon and the tail away from the surgeon. A 
vascular clamp was applied at the ampulla on the duodenum wall to block the injected enzymes 
from entering the duodenum (Figure 2.1A). The common bile duct was cannulated with a 31G 
needle near the junction of the common hepatic duct and cystic duct which leaves room for a 
second injection if the pancreas fails to perfuse the first time. About 2 ml of cold enzyme mixture 
was slowly injected into the mouse common bile duct. The pancreas will be perfused quickly if the 
clamp is in the right position (Figure 2.1C).  
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Figure 2.1: Pancreatic perfusion for islet isolation (Do, Low et al. 2015) 
(A.) Diagram of the sites of clamping and injection 
(B, C) The pancreas before and after the perfusion with the enzyme mixture 
After the pancreas was perfused, the pancreas was removed quickly, put into a glass vial and 
incubated for ~19 minutes in a 37
0
C water bath. After the incubation time, the digesting process 
was stop by adding ~20 ml of cold isolation media. The vial was shaken gently to disrupt the 
pancreas and pour through a normal tea sieve (pore diameter of 1 mm) into a sterile 50 ml tube. The 
tube was topped up with isolation media and centrifuged at 1500 rpm for 1 minute at 4
0
C with 
brake off. The pellet was dissolved in the isolation media again and transferred to two 15 ml tubes, 
then centrifuged at 1500 rpm for 1 minute at 4
0
C with brake off. After aspiration the supernatant, 
each pellet was mixed well with 6 ml of Histopaque 1077 solution (Sigma Aldrich, Australia) by 
pipetting up and down, then ~6 ml of the isolation media was gently add to the side of the tube on 
top of the Histopaque and centrifuged at 700 rpm for 10 minutes at 4
0
C with brake off. The 
supernatant was collected in separated petri disks and the islets were handpicked using a pipette 
under a dissecting microscope. The middle layer contains most of the islets (Figure 2.2). 
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Figure 2.2: Wild type islets right after isolation under a dissecting microscope 
2.2.3. Islet culturing 
To help the islets recover from the enzyme digestion, groups of 40 islets was cultured in a 
25 cm petri dish with 6 ml RPMI culture media (10 mM glucose) at 37
0
C, 5% /95% CO2/O2 for 2 
days before performing functional experiment including insulin assay, intracellular calcium 
measurement and live-cell two-photon imaging. The cultured media was changed daily. 
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2.3. Homogeneous time resolved fluorescence insulin assay 
2.3.1. Assay principle and set up 
The homogeneous time resolved fluorescence (HTRF) with reagents supplied by Cisbio 
(HTRF Insulin Kit, cat. no. 62INSPEB, QLD, Australia) was used to measure the insulin secretion. 
This is a sandwich immunoassay that involves two monoclonal anti-insulin antibodies, one labeled 
with europium cryptate and the other with XL665, that recognize distinct epitopes of insulin. 
Whenever a sandwich is formed with insulin molecules, the two antibodies come into close 
proximity allowing the transfer of energy between a long-lived fluorescence donor (cryptate, 
emission 620 nm) and the short-lived fluorescence acceptor (XL665, emission 665 nm), both were 
excited at 320 nm (Figure 2.3). This Fluorescence Resonance Energy Transfer (FRET) phenomenon 
increases proportionally with the insulin concentration. 
One unique feature of this assay is the time delay (150 μs)  in signal measurment after 
excitation  which allows the recognization of the long-lived signal generated by donor-acceptor pair 
rather than other prompt fluorecene generated  from free acceptor molecules and media 
componenents. Another characteristics of the HTRF asssay is its ratio measurement (665:620nm) 
which minimizes the interference from buffer componens and compounds (Jia 2008; Degorce, Card 
et al. 2009). 
 
Figure 2.3: HTRF insulin assay (Degorce, Card et al. 2009). 
(A) The two antibodies labeled with cryptate and XL665 recognizing distinct epitopes of insulin 
molecule. 
(B) When the donor and acceptor apart, there is no FRET signal but when they are brought in 
proximity, the FRET signals are generated. 
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All kit reagents including insulin standard, insulin control, anti-insulin antibody cryptate and 
anti-insulin antibody XL665 were reconstituted according to the Cisbio insulin kit instructions, 
aliquoted into eppendorf tubes and stored at -20
0
C. Assay calibrators were prepared using the 
insulin standard supplied in the kit with serial dilutions in fresh sodium-rich extracellular buffer 
(ECB) containing 0.2% BSA. This fresh ECB was also used as a negative control reference.  
2.3.2. Insulin measurement 
Freshly prepared sodium-rich extracellular buffer (ECB) (140 mM NaCl, 5 mM KCl, 2.5 
mM CaCl2, 1 mM MgCl2, 5 mM NaHCO3 and 10 mM HEPES, adjusted to pH 7.4 with NaOH) was 
used for HTRF insulin assay. 
Briefly, for each sample, 10 μl of islet supernatant, 5 μl of anti-insulin Europium cryptate 
and 5 μl of anti-insulin XL665 were sequentially added to a 384 well plate (Perkin Elmer Proxiplate 
384-Plus). The plate was covered with a parafilm sheet to prevent evaporation and incubated on lab 
bench for 18 hours before reading on an Infinite 200 PRO (Tecan group Ltd.) machine with the 
Magellan
TM
 software (Tecan group Ltd.). Insulin concentrations (ng/ml) for each well were 
determined using insulin standard curves. The sensitive range protocol (0.2-10 ng/ml) was used for 
pancreatic beta-cell supernatants. 
 Islet insulin secretion 
 Prior to the HTRF assay, islets were pre-incubated in the ECB containing 3 mM glucose at 
37
0
C, 95/5% air/CO2 for 30 minutes to allow sufficient time for adjustments in metabolism to 
occur. Thereafter, groups of three islets were transferred to individual eppendorf tubes containing 
ECB, 0.2% BSA and a stimulus such as glucose (3 mM/ 15 mM), high potassium (50 mM, 
isosmotic substitution with NaCl) or ionomycin (5 μm) (Sigma Aldrich, Australia). The tubes were 
incubated (37°C, 95/5% air/CO2) for 20 minutes, then supernatants from each tube were collected 
and used for HTRF insulin assay.  
Islet insulin content 
At the end of the experiment, after supernatants were taken for insulin measurement, the 
remaining islets were subjected to insulin extraction with acid ethanol mixture (71.25 volume % of 
ethanol, 1.5 volume % of concentrated HCl and 27.25 volume % of water). Group of three islets in 
each eppendorf tube was extracted by sonication in 150 μl acid ethanol overnight at 40C. This 
extraction supernatant was further diluted 50 times with ECB before measurement. 
Pancreas insulin content 
Page | 48  
 
For each mouse, a piece of pancreas (~10-20 mg) was removed from the middle part of the 
pancreas upon opening the mouse’s abdominal cavity for islet isolation. This piece of pancreatic 
tissue was weighted and homogenized in an eppendorf tube with a homogenizer in 200 μl of acid 
ethanol solution and incubated for 48 hours at 4
o
C. The tube was centrifuged at 5000 rpm for 10 
minutes at 4
0
C and the supernatant was transferred into another tube, diluted 200 times in ECB 
prior to the insulin measurement.  
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2.4. Intracellular calcium assay 
2.4.1. Measurement of intracellular calcium levels 
For intracellular calcium measurement, the ratiometric calcium indicator Fura2-AM 
(Molecular Probes, Life Technologies, Vic, Australia) was used. The main advantage of this 
ratiometric measurement is the cancellation of artifactual variations in the fluorescence signal such 
as photo-bleaching, leakage, non-uniform loading and variable cell thickness.  
Firstly, 2 mM Fura-2AM stock in dimethyl-sulfoxide (DMSO) was prepared and stored at -
20
0
C. 10% pluronic acid stock (Invitrogen, Life Technologies, Vic, Australia) was prepared in 
DMSO and stored at room temperature. On the day of the experiment, the pluronic acid was 
warmed up to 42
0
C, mixed well 2 μl of Fura2-AM 1 mM with 2 μl of pluronic acid 10% in an 
eppendorf tube before adding into 1 ml of ECB to make up the loading buffer (4 μm Fura-2-AM, 
0.02% pluronic acid). 
Two-day cultured islets were placed into this Fura-2 loading solution containing 3 mM 
glucose and incubated (37
0
C, 95/5% air/CO2) for 30 minutes. After labeling, the islets were washed 
and incubated in an ECB containing 3 mM glucose for an additional 2 minutes. Then single islets 
were transferred to a small chamber containing 500 μl of ECB (3 mM glucose), mounted on the 
stage of an inverted fluorescence microscope with a 25x objective (Nikon Diaphot 200). The whole 
islet was alternatingly excited at 340 and 380 nm, and the ratio was collected at 490 nm. Images 
were acquired every 7 seconds for 20 minutes with a digital camera using a filter wheel (Sutter 
Instrument Lambda 10-3, CA, USA) equipped with 340 and 380 nm. Basal readings were taken for 
3 minutes at 3 mM glucose before stimulus was added into the chamber to make up the final 
stimulation concentration of 15 mM glucose, 50 mM KCl (isosmotic substitution with NaCl) or 5 
μm ionomycin. 
Data were acquired and analyzed with the Metamorph software (Molecular Devices 
Corporation, CA, USA). To convert the set of ratio images into time-lapse calcium measurements 
for individual islets, choose a region of interest (ROI) that cover the whole islet area and play the 
movie of the images to verify that the islets do not move during the course of the experiment. 
Intracellular calcium concentrations ([Ca
2+
]i) was determined from the fluorescence ratio (R) of 
Ca
2+
-bound Fura-2 (excited at 340 nm) to unbound Fura-2 (excited at 380 nm) after background 
subtraction. 
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2.4.2. Calibration of intracellular calcium concentrations 
However, for quantitative evaluation of [Ca
2+
]i from fluorescence intensity measurements, 
calibration must be undertaken using a standard equation (Grynkiewicz, Poenie et al. 1985): 
 [Ca
2+
]i  (nM)= Kd * (R-Rmin) / (Rmax-R) * Sf2/Sb2 
Where Kd is the dissociation constant for the Fura2-calcium binding which is about 225 nM 
in normal condition, Rmin and Rmax are the ratio values measured in the absence or in the saturating 
of calcium respectively, Sf2 and Sb2 are fluorescence intensity values of the denominator wavelength 
(380 nm) in the calcium free or calcium-saturating conditions respectively. In order to obtain these 
calibration values, dispersed beta-cells were exposed to extracellular buffer containing 0 mM Ca
2+ 
and
 
5 mM EGTA (calcium-free) or 10 mM Ca
2+ 
and 5 μM ionomycin (calcium-saturating) 
environment (Figure 2.4B). The calibration values obtained within our recording system were as 
follow: Rmin = 0.049869, Rmax = 0.320826, Sf2 = 879.2985 and Sb2 = 216.943. 
    
    Figure 2.4: Calibration of intracellular calcium levels 
(A) Fura2-labelled pancreatic beta-cells excited at 380nm. 
(B) [Ca
2+
]i expressed as fluorescence ratio under the calcium-free and calcium-saturating 
conditions. 
(C) Represents the calcium measurement of a WT islet before calibration 
(D) Represents the calcium measurement of the same islet after calibration. 
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2.5. Real-time polymerase chain reaction 
Right after isolation, WT or db/db islets were washed in phosphate buffered saline (PBS), 
transferred to an eppendorf tube and stored at -80
0
C for ribonucleic acid (RNA) extraction. Total 
RNA from WT and db/db islets was extracted at the same time using the RNeasy plus micro kit 
(Qiagen, USA.) according to the manufacturer’s instruction and quantified at OD 260/280 by 
spectrophotometer (NanoDrop, Thermo Scientific, Australia).  
Complementary deoxyribonucleic acid (cDNA) was synthesized from 100 ng of total RNA 
using the superscript III reverse transcriptase (Invitrogen, Life Technologies, Vic., Australia) in a 
20 μl reaction volume following the provider’s protocol. Briefly, RNA was denatured at 65°C for 5 
minutes with random hexamers and dNTP mix before adding the cDNA synthesis mix (2 μl 10x RT 
buffer, 4 μl 25 mM MgCl2, 2 μl 0.1M DTT, 1 μl RNaseOUT
TM 
40 U/μl , 1 μl SuperScript III RT 
200 U/μl). The tubes were then incubated at 250C for 10 minutes before the reaction was carried at 
50°C for 50 minutes followed by enzyme inactivation at 85°C for 5 minutes.  
The SYBR green qPCR method was used with the following mouse specific primers (Life 
Technologies, Australia or Sigma Aldrich, Australia): 
Target gene Forward primer Reverse primer 
18S 5’- TCGAGGCCCTGTAATTGGAA-3’ 5’- CCCTCCAATGGATCCTCGTT-3’ 
SLC2A2 5’-TCAGAAGACAAGATCACCGGA-3’ 5’-GCTGGTGTGACTGTAAGTGGG-3’ 
Cacna1c 5’-TCCTGAACTCCATCATCAAG-3’ 5’-CTGCCGGAACATCTATTATG-3’ 
Cacna1d 5’-GTTAATGATGCGATAGGATGG-3’ 5’-GAATTCTCCACTAAGGACAC-3’ 
SNAP25 5’-GGACTTTGGTTATGTTGGATG-3’ 5’-GGATTTAAGCTTGTTACAGGG-3’ 
syntaxin-1A 5’-AGATGATTGACAGGATCGAG-3’ 5’- GTGGTTTCTATCCAAAGATGC-3’ 
VAMP2 5’-ATCATCGTTTACTTCAGCAC-3’ 5’-TGAAAGATATGGCTGAGAGG-3’ 
A 20 μl reaction was used with 2 µl cDNA, 0.8 µl of 10 µM forward primer, 0.8 µl of 10 
µM reverse primer, 10 µl 2x SYBR green master mix and 6.4 µl RNase-free water. The component 
was mixed thoroughly in a micro tube and dispensed into the appropriate wells in a 96 well PCR 
plate before adding cDNA. The plate was sealed with an optical adhesive cover and briefly 
centrifuged to spin down the contents and eliminate air bubbles. All samples were run in duplicate 
and 18S was used as the endogenous control. Real-time PCR was carried by the Applied 
Biosystems- Quantstudio
TM
 6 Flex real-time PCR system with samples holding at 50°C for 2 
minutes, 95°C for 10 minutes, and 40 cycles at 95°C for 15 seconds and 60°C for 1 minute. Results 
were analyzed according to the arithmetic formula of the comparative Ct method (fold difference = 
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2
−ΔΔCt, ΔΔCt = ΔCt db/db sample – ΔCt WT sample). mRNA level of the gene of interest was 
presented as the fold difference between db/db and WT islets. 
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2.6. Live cell two-photon imaging  
2.6.1. Reagent preparation 
Extracellular buffer (ECB): 140 mM NaCl, 5 mM KCl, 2.5 mM CaCl2, 1 mM MgCl2, 5 mM 
NaHCO3 and 10 mM HEPES, adjusted to pH 7.4 with NaOH.  
Extracellular dye: stock sulforhodamine-B (SRB, 8 mM) and 8-Hydroxy-pyrene-1,3,6- 
trisulphonate (HPTS, 8 mM) was prepared in ECB, aliquoted into small tubes and stored at -20
0
C. 
The stock SRB/ HPTS was diluted 1:10 in fresh ECB to get a working concentration of 0.8 mM. 
2.6.2. Two-photon imaging 
A glass slide was placed onto the thermo-control chamber mounted on the microscope stage.  
Grease was used to prevent the leaking of solution. The chamber was covered with 500 μl of ECB 
containing 0.8 mM SRB with different glucose concentrations (3 mM, 6 mM, 15 mM or 20 mM) or 
high potassium (50 mM KCl). Two-day cultured islets were pre-incubated in 3 mM glucose ECB 
for 30 minutes (37°C, 95/5% O2/CO2). The pre-incubated islet was then put into the middle of the 
chamber and focused to 3-4 cell layers into the islet where, in rodent islets, immunostaining for 
insulin shows that most cells are beta-cells. The SRB dye will outline all the cell membrane of the 
islet quickly and the islet is ready to image. 
A custom-made, microscope with a 60x oil immersion objective (NA1.42, Olympus, NSW, 
Australia) was used together with a femtosecond laser source and the Matlab software (Figure 2.5). 
Exocytic events were imaged using SRB as a membrane impermeant fluorescent extracellular 
marker excited by femtosecond laser pulses at 880 nm, with fluorescence detected at 550-650 nm. 
Two-photon imaging was recorded at a speed of 3 frames per second for 20 minutes at 34
o
C.   
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Figure 2.5: The custom-made two-photon microscopy (Do, Low et al. 2015). 
(A) Main components of the two-photon microscope. 
(B) The custom-made two-photon microscope. 
Images (resolution 10 pixels/μm) were analyzed with the Metamorph program (Molecular 
Devices Corporation, Sunnyvale, CA, USA). Exocytic events were identified by the sudden 
appearance of a small fluorescent spot reflecting the entry of extracellular SRB into the fused 
granules which was confirmed by the fast rising phase of the fluorescent signal over a region of 
interest (ROI) (~0.78 μm2) (Figure 2.6). Traces were rejected if extensive movement was observed. 
 
 Figure 2.6: Insulin-granule fusion event recorded with two-photon microscopy 
 (A) The cell before and (B) after the appearance of an exocytic event (arrow) in response to 15mM 
glucose 
(C) illustrates the entering of the extracellular dye SRB into the granule when it fuses with the plasma 
membrane. 
 (D) shows the fluorescence intensity over a ROI of an exocytic event as well as the sequential images of 
this exocytic event (scale bar 1 μm).  
This indirect assay has advantages. It is a sensitive assay capable of recording single 
exocytic events from many cells within intact islets with high spatial and temporal resolution. 
Moreover, it does not involve labelling of heterologously expressed proteins or loading of tracers 
into the cell. Within the time of recording, we identify all the exocytic events in response to the 
stimulus and characterise the location of the events, the time of the appearance, the duration and 
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type of the fusion events like “kiss-and-run” or full fusion. These characteristics of the fusion 
process are valuable for assessing any defect in the granule fusion in models of T2D. We have 
found that the number of granule fusion events and their timing is consistent with the amounts and 
temporal profile of insulin secretion (Low, Mitchell et al. 2013). This suggests the method detects 
the majority of insulin granule fusion events. Given that dye entry into the fusing granules is not a 
specific method for detecting insulin granule fusion events, various experiments have been carried 
out to validate this assay as a measurement of fusion of insulin-containing granules like the glucose 
dose dependent of increasing number of granule fusion events with the expected amount of insulin 
secretion, the consistent size of the responded cells in the two-photon with that of a beta-cell, the 
similar granule diameter measured by the two-photon and the electron microscope, the 
colocalization of the dye uptake and insulin staining. However, a component of this evidence is 
dependent on the structure of the rodent islet where beta-cells are enriched in the core of the islet 
(Low, Mitchell et al. 2013; Do, Low et al. 2014).   
To quantify the percentage of re-acidified (or “kiss-and-run”) fusion events, both SRB, a pH 
insensitive dye (excited at 950 nm, detected at 550-650 nm), and HPTS (8-Hydroxy-pyrene-1,3,6- 
trisulphonate), a pH-sensitive polar tracer (excited at 950 nm, detected at 420-520 nm) were 
employed. Under normal condition, the V-type H
+
-ATPase on the vesicle membrane of the insulin-
containing granule pumps H
+
 into the secretory vesicles and acidifies them to a pH around 5-6 
which provides optimal condition for the crystallization of zinc-insulin hexamers (Hutton 1982). 
When the secretory vesicles fuse with the plasma membrane, the acidic pH of the granule would be 
rapidly neutralized by equilibration with the extracellular environment (pH 7.4). However, when the 
fused granules are recaptured (prematurely closed), they are re-acidified by the proton pumps on the 
vesicle membrane which suppress the fluorescent signal of HPTS (pH sensitive) but not SRB (pH 
insensitive) (Figure 2.7). It is worth noting that this assay could only identify re-acidified granules 
when the fusion pore has closed for a sufficient time for the proton pumps to induce a considerable 
intra-granular pH change. 
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Figure 2.7: Re-acidification of the recaptured granule (“kiss-and-run” exocytosis) 
Normally, the proton pumps acidify the insulin-granules. This granule-acidification is neutralized by 
equilibration with the extracellular environment upon fusion with the plasma membrane. When the 
granules are recaptured, they will be re-acidified by the proton pumps on the vesicle membrane reflecting 
by the drop in the pH-sensitive HPTS signal. 
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2.7. Immunofluorescence staining 
Right after isolation, groups of 6-8 islets were transferred to a staining dish containing small 
volume (100 μl) of PBS. After washing in PBS, these islets were fixed with 100 μl of 4% 
paraformaldehyde for 15 minutes and blocked in a blocking buffer containing 3% donkey serum, 
3% BSA and 0.3% Triton X for 1 hour at room temperature. Islets were then incubated at 4
0
C 
overnight with the following primary antibodies diluted in blocking buffer: mouse anti-SNAP25 
(Synaptic Systems, Germany, 1:200); mouse anti-VAMP2 (Synaptic Systems, Germany, 1:200); 
mouse anti-Syntaxin-1A (Synaptic Systems, 1:200); mouse anti-neurogenin3 (BD Pharmingen
TM
, 
Australia, 1:200), mouse anti-Oct3/4 (BD Pharmingen
TM
, Australia, 1:200), rabbit anti-Ki67 (Sigma 
Aldrich, Australia, 1:200),  rabbit anti-glucagon (Sigma Aldrich, Australia, 1:200), rabbit anti-
insulin (Cell Signaling, Australia, 1:200) or guinea-pig anti-insulin (Abcam, Australia, 1:200). In 
the next morning, islets were washed 3 times in PBS and incubated for 3 hours at room temperature 
with the following secondary antibodies diluted in blocking buffer: Alexa Fluor 488 donkey anti-
mouse (Invitrogen, 1:200), Alexa Fluor 546 donkey anti-rabbit (Invitrogen, 1:200) and Alexa Fluor 
633 goat anti-guinea pig (Invitrogen, 1:200). Nuclear staining was obtained by including DAPI 
(Sigma Aldrich Australia, 100 ng/ml final concentration) in the blocking buffer together with 
secondary antibodies. After washing 3 times in PBS, these islets were transferred by pipetting to a 
slide containing a drop of prolong anti-fade (Invitrogen, Life Technologies, Australia) and covered 
with a coverslip. The edge of the coverslip was sealed with nail polish for better sample 
preservation. Images were obtained on an Olympus Fluo View FV1000 upright confocal 
microscope with a 60x oil, 1.4 NA objective.  
Each pairs of WT and db/db islets were isolated on the same day, fixed right after isolation 
and simultaneously processed. For the data acquisition, the settings were calibrated to image below 
the saturating level of fluorescence intensity for each pair of WT and db/db samples across 6 z-
stacks (1.5 μm apart), starting from the plane closest to the coverslip. Quantification of 
immunofluorescence intensity was performed in pairs to control for variations in experiment 
conditions and imaging settings from different days, using the Metamorph software (Molecular 
Devices Corporation, CA, USA). For the insulin and SNARE proteins (SNAP25, VAMP2, 
Syntaxin-1A), average intensities taken from z-stacks within the whole islet area of the db/db were 
expressed as percentage of the paired WT’s intensity. Whereas, for the Neurogenin3, Oct3/4, Ki67 
and glucagon, the number of cells that positive for these markers were normalized by the total 
number of DAPI positive cells in the middle z of each sample. 
For the islet cell size, the total area of individual islets in a focal plane (μm2) was measured 
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using the immunofluorescent image of islets stained for insulin and glucagon. This figure was then 
divided by the total number of islet cells of that focal plane counted with DAPI staining to give the 
islet cell size (μm2). 
2.8. Electron microscopy imaging 
After two-day in culture, db/db and WT islets were pre-incubated in ECB containing 3 mM 
glucose at 37
0
C, 95/5% air/CO2 for 30 minutes. These islets were then stimulated in ECB 
containing 15 mM glucose, 0.2% BSA for 7 minutes at 37
0
C, 95/5% air/CO2 before fixing with 
2.5% glutaraldehyde for 1 hour at room temperature. Fixed islets were then kept at 4
0
C overnight 
and sent to the centre of microscopy and microanalysis (Australian Institute for Bioengineering and 
Nanotechnology, the University of Queensland, Australia) for processing as per the unit’s 
established protocol. 
Briefly, fixed islets were washed in PBS and double post-fixed by using 2% OsO4 with 
1.5% potassium ferricyanide followed by 1% thiocarbohydrazide and then another 2% OsO4. 
Samples were stained overnight with 1% uranyl acetate and then for 1 hour at 60
oC in Walton’s 
lead aspartate. They were then serially dehydrated with acetone and then embedded with Durcapan 
resin and polymerised. Individual islets were cut out of the resin, mounted and then imaged and 
sectioned using a Zeiss Sigma SEM fitted with a 3View (Gatan, CA, USA) at 2.25kv and 10Pa. The 
machine will collect the image of the block-face, and then the microtome will cut the sample 
exposing the next layer of sample to be imaged 50 nm below the surface. This sectioning and 
imaging process is automatically repeated over long period of time to obtain high-resolution 3-
dimensional images of the islets.  
Data analysis including quantification of insulin-containing granule size and density was 
obtained by the Metamorph software (Molecular Devices Corporation, CA, USA). For three 
dimensional reconstruction and modeling of the compound exocytosis events, the open-source imod 
software developed by the Boulder laboratory (University of Colorado, Boulder, CO 80309) was 
used.   
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CHAPTER 3: 
 
DYNAMICS OF INSULIN GRANULE FUSION 
IN INTACT ISLETS OF DIABETIC LEPR
DB
 MICE 
 
 
 
 
 
This chapter was reproduced from the following paper: 
 
Do, O. H., Low, J. T., Gaisano, H. Y. & Thorn, P. 2014. The secretory deficit in islets from db/db 
mice is mainly due to a loss of responding beta-cells. Diabetologia, 1-10. 
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Abstract 
Aims/hypothesis Lepr
db
 model of type 2 diabetes was used to determine the nature of the secretory 
defect in intact diabetic islets and to test the prevalent hypothesis that insulin-granule fusion 
behaviour changes in disease. 
Methods Glucose tolerance was compared in db/db and wild-type (WT) mice. Isolated islets were 
used to measure insulin secretion, intracellular calcium and immunofluorescence of soluble N-
ethylmaleimide-sensitive factor attachment proteins (SNAREs). Moreover, using a two-photon live-
cell assay, the fusion granule behaviours were compared between db/db mice and the WT. 
 Results 13-18 week-old frank diabetic db/db and WT mice were used. Isolated db/db islets showed 
a 77% reduction in insulin secretion induced by 15 mM glucose and reductions in the amplitude, 
and rise-time of the calcium response to glucose. Ionomycin induced insulin secretion in WT but 
not db/db islets. Immunofluorescence showed an increase in the levels of the SNAREs 
synaptosomal-associated protein 25 (SNAP25) and vesicle-associated membrane protein 2 
(VAMP2) in db/db islets, but reduced syntaxin-1A. Therefore, db/db islets have both a 
compromised calcium response to glucose and a compromised secretory response to calcium.    
  Two-photon microscopy of isolated islets examined the number, the distribution and the 
fusion-pore dynamics of insulin granule exocytic events. Compared with WT, db/db islets showed 
far fewer exocytic events (an 83% decline at 15 mM glucose). This decline was due to a 73% loss 
of responding cells and, in the remaining responsive cells, a 50% loss of exocytic responses per cell. 
On the other hand, two-photon assay revealed no difference in the granular lifetime and post-fusion 
fluorescent intensity between WT and db/db islets. An assay measuring granule re-acidification 
showed evidence for more “kiss-and-run” exocytosis in db/db islets (increased by 5% compared 
with WT) which may involve but cannot play a dominant role in the secretory deficit of db/db 
islets. 
Conclusions The results indicated that db/db had a reduced calcium response to glucose and a 
reduction in syntaxin-1A. Within the db/db islets changes are manifest as both a reduction in 
responding cells and a reduction in insulin-granule fusion events per cell with a small increase in 
“kiss-and-run” exocytosis.  
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3.1 Introduction 
The db/db leptin receptor mutant mouse is a model for T2D (Lee, Proenca et al. 1996). The 
animals gain weight, develop insulin intolerance and reduced insulin secretion (Berglund, Frankel 
et al. 1978). The explanation for this reduction in secretion, as in T2D, is still not clear, but may 
include: loss of islets, loss of beta-cells (Baetens, Stefan et al. 1978), loss of insulin content 
(Boquist, Hellman et al. 1974; Berglund, Frankel et al. 1978; Ishida, Takizawa et al. 2004) or 
reduced exocytic capacity. Direct comparison shows the proportionate loss of secretion parallels the 
loss of insulin content; ~4.5 to 6 fold for both (Boquist, Hellman et al. 1974; Ishida, Takizawa et al. 
2004). However, even though content is reduced, there is still more insulin present than that 
required to maintain normoglycemia (Boquist, Hellman et al. 1974). This suggests defects in insulin 
secretion are important in disease; an idea supported by work in humans (Marchetti, Del Guerra et 
al. 2004; Rosengren, Braun et al. 2012) and in other models of T2D, such as the Goto-Kakizaki 
(GK) rat (Nagamatsu, Nakamichi et al. 1999; Rose, Efendic et al. 2007). 
The reduced insulin secretion could arise because of defects anywhere along the complex 
stimulus-secretion cascade. In db/db mice there is evidence for reduced GLUT2 expression 
(Thorens, Wu et al. 1992; Brenner, Gromada et al. 2003; Kjørholt, Åkerfeldt et al. 2005; Chan, 
Luzuriaga et al. 2013), and reduced ATP production (Brenner, Gromada et al. 2003). The next step 
in the cascade is the calcium response. In db/db mice, both the size (Brenner, Gromada et al. 2003), 
and the temporal profile of the calcium response are altered (Roe, Philipson et al. 1994). Most 
recently, in other models of disease, there is evidence for a mis-positioning of calcium channels 
relative to the sites of insulin granule fusion (Rose, Efendic et al. 2007; Hoppa, Collins et al. 2009).  
The final step of granule fusion is dependent on the soluble N-ethylmaleimide-sensitive 
factor attachment proteins (SNAREs). In db/db islets mRNA for SNAP25 and VAMP2 increase and 
syntaxin-1A decreases (Kaneko, Ueki et al. 2010). This contrasts with the GK rats, in which all 
these SNAREs decrease (Nagamatsu, Nakamichi et al. 1999; Gaisano, Ostenson et al. 2002).  
Functional studies in the GK rat, showed a reduction in insulin granule fusion (Ohara-Imaizumi, 
Nishiwaki et al. 2004). It has been suggested that different modes of fusion might be prevalent in 
models of “acute” disease that use high glucose or palmitate exposure (Tsuboi, Ravier et al. 2006; 
Olofsson, Collins et al. 2007). Here, transient granule fusion, often termed “kiss-and-run”, could 
preferentially release low molecular mass compounds and only partially release insulin (Eliasson, 
Abdulkader et al. 2008). If this was the prevalent form of granule fusion in disease this could 
explain the reduction in insulin secretion. However, the relevance of full fusion or “kiss-and-run” 
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fusion in islets is questioned (Takahashi, Kishimoto et al. 2002; Ma, Bindokas et al. 2004) and 
possible roles are not known in animal models of disease.     
Within the intact islet it is known that the structural and physical relationships between the 
cells are important for secretion (Halban, Wollheim et al. 1982), and are factors that change in 
disease (Boquist, Hellman et al. 1974; Baetens, Stefan et al. 1978). To understand beta-cell 
secretory function within an islet we have developed a live-cell two-photon assay to measure single 
insulin granule fusion events (Low, Mitchell et al. 2013). We have validated this method on WT 
islets to prove that it measures insulin granule fusion and that the time-course and number of fusion 
events fully accounts for the measured amount of insulin secretion (Low, Mitchell et al. 2013). 
While the method lacks the temporal resolution of capacitance measurement (Gopel, Zhang et al. 
2004), its key advantage is that it records responses from all cells within the two-photon image 
slice. 
Using this method, the results turn out that different modes of fusion (from complete fusion 
to “kiss-and-run” exocytosis) are present in the beta-cells of both the diabetic db/db and WT islets. 
However, there is no significant difference in 2 indices of the fusion granule behaviour (granular 
lifetime and post-fusion fluorescent intensity) and only a small increase in “kiss-and-run” 
exocytosis in db/db mice compared with the WT.  
Therefore, these data highlight that the secretory deficit in db/db islets is primarily due to a 
loss of responding cells and a reduction in granule fusion in the remaining responsive cells rather 
than changes in the fusion granule kinetics. 
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3.2 Methods 
Experimental solution Experiments were performed in an extracellular buffer (ECB) (140 
mM NaCl, 5 mM KCl, 1 mM MgCl2, 2.5 mM CaCl2, 5 mM NaHCO3, 5 mM HEPES and glucose 
[according to test conditions]) adjusted to pH 7.4 with NaOH. 
Cell preparation Mice (BKS.Cg-Dock7
m 
WT Lepr
db
/J, the Jackson Laboratory, Bar Harbor, 
Maine, USA) were humanely killed according to local, University of Queensland, animal ethics 
procedures (approved by the University of Queensland, Anatomical Biosciences Ethics 
Committee). Isolated mouse pancreatic tissue was prepared by a collagenase (type IV) (Gibco, 
Victoria, Australia) digestion method in Hanks buffer (Sigma-Aldrich, NSW, Australia), adjusted to 
pH 7.4 with NaOH. Isolated islets were maintained (37°C, 95/5% air/CO2) in RPMI-1640 culture 
medium  (Gibco, Life Technologies,Victoria, Australia) supplemented with 10% FBS (Gibco, 
Victoria, Australia), and 100 U/ml penicillin/ 0.1mg/ml streptomycin (Invitrogen, Victoria, 
Australia). 
Two-photon imaging Two-day cultured islets were pre-incubated in ECB containing 3 mM 
glucose for 30 minutes (37°C, 95/5% air/CO2) prior to two-photon imaging. Two-photon imaging 
was performed at 34°C, with exocytic events recorded as the entry of extracellular dye into each 
fused granule. The image plane was consistently set at three cell thicknesses above the bottom of 
the cover-slip (ie into the islet) where the vast majority of cells in a rodent islet are beta-cells. This 
indirect assay is a sensitive method capable of recording single exocytic events in our system at a 
rate of 3 frames per second. It spatially and temporally distinguishes exocytic events within single 
cells within an intact islet. It does not involve labelling of heterologously expressed proteins or 
loading of tracers into the cell (Takahashi, Kishimoto et al. 2002; Low, Mitchell et al. 2013). 
A custom-made, video-rate, two-photon microscope with a 60x oil immersion objective 
(NA 1.42, Olympus, NSW, Australia) was used; providing an axial resolution (full width, half 
maximum) of ~1 µm. I imaged exocytic events using sulforhodamine B (SRB, 800 μM) as a 
membrane-impermeant fluorescent extracellular marker excited by femtosecond laser pulses at 950 
nm, with fluorescence emission detected at 550-650 nm. 8-Hydroxypyrene-1,3,6-trisulfonic acid 
(HPTS) was excited at 950 nm and emission detected at 420-520 nm. Images (resolution 10 
pixels/µm) were analysed with the Metamorph program (Molecular Devices Corporation, 
Sunnyvale, CA, USA). Exocytic event kinetics were measured from regions of interest (0.78 μm2, 
78 pixels) centred over individual granules.  
Page | 64  
 
Glucose tolerance test After an overnight fast (5:00 pm to 9:00 am), FBG concentrations 
were obtained by the Accu-check Active (Roche, Castle Hill, NSW, Australia) glucometer with a 
small drop of blood (~5 μl) from the tail tip. Then glucose 25% (wt/vol.) was injected intra-
peritoneally (1g/kg) and blood samples were taken at 15, 30, 60, 90 and 120 minutes and glucose 
concentrations measured. 
  Immunofluorescence Isolated islets were fixed in 4% paraformaldehyde, permeabilised with 
Triton X-100 or saponin, blocked with donkey serum prior to incubation with primary antibodies. 
For primary antibodies, mouse anti-SNAP25 (Synaptic Systems 111 011); mouse anti-VAMP2 
(Synaptic Systems 104 211); mouse anti-syntaxin-1A (Synaptic Systems 1110 111); rabbit anti-
insulin (Genesearch 3014S) were used. Secondary antibodies were highly cross absorbed donkey or 
goat antibodies (Invitrogen) labelled with Alexa 488 or Alexa 546. All were used at a 1/200 
dilution. DAPI (Sigma, 100 ng/ml final concentration). 
Insulin assay Homogeneous time resolved fluorescence (HTRF) assay with reagents 
supplied by Cisbio (QLD, Australia) was used to measure islet insulin secretion. To acquire insulin 
samples, pancreatic mouse islets were preincubated in a ECB containing 3 mM glucose for 30 
minutes. Groups of four islets were then transferred to individual eppendorf tubes containing ECB, 
0.2% BSA (Sigma Aldrich), glucose (3 mM, 15 mM) or ionomycin (5 μm) (Sigma Aldrich) and 
incubated (37°C, 95/5% air/CO2) for  20 minutes. Supernatants from each tube were collected and 
used for HTRF as per Cisbio insulin kit instructions.  
Calcium measurement Two-day cultured islets were loaded with 4 μm Fura-2-AM 
(Invitrogen, Victoria, Australia), 0.02% pluronic acid (Sigma Aldrich) and incubated (37
0
C, 95/5% 
air/CO2) for 30 minutes. After labelling, islets were washed and incubated in a sodium-rich ECB 
containing 3 mM glucose for an additional 2 minutes. Then single islets were transferred to a small 
volume chamber mounted on the stage of an inverted fluorescence microscope with a 25x objective. 
The cells were alternatingly excited at 340 and 380 nm, and the ratio was collected at 490 nm. 
Statistical Analyses Data are presented as mean  SEM. Statistical analysis was performed 
using Microsoft Excel and GraphPad Prism. Data sets were subjected to a Student’s t-test; * p<0.05, 
**p<0.01, ***p<0.001. Islets from at least 4 animals were used in each experiment.  
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3.3 Results 
Diabetic phenotype of the db/db mice The B6.BKS(D)-Lepr
db/db
 mice became significantly 
heavier than their WT littermates (Figure 3.1A, n=38 mice, one-way ANOVA p<0.0001). At 13-18 
weeks the db/db mice showed significant differences in glucose tolerance tests (GTTs) indicative of 
the development of diabetes (Figure 3.1B and C, n=38 mice, one-way ANOVA p<0.0001). These 
changes in the db/db animals are due to both peripheral insulin resistance (Berglund, Frankel et al. 
1978) and deficit in insulin secretion of the islets (Boquist, Hellman et al. 1974; Berglund, Frankel 
et al. 1978). 
 
 Figure 3.1: The diabetic phenotype of db/db mice 
(A) shows the increase in body weight in littermates of the WT, HET and db/db animals. 
(B,C) Signifcant changes were observed in the GTTs and integrated AUCs from 13-18 week-old mice. 
**p<0.01, ***p<0.001 
Insulin secretion is reduced in db/db islets Islets were isolated from WT and db/db mice, 
cultured for 2 days and tested for glucose-dependent insulin secretion. 15 mM glucose was applied 
for 20 minutes and the secreted insulin was measured. Islets from db/db mice had a significantly 
reduced response (Figure 3.2A, n=10 WT, 12 db/db mice, Student’s t test, p<0.01). Together, the 
weight gain, decreased GTT, and the reduction in insulin secretion, are consistent with previous 
results (Berglund, Frankel et al. 1978; Ishida, Takizawa et al. 2004; Kawasaki, Matsuda et al. 
2005). 
I next focused on studying the two distal steps of the stimulus-secretion cascade; the rise in 
cytosolic calcium and the exocytic fusion of insulin-containing granules. 
Calcium responses are attenuated in db/db islets Fura-2-AM loaded WT islets were 
stimulated with 15 mM glucose. The calibrated fluorescent signals showed a rapid increase in 
cytosolic calcium from 50 to ~250 nM (Figure 3.2B, n=8 WT, 9 db/db mice) that appeared 
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relatively uniform across individual islets (Figure 3.2C). In contrast, db/db islets had significantly 
higher resting calcium levels (WT 37.6 nM vs db/db 56.8 nM, p<0.05) and a significantly lower 
rate of increase in calcium (WT 3.48 nM/second vs. db/db 0.95 nM/cecond, p<0.001) and peak 
response to glucose (Figure 3.2B, WT 281.7 nM vs. db/db 193.0 nM, p<0.01); again, the calcium 
response was relatively uniform across the islets (Figure 3.2C).    
  
  Figure 3.2: Insulin secretion in overt diabetic db/db islets is decreased 
(A) A static insulin secretion assay, performed over 20 minutes, shows that the glucose-dependent increase 
in insulin secretion in WT islets is almost completely lost in db/db islets. 
(B) The calcium response to glucose is smaller and slower in db/db islets compared with WT islets. 
Individual data were aligned to the rising phase.  
(C)For both WT and db/db islets, the calcium response is relatively uniform across individual islets. Scale 
bar 50 μm. **p<0.01 
The final stages of granule fusion are impaired in db/db islets To test for a deficit in the last 
stage of the stimulus-secretion cascade, cytosolic calcium was artificially raised using 5 µM 
ionomycin. Ionomycin induced large cytosolic calcium responses in both WT and db/db islets 
(Figure 3.3 A, n=6 WT, 8 db/db mice). However, ionomycin-induced insulin secretion was 
observed only in WT islets (Figure 3.3B, n=11 WT, 12 db/db mice). This shows that the secretory 
response to a calcium signal is reduced in db/db islets and demonstrates a small but specific defect 
in granule fusion. 
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Figure 3.3: Ionomycin fails to induce insulin secretion in db/db islets 
(A) The calcium response to ionomycin, measured as calibrated Fura 2-AM fluorescence, in WT and db/db 
islets have similar kinetics, but db/db islets have a bigger magnitude. 
(B) A static insulin assay, performed over 20 minutes, shows WT islets respond to 
ionomycin with a 1.6-fold increase in insulin secretion whereas the db/db islets  show no response, 
*p<0.05 
Immunofluorescence was then used to determine the relative expression and distribution of 
SNAREs in the islets. Based on insulin immunostaining, almost all the cells in the core of the islets 
were beta-cells (Figure 3.4, n=4 WT, 4 db/db mice). SNAP25 and syntaxin-1A localized to the 
beta-cell membrane and VAMP2, the granule SNARE, was found within the cell. Consistent with 
previous measurement of mRNA levels (Kaneko, Ueki et al. 2010), the levels of SNAP25 and 
VAMP2 proteins were increased in the db/db islets but syntaxin-1A was reduced (Figure 3.4).  
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Figure 3.4: SNARE protein distribution and expression are altered in db/db islets 
Immunofluorescence of fixed islets shows insulin staining, SNAP25, VAMP2 and syntaxin-1A in beta-cells. 
The histograms show average fluorescence intensity changes in db/db islets normalised to WT and % of 
fluorescence intensity in cytosol regions compared with plasma membrane regions in db/db and WT islets,. 
Scale bar 10 μm. *** p<0.001. Syn1A, syntaxin-1A 
Taken together, these data indicate that the overt diabetic db/db islets have a reduced 
calcium response to glucose and a compromised secretory response that is possibly due to a lower 
level of syntaxin-1A. 
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Specific measurement of single granule fusion events in islets To understand how these 
secretory defects are manifest in an islet, a two-photon assay was employed to measure single 
granule fusion events within the core of intact islets of Langerhans (Low, Mitchell et al. 2013) 
where almost all the cells in rodent islets are beta-cells. This assay tracks the entry of extracellular 
dye as each insulin granule fuses; it has been extensively validated in our previous work (Low, 
Mitchell et al. 2013). 
Isolated islets were bathed in extracellular solution containing the fluorescent dye SRB and 
imaged with two-photon microscopy (Takahashi, Hatakeyama et al. 2004; Low, Mitchell et al. 
2013). The concentration of extracellular glucose was changed and the total numbers of fusion 
events occurring within the two-photon sample volume (~40 x 50 x 1 µm) was recorded over 20 
minutes. Figure 3.5A shows a single beta-cell, within an islet, where 15 mM glucose induced 5 
granule fusion events; with each event showing a characteristic rapid rise in fluorescence after 
fusion and then a slower decay back to baseline fluorescence (Figure 3.5B).  
 
Figure 3.5: Extracellular fluorescent dye enters each insulin granule as it fuses with the cell 
membrane.  
(A) A WT beta-cell within an islet before stimulation (upper) that is outlined by extracellular dye (SRB). 
During glucose stimulation exocytosis around the periphery of the cell is identified as the entry of dye into 
each fusing granule (arrows) here shown as a maximum projection image of a series of images captured 
during the response (lower). 
(B) A typical graph of average fluorescence over time, from a region of interest (ROI) placed over the 
area of single fusion event is shown. Scale bar 5 µm. 
Control, WT islets, showed a glucose dose-dependent increase in the number of fusion 
events, consistent with my previous data (Figure 3.6A and B, n=177 islets, 21 mice) (Low, Mitchell 
et al. 2013). In contrast, islets from db/db animals showed significantly lower numbers of fusion 
events induced by glucose (Figure 3.6B, one-way ANOVA: 3 mM p=0.11; 6 mM p=0.061; 15 mM 
p=1.23x10
-9
; 20 mM p=8.24x10
-8
, eg. an 83% loss at 15 mM). Further analysis demonstrates that, 
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in response to 15 mM glucose, the number of responding cells in db/db islets was reduced by 73% 
(Figure 3.6C, one-way ANOVA: 3 mM p=0.15; 6 mM p=0.0096; 15 mM p=5.83x10
-12
; 20 mM 
p=1.8x10
-10
) and the number of granule fusion events in the remaining responsive cells was reduced 
by 50% (Figure 3.6C, one-way ANOVA: 3 mM p=0.38; 6 mM p=0.11; 15 mM p=0.0001; 20 mM 
p=9.12x10
-8
). 
The time-course of the cumulative exocytic responses in WT islets showed an increase, up 
to a plateau, in response to 15 mM glucose (Figure 3.6E). In contrast, db/db islets had a steady and 
small exocytic response. 
  
Figure 3.6: Loss of glucose induced fusion granule from beta-cells within intact db/db 
islets 
(A) Typical two-photon cross sections taken across intact islets include many cells. Each granule fusion 
event over a 20 minutes time period is identified (as shown in figure 3.5) and its position marked as a 
yellow circle. 
(B) Quantification of the numbers of granule fusion events (in the two-photon volume, over 20 minutes), 
across a range of glucose concentrations, shows a significant reduction in granule fusion in db/db beta-
cells. The reduction in fusion events observed occurs because of both (C) a decrease in the number of 
responding cells and (D) a decrease in the number of fusion events per responding cell. 
(E) Cumulative plots of insulin granule fusion events over time, in response to 15 mM glucose. 
**p<0.01 and *** p<0.001. 
These data show db/db beta-cells have dramatically reduced numbers of exocytic fusion 
events. However, there may be additional parameters of fusion that differ in db/db cells. For 
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example, the duration of granule fusion and the behaviour of the granule after fusion could be 
different and both could have an influence on the amount of insulin secreted (Rutter and Tsuboi 
2004; Eliasson, Abdulkader et al. 2008). 
Exocytic lifetimes and granule fusion characteristics are not different in db/db beta-cells 
Granule fluorescence lifetimes were quantified by arbitrarily defining the start of the event where 
the fluorescence rose to the half maximal fluorescence intensity and the end of the event when the 
signal dropped to below the two standard deviations above the baseline fluorescence noise (Figure 
3.7A, start and end indicated by arrows). Frequency lifetime histograms show a modal value of ~4 
seconds (Figure 3.7C,D; n=4 WT, 743 fusion events; 9 db/db, 314 fusion events), with no evidence 
for distinct populations of lifetimes, and no differences between db/db and WT (Kolmogorov-
Smirnov test, p=0.422). 
 
Figure 3.7: Insulin granule fusion lifetimes are not changed in db/db beta-cells 
(A) Examples of short and (B) longer granule lifetimes as identified by the average fluorescence signal 
from ROIs placed over each individual fusion event. Arrows show the start and end of the event. 
(C,D) Frequency graphs of the binned granule lifetimes; WT and db/db islets have similar distributions. 
Another variable is the post-fusion fluorescence intensity, which is different for each 
granule. In some fusion events the fluorescence stays high; we have previously shown that this 
reflects retention of granule content (and dye) within the granule lumen (Thorn and Parker 2005). 
Figure 3.8A and B show two examples of the fluorescence profile over time from two different 
exocytic events. In one event there is a rapid loss of fluorescence and in the other the fluorescence 
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signal is maintained at a high intensity (Figure 3.8A,B). To quantify this for each granule fusion 
event, I measured the fluorescence intensity 15 seconds after the peak fluorescence, normalized this 
fluorescence to the peak fluorescence and plotted out a frequency graph (Figure 3.8C). The modal 
value of this fluorescence signal was around 0.3 (ie. a plateau level of 30% of the peak 
fluorescence) and the distribution of values did not differ between WT, HET and db/db islets 
(Kolmogorov-Smirnov test between WT and db/db, p=0.514). 
 
Figure 3.8: The post-fusion fluorescence plateaus are not changed in db/db beta-cells. 
Two examples of single-granule-fusion events: (A) a low fluorescence plateau (fluorescence returns to 
background levels) (plateau=0.09); and (B) a high fluorescence plateau (plateau=0.87). In each case the 
mean fluorescence changes within a ROI placed over the granule fusion site is shown. Images taken at 1 
second intervals over the duration of the fusion event. Scale bar 1 μm. 
(C) Graphs of frequency plotted against fluorescence (SRB) plateau (normalized to the peak fluorescence) 
are similar for WT, HET and db/db islets. 
I conclude that, using the live-cell two-photon assay, the insulin granule fusion events in 
db/db beta-cells are indistinguishable from those in WT cells.  
“Kiss-and-run” exocytosis After fusion, granule fluorescence persisted for a short period of 
time and then was lost, which could be interpreted as a collapse of the granule into the cell 
membrane. However, another alternative granule behaviour is that the fusion pore can close while 
the granule is at the cell membrane, sometime called “kiss-and-run”, which is well-documented in 
beta-cells (Tsuboi, McMahon et al. 2004; Eliasson, Abdulkader et al. 2008). After fusion pore 
closure the granule lumen rapidly acidifies because of the action of the vacuolar (H
+
)ATPase on the 
granules (Ohara-Imaizumi, Nakamichi et al. 2002).  
To detect this pH shift I added a pH-sensitive dye (HPTS) to the extracellular solution (in 
addition to SRB, which is pH insensitive) and tracked the fluorescence changes after granule fusion 
(Behrendorff, Dolai et al. 2011). Acidification reduces the HPTS fluorescence (Behrendorff, 
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Floetenmeyer et al. 2010), and a different fluorescence signal between the two dyes indicates 
granule recapture (Figure 3.9). To quantify these changes I define a “recaptured” granule as one 
where, at 15 seconds after the peak, the HPTS had dropped by more than 20% of the SRB signal. 
This quantification demonstrates that the proportion of granules that acidified was small but 
interestingly there were significantly more recaptured granules (x1.75 increase) in the db/db islets 
(Table 3.1, Student’s t test, p=0.022). I conclude that transient fusion (“kiss-and-run”) is more 
common in the diseased islets. 
 
Figure 3.9: “Kiss-and-run” granule recapture is increased in the db/db beta-cells 
2 extracellular dyes, SRB (pH insensitive) and HPTS (pH sensitive) both enter each fusing granule.  
(A) For most granule fusion events the average fluorescence intensity changes are similar for both dyes. 
(B) In contrast, some granule fusion events show a selective decrease in the HPTS signal where it is 
quenched by acidification. Scale bars 1 μm; n=4 WT and n=4 db/db mice; total of 580 events.      
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Table 3.1 Proportions of recaptured granules (“kiss-and-run” events) in WT and db/db islets. 
Islet Total exocytic events Number (%) of “kiss-and-run” events 
Wild type 408 27 (6.6) 
Db/db 172 20 (11.6) 
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3.4 Discussion 
The basis of the insulin secretory defect in T2D is still not fully understood. In principle, 
changes could occur in the number of responding islets, number of beta-cells or in the secretory 
function of individual beta-cells. My data provide clear evidence for a reduction in the number of 
responding cells and a decrease in granule fusion.  
Decrease in the number of responding cells I showed that the number of glucose-responsive 
cells in the db/db islets is reduced by 73%, indicating it is the major factor that explains the loss of 
insulin secretion from islets. This pattern of loss of cell responsiveness is the likely outcome of both 
intrinsic defects in intracellular beta-cell morphology (Boquist, Hellman et al. 1974) and function in 
part caused by endoplasmic reticulum stress (Laybutt, Preston et al. 2007) that result in apoptosis 
and dedifferentiation (Talchai, Xuan et al. 2012). There is also likely to be a contribution from 
perturbation of intercellular communication between the islet cells (Speier, Gjinovci et al. 2007),  
much of which is unknown and requires further study with approaches like ours to measure cell 
activity within intact islets. The data I show are the first to characterise the functional outcomes of 
these cellular changes in diseased islets and demonstrate that complete loss of beta-cell function is 
the most significant factor contributing to the overall loss of insulin secretion from islets. 
Decrease in single-cell secretion I further show that in the cells that remain responsive there 
is a 50% loss of exocytic fusion. My two-photon assay unequivocally identifies loss of the number 
of granule fusion events as the manifestation of this secretory defect. There are two other studies 
that have looked at insulin granule fusion in models of disease. Using the GK rat model, a study 
focusing on granule motion before fusion, showed a reduction in fusion events (Ohara-Imaizumi, 
Nishiwaki et al. 2004). The second study used cultured single cells to show incubation in high 
glucose selectively reduced full-fusion events compared with transient fusion (Tsuboi, Ravier et al. 
2006). These studies are limited to single cell work, but both agree with my finding that loss of 
secretion in the damaged beta-cell is characterised by a loss of granule fusion. Where this study 
differs is that I see no evidence that transient fusion (“kiss-and-run”) is a significant contributor to 
the deficit in insulin secretion and my method records the relative contribution of the loss of 
responsive cells. 
Secretory defect In the beta-cells that poorly secrete, my data suggests some important 
factors that might explain this reduction in secretory competence.  
First, I show changes in calcium signaling that lead to an increased resting calcium and a 
decreased response to glucose. These observations are consistent with a single-cell study on db/db 
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beta- cells (Gustavsson, Larsson-Nyren et al. 2005), but in intact db/db islets there is evidence for 
larger (Roe, Philipson et al. 1994) and smaller (Brenner, Gromada et al. 2003) calcium responses. 
These differences may reflect stages in disease progression in individual animals with the larger 
responses (also seen in the GK rat model (Rose, Efendic et al. 2007)) representing an early stage of 
compensatory up-regulation of responsiveness. To date, I have been unable to reliably measure 
calcium and exocytosis simultaneously in single cells within the islet and therefore cannot directly 
relate the changed calcium responses to secretory output. However, it seems reasonable that the 
reduced rate of increase in the calcium signal and the reduced amplitude would lead to a decreased 
exocytic response. Interestingly the increased basal calcium levels observed could explain the 
increased basal insulin secretion that I and others (Roe, Philipson et al. 1994) see in the db/db islets. 
This whole islet calcium measurement method does not spatially or temporally resolve single-cell 
responses. However, the noticed slowed rate of rise of the db/db calcium response (Figure 3.2B) is 
consistent with studies that indicate displacement of calcium channels around the cells and away 
from the sites of exocytosis (Hoppa, Collins et al. 2009). What the work with ionomycin clearly 
indicates is that, on top of a reduced glucose-induced calcium response, there is also a small but 
specific loss of exocytic competence in the db/db beta-cells.   
The second factor identified in this study is change in the expression of SNARE proteins 
which could contribute to this loss of secretory competence. Interestingly, the increase in SNAP25 
and VAMP2 and decrease in syntaxin-1A expression is the same pattern as previously observed in 
db/db mice using quantitative PCR (Kaneko, Ueki et al. 2010), which demonstrates a specificity to 
the cell damage. The changes in SNAREs expression are consistent with previous reports 
(Nagamatsu, Nakamichi et al. 1999; Gaisano, Ostenson et al. 2002; Ostenson, Gaisano et al. 2006) 
and with evidence that manipulation of SNARE expression changes insulin secretion (Spurlin and 
Thurmond 2006). However, if SNARE reduction was the only defect, it should lead to granule 
accumulation, something observed in other cell types with a SNARE defect (Behrendorff, Dolai et 
al. 2011). In fact, in db/db islets the granule density (per unit cell volume) is approximately half that 
of WT (Xue, Zhao et al. 2012) indicating that there must be additional factors that are changed in 
disease. This reduction in granule numbers alone does not explain the ~80% reduction in granule 
fusion I observe (Figure 3.6) and leads me to conclude that the combination of loss of granules, 
changes in SNARE expression and changes in the calcium signal all contribute to the secretory 
defect. Such a multifaceted phenotype is consistent with gross cellular changes due, for example, to 
dedifferentiation (Talchai, Xuan et al. 2012).   
Changes in insulin granule fusion behaviour This work shows that granule lifetimes and the 
granule fluorescence plateau are not changed indicating that the essential exocytic mechanisms are 
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not altered in overt diabetes. The increase in “kiss-and-run” events could be due to the changed 
expression of SNAREs. The increase in recaptured granules cannot explain the loss of insulin 
secretion but, instead, could be part of the mechanism of disease. For example, it has been observed 
that diseased beta-cells contain many granules (or at least granule-like objects) in which the insulin 
crystal is absent (Xue, Zhao et al. 2012). It has been speculated this is due to misprocessing of 
granule cargo (Xue, Zhao et al. 2012), an idea supported by work on mutations in the zinc 
transporter (Nicolson, Bellomo et al. 2009). But the increased “kiss-and-run” events that I observed 
would also be consistent with the appearance of “empty” vesicles. If these “empty” vesicles could 
not fuse again then they could form a barrier to exocytosis of normal vesicles and thus contribute to 
disease progression. Whatever the reason for the upregulated “kiss-and-run” exocytosis, the 
magnitude of the change (increase by 5%) cannot explain for the marked reduction in islet insulin 
secretion of frank diabetic db/db islets but rather acts as an aggregated factor to the disease 
phenotype.  
3.5 Conclusion  
Among the possible explanations of the diabetic phenotype in db/db mice I here show that 
the major factors are the loss of responding cells and the loss of the number of fusing insulin 
granules rather than differences in the kinetics of these fusion-granules.  
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CHAPTER 4: 
 
STRUCTURAL CHANGES OF PANCREATIC ISLETS 
AND BETA-CELLS ACROSS DIFFERENT STAGES 
OF DISEASE PROGRESSION IN LEPR
DB
 MICE 
 
 
 
 
Part of this chapter was adapted and modified from the manuscript submitted to the Diabetologia 
and is under review 
 
Do, O. H., Gunton, J., Gaisano, H. Y. & Thorn, P. 2016. Changes in beta cell function occur 
in prediabetes and early disease in the Lepr
db
 mouse model of diabetes. 
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4.1 Introduction 
  Diabetes mellitus including T2D is not a stable disease, but progressive in nature (Prentki 
and Nolan 2006; Fonseca 2009). Studies from the whole genome wide association as well as studies 
of discordant identical twins have supported the crucial role of beta-cell dysfunction in the 
pathology of T2D (Gerich 1998; Florez 2008; Perry and Frayling 2008). Moreover, as soon as 
hyperglycemia begins even with a subtle increase in blood glucose, it starts to exert detrimental 
effects on the islet beta-cells, worsening the imbalance between insulin supply and demand 
(Brunzell, Robertson et al. 1976; Leahy, Bonner-Weir et al. 1988; Gastaldelli, Ferrannini et al. 
2004). These data implicates that studies targeting the disease should focus on changes in islet 
biology earlier in the disease sequence which hardly obtains in human. 
  Therefore, animal models especially rodents have been used extensively due to its small 
size, short generation interval and easy availability. Although there is no single model that 
encompasses all the characteristics of T2D in humans, there are very appropriate models relevant to 
human disease (Cefalu 2006). Among them, Lepr
db 
is the most commonly used that mimics several 
of the pathophysiological conditions in humans such as insulin resistance and hyperinsulinemia 
preceding hyperglycemia; which has previously been compared with human T2D in terms of 
treatment requirement (Hummel, Dickie et al. 1966; Yamazaki, Kato et al. 2009). Although db/db 
mice have been considered as having a natural history that closely parallels that of humans (Cefalu 
2006; Yamazaki, Kato et al. 2009), the underlying changes at the pancreatic islet and beta-cell 
levels across the course of the disease remain to be elucidated.  
Therefore, in this chapter, I aim to categorize db/db mice into stages of disease along the 
lines of human T2D (Weir, Laybutt et al. 2001; Weir and Bonner-Weir 2004). Performing glucose 
tolerance test (GTT) on single db/db mice (13-18 week-old), I were able to classify them into 
different levels of disease severity: compensation and or adaptation, early, late and severe 
decompensation based on the area under the curve (AUC) of the GTT. This is not unusual given the 
heterogeneity of the db/db colony reported previously but has not been further explored (Hummel, 
Dickie et al. 1966; Boquist, Hellman et al. 1974; Yamazaki, Kato et al. 2009). This way of 
delineating the disease will provide a rich array of opportunities for future work on this model to 
investigate the complex pathophysiological processes of the disease as well as to evaluate new drug 
candidates for T2D. Subsequently, I characterised the morphological changes of pancreatic islets 
and beta-cells across the disease severity in this mouse model.  
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4.2 Methods 
Glucose tolerance test After an overnight fast (5:00 pm to 9:00 am), FBG concentrations 
were obtained by the Accu-check Active (Roche, Castle Hill, NSW, Australia) glucometer with a 
small drop of blood (~5 μl) from the tail tip. Then glucose 25% (wt/vol.) was injected intra-
peritoneally (1g/kg) and blood samples were taken at 30, 60, 90 and 120 minutes to measure blood 
glucose. 
Cell preparation Mice (BKS.Cg-Dock7
m 
WT Lepr
db
/J, the Jackson Laboratory, Bar Harbor, 
Maine, USA) were humanely killed according to local, University of Queensland, animal ethics 
procedures (approved by the University of Queensland, Anatomical Biosciences Ethics 
Committee). Pancreatic islets isolation and culturing were performed as described previously (Do, 
Low et al. 2015). 
Serum insulin Blood samples were collected from the cardiac puncture right after sacrificing 
the mice. Allow the blood to clot by leaving it undisturbed for 15 minutes on ice. Remove the clot 
by centrifuging at 5000 rpm for 10 minutes at 4
0
C. Carefully aspirate the supernatant (serum), pool 
into an eppendorf tube and store at 4
o
C for insulin measurement. 
Islet diameter Right after isolation, all islets from one batch of isolation were transferred 
into a petri disk containing culture media and imaged with the 10x objective of the Olympus 
FV1000 inverted confocal microscope. Islet diameter of WT and db/db mice was measured with the 
Metamorph program (Molecular Devices Corporation, Sunnyvale, CA, USA). 
Islet insulin content Groups of three islets were subjected to insulin extraction with 150 μl 
acid ethanol mixture (71.25 volume % of ethanol, 1.5 volume % of concentrated HCl and 27.25 
volume % of water) overnight at 4
0
C. This extraction supernatant was further diluted 50 times with 
ECB before measurement. 
Pancreas insulin content For each mouse, a piece of pancreas (~10-20 mg) was removed 
from the middle part of the pancreas upon opening the mouse’s abdominal cavity for islet isolation. 
This piece of pancreatic tissue was weighted and homogenized in an eppendorf tube with a 
homogenizer in 200 μl of acid ethanol solution and incubated for 48 hours at 4oC. The tube was 
centrifuged at 5000 rpm for 10 minutes at 4
0
C and the supernatant was transferred into another tube, 
diluted 200 times in extracellular buffer prior to the insulin measurement.  
 Immunofluorescence Isolated islets were fixed in 4% paraformaldehyde, permeabilized with 
Triton X-100, blocked with donkey serum prior to incubation with primary antibodies. For primary 
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antibodies, mouse anti-neurogenin-3 (BD Pharmigen, 1:200); mouse anti-oct-4 (BD Pharmigen, 
1:200); rabbit anti-ki67 (Sigma Aldrich, 1:200); guinea-pig anti-insulin (Abcam, 1:200) were used. 
Secondary antibodies were highly cross absorbed donkey or goat antibodies (Invitrogen, Australia) 
labeled with Alexa 488, Alexa 546 or Alexa 633. DAPI (Sigma Aldrich, 100 ng/ml final 
concentration). 
Real-time polymerase chain reaction: Right after isolation, WT or db/db islets were washed 
in PBS, transferred to an eppendorf tube and stored at -80
0
C for ribonucleic acid (RNA) extraction. 
Total RNA from WT and db/db islets was extracted at the same time using the RNeasy plus micro 
kit (Qiagen, USA.) and quantified at OD 260/280 by spectrophotometer (NanoDrop, Thermo 
Scientific, Australia). Complementary deoxyribonucleic acid (cDNA) was synthesized from 100 ng 
of total RNA using the superscript III reverse transcriptase (Invitrogen, Life Technologies, 
Australia) in a 20 μl reaction volume following the provider’s protocol. The SYBR green qPCR 
method was used.  Mouse specific primers (Life Technologies, Australia or Sigma Aldrich, 
Australia) were used as follow: 18S forward, TCGAGGCCCTGTAATTGGAA ; 18S reverse 
CCCTCCAATGGATCCTCGTT; Cacna1c forward, TCCTGAACTCCATCATCAAG ; Cacna1c 
reverse, CTGCCGGAACATCTATTATG; Cacna1d forward, GTTAATGATGCGATAGGATGG; 
Cacna1d reverse, GAATTCTCCACTAAGGACAC; SNAP25 forward, 
GGACTTTGGTTATGTTGGATG; SNAP25 reverse, GGATTTAAGCTTGTTACAGGG; 
Syntaxin-1A forward, AGATGATTGACAGGATCGAG; Syntaxin-1A reverse, 
GTGGTTTCTATCCAAAGATGC; VAMP2 forward, ATCATCGTTTACTTCAGCAC; VAMP2 
reverse, TGAAAGATATGGCTGAGAGG. Real-time PCR was carried by the Applied Biosystems- 
Quantstudio
TM
 6 Flex real-time PCR system. All samples were run in duplicate and 18S was used as 
the endogenous control. Results were analyzed using the Applied Biosystems- QuantStudio™ 6 
software (Thermo Fisher Scientific, Australia). mRNA level of the gene of interest was presented as 
the fold difference between db/db and WT islets. 
Statistical Analyses Data are presented as mean SEM. Statistical analysis was performed 
using Microsoft Excel and GraphPad Prism. Data sets were subjected to a Student’s t-test; * 
indicates p<0.05, ** p<0.01, *** p<0.001. Islets from at least 3 animals were used in each 
experiment.  
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4.3 Results 
The Lepr
db
 spontaneous mutation (Lepr
db
, C57BLKS, Doc7m, DBA/J) is a recognized 
model for T2D diabetes (Berglund, Frankel et al. 1978). At 3-4 months of age, the db/db animals 
were significantly heavier than the WT (Figure 4.1B, n=25 mice), and developed the disease, 
tracked, for example, using GTTs (Figure 4.1C, n=7 WT, 4 HET and 112 db/db mice). As in human 
disease, there was great variability in diabetes phenotype among individual animals (13-18 weeks) 
(Festa, Williams et al. 2006). In the db/db animals the AUC, derived from the GTTs, showed a 
spread ranging from animals within the normal range to animals with a 5-fold increase in AUC 
compared to normal (Figure 4.1D, n=7 WT, 4 HET and 112 db/db mice). This provides us with an 
opportunity to study changes in islet morphology and function across a range of disease severity. To 
facilitate our subsequent work, the mice were categorized into 4 stages of severity: stage 1 (AUC 
<1600 mM.minutes), stage 2 (AUC 1600 -2200), stage 3 (AUC 2200 -2800) and stage 4 (AUC 
>2800) (Figure 4.1D). GTTs performed before animal sacrifice thus enabled us to classify, for each 
animal, the severity of the disease from stages 1-4. Among 112 db/db mice (13-18 week-old) tested 
for the GTT, there was 17.9% in stage 1, 26.8% in stage 2, 17.9% in stage 3 and 37.5% in stage 4 of 
the disease progression. 
 
 
Page | 83  
 
  
Figure 4.1: Classification of db/db animals into 4 stages of disease based on AUC of the 
GTT. 
(A)13 week-old  db/db mice (left), compared to their WT littermate (right). 
(B) shows the increase in body weight of db/db vs WT animals diverges significantly at 7 weeks of age. 
(C) Glucose tolerant response for each stage of disease severity compared to WT and HET animals.  
(D) The widespread AUC (mM.minutes), derived from the GTT in the db/db animals, is arbitrarily divided 
into: stage 1 (<1600), stage 2 (1600 -2200), stage 3 (2200 -2800) and stage 4 (>2800). (n=7 WT, 4 HET 
and 112 db/db mice). ***,p<0.001.  
This scheme of classification is somewhat analogous to that done for fasting blood glucose 
in human disease (Figure 4.2) (Weir and Bonner-Weir 2004).  
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Figure 4.2: Comparison between human disease classification based on Weir & Bonner-
Weir (Weir and Bonner-Weir 2004) and my data from the db/db mice. 
Mice have higher normal blood glucose than human, and therefore I have adjusted the mouse scale for 
fasting glucose by 1.7x. The stage classification I used is based on the AUC of the GTT, for each mouse I 
measured the FBG and this plot shows the 25-27 % percentile. (n=7 WT, 4 HET and 112 db/db mice). 
Islet cells plasticity over the 4 stages of disease Both serum insulin and pancreatic insulin 
content (measured using a pancreatic autopsy) increased at stages 1-3 db/db mice and decreased at 
stage 4 (Figure 4.3A and B, n=14 WT and 20 db/db mice). These changes closely reflect changes in 
insulin content from isolated individual islets (Figure 4.3C, n=23 WT and 24 db/db mice).  
Additionally, islet size was larger at all stages db/db than the WT (Figure 4.3D, n=6 WT and 
8 db/db mice). This change in islet size is consistent with evidence in human T2D where peripheral 
insulin resistance is associated with a compensatory increase in islet size (Kloppel, Lohr et al. 1985; 
Butler, Janson et al. 2003). 
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Although larger islet size has been found to be associated with insulin resistant states, the 
relative role of increased beta-cell number and/or beta-cell hypertrophy is not yet clear especially in 
terms of the disease progression. The data suggested that at least part of the explanation for the 
increase in islet diameter at stage 1 disease is an increased number of cells, since no change in islet 
cell size was observed at stage 1 db/db (Figure 4.3 D, n=6 WT and 8 db/db mice). However, islet 
cell size was significantly larger in stage 2-4 db/db; suggesting that in advanced stages of disease 
cellular hypertrophy also contributes to the increase in islet size.  
  
Figure 4.3: Islet cells plasticity over 4 stages of db/db disease.  
(A,B) Both serum insulin and pancreatic insulin content increase at stage 1-3 but fail to increase at stage 4 
db/db, compared to WT. (n=14 WT and 20 db/db mice) 
(C) Isolated islet insulin content, compared to WT, increases at stages 1-2, is similar at stage 3 and 
significantly decreases at stage 4. (n=23 WT and 24 db/db mice) 
(D) While islet size in db/db is larger than WT at all stages, islet cell size is similar to WT at stage1 and 
increases at stage 2-4 db/db. (n=6 WT and 8 db/db mice). *,p<0.05;**,p<0.01;***,p<0.001. 
At stage 3-4, the increase in islet size and cell size, however, was not associated with higher 
insulin content in individual islets, suggesting that in advanced stages of disease there is a loss of 
insulin content from individual beta-cells (Figure 4.3C,D). To determine if insulin content in single 
cells was changing, immunofluorescence of insulin was performed in isolated islets. This identified 
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an increase in cellular insulin storage at stage 1 and a decrease at stages 2-4 (Figure 4.4 C, n=13 
WT, 13 db/db mice). 
Co-immunostaining for Ki67, a marker for actively dividing cells, failed to show changes at 
any stage indicating that, consistent with observations in human (Butler, Janson et al. 2003), there 
was not a dramatic up regulation of cell division (Figure 4.4A, B). Overall the data showed that, at 
stage 1 disease, there was an increase in islet insulin content due to both an increased number of 
beta-cells and increased insulin content in each cell. In more severe, stages 2-4 of disease, there is a 
progressive loss of islet insulin content that is a reflection of loss of content from beta-cells. 
 
Figure 4.4: Immunofluorescence shows changing insulin content but no change in actively 
dividing cells across the stages of db/db disease.  
(A) The panel shows immunofluorescent images of isolated islets in WT and db/db. 
(B) The percentage of Ki67 positive cells show no significant change in the db/db compared to WT.  
(C) Histogram of average fluorescent intensity demonstrates a small increase in insulin staining at stage 1 
and then a substantial decline at stages 2-4. (n=13 WT, 13 db/db mice). **,p<0.01;***,p<0.001. 
Increase in the percentage of beta-cells that are positive for dedifferentiation markers at all 
stage of db/db: Immunofluorescence of progenitor markers showed that db/db islets have more 
beta-cells that are positive for neurogenin-3 or oct-4 than the WT. On average, about 5% of the 
beta-cells in all stages db/db expressed these dedifferentiation makers compared to <2% in the WT. 
Interestingly, these markers appeared early in the disease, at stage 1, and did not increase with the 
disease severity (Figure 4.5, n=12 WT, 12 db/db mice). 
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Figure 4.5: Immunofluorescence shows an increase in the percentage of neurogenin-3 or oct-
4 positive beta-cells in db/db, compared to WT islets. 
(A, B) The panels show immunofluorescence images of isolated islets in WT and db/db islets. Counts of the 
percentage of neurogenin-3 or oct-4 positive cells show a significant increase in the db/db compared to 
WT. (n=12 WT, 12 db/db mice);*,p<0.05;**,p<0.01. 
Changes in SNAREs and L-type calcium channels expression in db/db islets: In chapter 3, 
performing islet immunostaining of the SNARE proteins, the data suggested that overt diabetic 
db/db islets have increased expression of SNAP25 and VAMP2 and decreased expression of 
syntaxin-1A (Figure 3.4). In quantitative PCR experiments, on isolated islets, these changes were 
now shown to occur at all stages (1-4) of the disease (Figure 4.6, n=8 WT and 8 db/db mice). 
Furthermore, mRNA expression of the L-type calcium channels especially the Cav1.2 which are 
thought to be important for insulin secretion are also significantly upregulated in all stages of db/db 
(Figure 4.6). It is noteworthy that the compensated upregulation of the calcium channels and 
SNAREs mRNA expression is increased with the disease severity.   
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Figure 4.6: Quantitative PCR shows altered mRNA expression of the L-type calcium 
channels and SNAREs in all stages db/db.  
(n=8 WT and 8 db/db mice); *,p<0.05. Cacna1c: Cav1.2, Cacna1d: Cav1.3  
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4.4 Discussion 
Phenotypic characterization of disease progression in db/db mice The db/db colony 
(BKS.Cg-Dock7m WT Lepr
db
/J) was originated from the Jackson Laboratory (Bar Harbor, Maine, 
USA). In previous work, I have shown that the db/db phenotype is comparable with published work 
both in body weight gain and glucose levels in response to the GTT (Ishida, Takizawa et al. 2004; 
Matsuda, Kido et al. 2008; Miyawaki, Inoue et al. 2008; Zhong, Wang et al. 2012; Do, Low et al. 
2014). Performing GTT on every 13-18 week-old db/db mice, I observed a full array of the disease 
severity from normal to very high blood glucose which is consistent with the mapping of T2D in 
humans (Weir and Bonner-Weir 2004). Therefore, I categorized the db/db mice into 4 stages of 
disease severity: compensation/adaptation (stage 1), early decompensation (stage 2), late (stage 3) 
and severe decompensation (stage 4) which is essential for future studies using this model. By 
restricting the window of observation to 13-to-18 week-old db/db mice, I by no means deny the 
disease progression through age but rather want to demonstrate that as in human T2D similar aged 
mice can be in different stages of disease severity (Figure 4.1C, D). 
Pre-diabetic db/db mice Interestingly, besides the full blown diabetic mice, there existed 
normal GTT db/db mice (13-18 weeks) with obese phenotype and slightly higher FBG. This is 
consistent with previous observations that there was a small percentage of  db/db mice differed 
from the others in terms of responding to glucose which according to these authors may represent 
an earlier stage in the course of diabetes (Hummel, Dickie et al. 1966; Boquist, Hellman et al. 
1974). 
Serum insulin and pancreatic insulin content over the course of disease In response to 
insulin resistance, db/db mice exhibit higher plasma insulin level which is in line with previous 
studies taking into account that I used older aged mice where the hyperinsulinemia is less extreme 
(Matsuda, Kido et al. 2008; Kaneko, Ueki et al. 2010). Moreover, my data indicate that stage 4 
db/db mice fail to maintain the hyperinsulinemia condition which results in the severe 
hyperglycemia of the mice. Notably, parallel changes were also observed at the level of pancreatic 
and islet insulin content. 
Islet morphological changes in different severity stages of T2D Further characterization 
showed that alterations in islet size and structure occurring across all stages of the disease. As in 
human T2D,  compensation and or adaptation occurs in stage 1 disease (Gastaldelli, Ferrannini et 
al. 2004; Festa, Williams et al. 2006) and is associated with increased islet size and insulin content 
(Kloppel, Lohr et al. 1985; Butler, Janson et al. 2003). Moving through to stages 2-4, a progressive 
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loss of insulin content was noticed, again consistent with human disease (Ward, Bolgiano et al. 
1984).  
Nevertheless, this work provides strong evidence that in the context of insulin resistance, 
before progressing to decompensation, the response of the beta-cells commences with a 
compensated and or an adaptive stage in which the islets increase their beta-cell numbers as well as 
their cellular insulin content. This is consistent with what has been proposed in human T2D (Weir, 
Laybutt et al. 2001; Weir and Bonner-Weir 2004) or in insulin resistant mice caused by insulin-
receptor antagonist (S961) (Yi, Park et al. 2013). Furthermore, another question related to these 
adaptive changes is the relative role of increased beta-cell number and beta-cell hypertrophy in 
insulin resistance state. By measuring the beta-cell size across all stages of the disease, the results 
indicated that the increase in islet size was solely due to increased beta-cell number in 
normoglycemic stage 1 db/db mice, while there was a role for beta-cell hypertrophy at later 
hyperglycemic stages (stage 2-4) which is in line with study in pancreatectomised rats where 
chronic hyperglycemia was shown to induce beta-cell hypertrophy (Jonas, Sharma et al. 1999). 
Islet replication behaviour is not different among stages of the disease Immunostaining for 
Ki67, a marker for actively dividing cells, failed to show changes at any stages of the disease 
indicating that, consistent with observations in human T2D (Butler, Janson et al. 2003), there was 
not a dramatic up regulation of cell division (Figure 4.4 A,B). Moreover, as 13-18 week-old mice 
were used, the result was understandable given that beta-cell replication reduced significantly after 
4 weeks of age in db/db mice (Guo, Dai et al. 2013). 
Dedifferentiation of the beta-cells across all stages of the disease Altered beta-cell 
differentiation in the context of diabetes recently attracts a great deal of attention. Current 
understanding is that dedifferentiation is the result of glucotoxicity which leads to the depletion of 
functional beta-cell mass (Talchai, Xuan et al. 2012; Weir, Aguayo-Mazzucato et al. 2013; Blum, 
Roose et al. 2014). Here I show that the expression of the progenitor phenotype occurs early in the 
disease well beyond marked hyperglycemia and that there is a great level of heterogeneity between 
beta-cells within an islet in terms of dedifferentiation. This result is in line with a recent study 
showing that Urocortin 3, a marker for mature beta-cells was reduced early in T2D mice with slight 
hyperglycemia, before the reduction in insulin gene expression (Blum, Roose et al. 2014). This 
undoubtedly will raise the question about the secretory capacity of these progenitor-like cells in 
different stages of the disease which is currently unresolved due to the lack of a reliable probe of 
dedifferentiation for live-cell imaging.  
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Changes in calcium channels and SNAREs mRNA expression in different courses of the 
disease In previous chapter using immunofluorescence, I have shown that db/db islets have an 
upregulation in SNAP-25, VAMP2 and down regulation in syntaxin-1A protein expression. 
Performing the quantitative PCR on all stages mice I now prove that similar pattern of changes 
occurs over the course of the disease (Figure 4.6). Not only the SNAREs but also the Cav1.2 L-type 
calcium channels mRNA expression is progressively upregulated across all stages of disease which 
could be one of the compensatory mechanisms of the diseased beta-cells in response to increased 
insulin demand. 
4.5 Conclusion 
In this study, the db/db mice were classified into different stages of disease severity based 
on the glycemic profile of the GTTs along the line of human T2D which is useful for future work 
on this model. My data also demonstrate that alterations in islet size and insulin content occur at all 
stages of disease and that there is a loss of insulin store from individual beta-cells when the disease 
progresses. 
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CHAPTER 5: 
 
FUNCTIONAL SHIFTS OF BETA-CELL BEHAVIOUR 
IN PREDIABETES AND EARLY DISEASE 
 
 
 
 
This chapter is reproduced from a manuscript submitted to Diabetologia and is under 
review. 
 
 
Do, O. H., Gunton, J., Gaisano, H. Y. & Thorn, P. 2016. Changes in beta cell function occur in 
prediabetes and early disease in the Lepr
db
 mouse model of diabetes 
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Abstract 
Aims/hypothesis Type 2 diabetes is a progressive disease that increases morbidity and risk of 
premature death. Glucose dysregulation, such as elevated fasting blood glucose, is observed prior to 
diabetes onset. This prediabetic state affects up to 1 in 3 American adults. Decline in beta-cell 
insulin secretion contributes to the later stages of diabetes but it is not known what, if any, 
functional beta-cell changes occur in prediabetes. 
Methods The Lepr
db
 mouse (13-18 week-old) was used as a model of type 2 diabetes and two-
photon granule-fusion assay was employed to characterise the secretory response of pancreatic 
beta-cells. 
Results A prediabetic state was identify where the animals respond normally to a glucose challenge 
but have elevated fasting glucose. Isolated islets from prediabetic animals are bigger, have more 
insulin content and an increase in insulin secretion. Direct measurement from beta-cells within 
these prediabetic islets showed increased granule fusion in response to a glucose stimulus, which 
was not observed at 5-6 week-old db/db. This increase is due to a specific modulation of the 
exocytic machinery and leads to an unusual prevalence of granule-to-granule fusion. Islets from 
animals at the next stage of disease show overt glucose intolerance, reduced glucose-induced 
granule fusion and a loss of glucose sensing.  
Conclusions/interpretation Using Lepr
db
 model, I showed that prediabetes is characterised by 
important functional changes in beta-cells with an upregulation in the number of fusion granules 
and compound exocytosis. Upon progression to diabetes, the beta-cells fail to secrete due to the 
development of upstream defects in the glucose sensing. The results provide a rationale for early 
intervention during prediabetes. 
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5.1 Introduction 
Type 2 diabetes is a chronic and progressive disease characterised by loss of glucose 
homeostasis that leads to morbidity and premature mortality (Lillioja, Mott et al. 1993; Weir and 
Bonner-Weir 2004; Prentki and Nolan 2006; Kahn, Zraika et al. 2009). Failure of insulin secretion 
from beta-cells to meet the demand of increased peripheral insulin resistance is a key feature 
(Prentki and Nolan 2006; Ashcroft and Rorsman 2012). The consensus is that this reduced insulin 
secretion is partly due to a loss of beta-cell mass but at least early after diagnosis is mainly due to 
defective beta-cell function (Ward, Bolgiano et al. 1984; Kahn, Zraika et al. 2009; Meier and 
Bonadonna 2013). In support of this, reduced insulin secretion is observed in isolated diseased 
human islets (Deng, Vatamaniuk et al. 2004; Del Guerra, Lupi et al. 2005) and in rodent models of 
diabetes (Tsuboi, Ravier et al. 2006; Olofsson, Collins et al. 2007; Do, Low et al. 2014).  
Prior to overt T2D, a prediabetic state can be identified by impaired fasting glucose (IFG) or 
impaired glucose tolerance (IGT) after a glucose tolerance test (GTT). It is estimated that as many 
as 1 in 3 adult Americans are prediabetic although, since it is asymptomatic, it largely goes 
unidentified (Bullard, Saydah et al. 2013). Study of prediabetic subjects, identified by IFG, showed 
an increased insulin secretion in response to an oGTT (Tripathy, Carlsson et al. 2000). Some studies 
have shown that subjects with IGT show enhanced insulin secretion (Reaven, Hollenbeck et al. 
1989; Tripathy, Carlsson et al. 2000). These data suggest that, in early disease, insulin secretion can 
increase to compensate for peripheral insulin resistance but it is not known whether this due to an 
up regulation of beta-cell secretion, or an increased number of beta-cells (Weir and Bonner-Weir 
2004).  
There is indirect evidence to show that compensatory increase in beta-cell number can 
occur, with two studies showing an increase in obese human subjects (Kloppel, Lohr et al. 1985; 
Butler, Janson et al. 2003). Further support for an increase in beta-cell number, comes from animal 
models where, increased beta-cell mass, or islet size, have been shown in pre-diabetic Zucker 
Diabetic Fatty rats (Pick, Clark et al. 1998), Tallyho diabetic mice (Mao, Dillon et al. 2014), ob/ob 
mice (Irles, Neco et al. 2015) and animals fed a high fat diet (Hull, Kodama et al. 2005; Terauchi, 
Takamoto et al. 2007; Gonzalez, Merino et al. 2013). 
There is no direct evidence to indicate that beta-cell function changes in prediabetes and 
early disease. However, we do know, in other contexts, that beta-cell function is remarkably plastic. 
Beta-cell secretory function is enhanced in pregnancy to cope with the increased demand from the 
developing foetus (Sorenson and Brelje 1997). Most recently, it has been shown in the ob/ob model 
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of obesity that, in addition to increased numbers of beta-cells, there is an increase in secretion per 
cell (Irles, Neco et al. 2015). 
Here, in this paper, I describe experiments using the Lepr
db
 mouse model of T2D (Berglund, 
Frankel et al. 1978) aimed at understanding beta-cell function during prediabetes and early disease. 
Prior to developing glucose intolerance, Lepr
db
 animals have increased blood insulin levels 
(Kaneko, Ueki et al. 2010) and therefore provide an ideal model for studying the basis of early 
increases in insulin secretion. To specifically study responses from single beta-cells within intact 
islets, a two-photon granule fusion assay was employed, which identifies each insulin granule as it 
fuses with the beta-cell membrane (Low, Mitchell et al. 2013; Do, Low et al. 2014).  
The results demonstrate that beta-cells do have functional changes during prediabetes by 
upregulating their exocytic capacity to enhance the secretory response to glucose. Moreover, upon 
progression to disease, exocytic capacity is still maintained, as judged by responses to high 
potassium, but glucose-induced responses are reduced due to a loss of glucose sensing. These data 
therefore suggest that pathological changes are already occurring in beta-cells in prediabetes and 
support the value of early intervention. 
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5.2 Methods 
Glucose tolerance test After an overnight fast (5pm- 9am), FBG were obtained by the Accu-check 
Active (Roche) glucometer with a small drop of blood (~5 μl) from the tail tip. Then glucose 25% 
was injected intra-peritoneally (1 g/kg) and glucose concentrations were measured at 30, 60, 90 and 
120 minutes. 
Cell preparation Mice were humanely killed according to local, University of Queensland, animal 
ethics procedures (approved by the University of Queensland, Anatomical Biosciences Ethics 
Committee). Isolated mouse pancreatic tissue was prepared by a liberase: collagenase mix (4:1) 
digestion method (collagenase type IV, Life Technologies, Victoria, Australia; Liberase Roche Life 
Sciences, NSW, Australia) in Hanks buffer (Sigma-Aldrich, NSW, Australia). Isolated islets were 
maintained (37°C, 95/5% air/CO2) in RPMI-1640 culture medium ( Gibco, Victoria, Australia) 
supplemented with 10% FBS (Gibco, Victoria, Australia), and 100 U/ml penicillin, 0.1mg/ml  
Streptomycin (Invitrogen, Victoria, Australia). 
Experimental solution Experiments were performed in sodium-rich extracellular solution (in mM: 
140NaCl, 5KCl, 1MgCl2, 2.5CaCl2, 5NaHCO3, 5HEPES, glucose) adjusted to pH 7.4 with NaOH. 
Two-photon imaging Two-day cultured islets were bathed in an ECB containing 3 mM glucose for 
30 minutes (37°C, 95/5% air/CO2). Islets were then transferred to an ECB containing glucose 15 
mM and 0.8 mM SRB. Two-photon imaging was performed at 34°C, with exocytic events recorded 
as the entry of extracellular dye SRB (excited at 950 nm, detected at 550-650 nm) into each fused 
granule.  
A custom-made, video-rate, two-photon microscope with a 60x oil immersion objective (NA 1.42, 
Olympus) was used, providing an axial resolution (full width, half maximum) of ~1 µm (Low, 
Zavortink et al. 2014). Microscope peripherals (shutter, scanners etc) were controlled and images 
acquired, using ScanImage software. Images (resolution 10 pixels/μm) were analysed with the 
Metamorph program (Molecular Devices Corporation, Sunnyvale, CA, USA). Exocytic event 
kinetics were measured from regions of interest (0.78 μm2, 78 pixels) centred over individual 
granules. 
Insulin assay To acquire insulin samples, single islets were transferred from culture to a petri dish 
containing a sodium-rich ECB (3 mM glucose) and incubated (37°C, 95/5% air/CO2) for 30 
minutes. Thereafter, groups of three islets were transferred to individual eppendorf tubes containing 
the sodium-rich ECB, 0.2% BSA and a stimulus such as glucose (3 mM/ 15 mM) or high potassium 
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(50 mM, isosmotic substitution with NaCl). Islets were then incubated (37°C, 95/5% air/CO2) for 
20 minutes. Supernatant from each tube was collected and used for HTRF as per Cisbio insulin kit 
instructions. Briefly, for each sample, 10 μl of islet supernatant, 5 μl of anti-insulin Europium 
cryptate and 5 μl of anti-insulin XL665 were sequentially added to a 384 well plate (Perkin Elmer 
Proxiplate 384-Plus, cat. no. 6008280). The plate was incubated on lab bench for 18 hours then read 
on a Tecan Infinite 200PRO (Tecan, Port Melbourne, Vic, Australia) machine. Insulin 
concentrations (ng/ml) for each well were determined from an insulin standard curve. 
Calcium measurement After 2 days in culture, islets were loaded with 4 μm Fura-2-AM (Invitrogen, 
Victoria, Australia), 0.02% pluronic acid (Sigma Aldrich) and incubated (37
0
C, 95/5% air/CO2) for 
30 minutes. Fura-2 loaded islet was washed and transferred to a small volume chamber mounted on 
the stage of an inverted fluorescence microscope with a 25x objective. The cells were alternatingly 
excited at 340 and 380 nm, and the ratio was collected at 490 nm. 
Immunofluorescence Freshly isolated islets were washed in warmed PBS, fixed in 4% 
paraformaldehyde for 15 minutes and blocked for 1 hour in 3% donkey serum, 3% BSA and 0.3% 
Triton X. Islets were then incubated in primary antibodies, rabbit anti-glucagon (Sigma Aldrich, 
1:200) and guinea pig anti-insulin (Abcam, 1:200) overnight at 4
0
C, washed 3 times and then 
incubated in secondary antibodies Alexa Fluor 546 donkey anti-rabbit and Alexa Fluor 633 goat 
anti-guinea pig (Invitrogen, 1:200) for 3 hours. DAPI (Sigma Aldrich, Australia, 100 ng/ml final 
concentration) was used. Images were obtained on an Olympus FV1000 confocal microscope with a 
60x oil, 1.4 NA objective. 
qPCR. Total RNA was isolated from islets using RNeasy plus Micro kit (Qiagen). cDNA was 
synthesized from 100 ng of total RNA using the SuperScript III reverse transcriptase (Invitrogen). 
Real-time PCR was carried by the Applied Biosystems, Quantstudio RT-PCR with samples holding 
at 50°C for 2 minutes, 95°C for 10 minutes, and 40 cycles at 95°C for 15 seconds and 60°C for 1 
minute. In a 20 μl reaction volume, 10 μl SYBR Green 2x master mix (Invitrogen) was applied with 
the cDNA and optimized primer condition (200 nM). Predesigned primers (Sigma Aldrich, 
Australia) were used as follows: 18S forward, TCGAGGCCCTGTAATTGGAA ; 18S reverse 
CCCTCCAATGGATCCTCGTT; SNAP25 forward, GGACTTTGGTTATGTTGGATG; SNAP25 
reverse, GGATTTAAGCTTGTTACAGGG; Syntaxin-1A forward, 
AGATGATTGACAGGATCGAG; Syntaxin-1A reverse, GTGGTTTCTATCCAAAGATGC; 
VAMP2 forward, ATCATCGTTTACTTCAGCAC; VAMP2 reverse, 
TGAAAGATATGGCTGAGAGG; SLC2A2 forward, 5’-TCAGAAGACAAGATCACCGGA-3’; 
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SLC2A2 reverse,5’-GCTGGTGTGACTGTAAGTGGG-3’. mRNA levels of genes of interest were 
presented as the fold difference between the db/db and WT islets.  
Serial Block-Face Scanning Electron Microscopy Two-day cultured islets were stimulated with 15 
mM glucose for 7 minutes before fixing with 2.5% glutaraldehyde. Fixed islets were double post-
fixed by using 2% OsO4 with 1.5% potassium ferricyanide followed by 1% thiocarbohydrazide and 
then another 2% OsO4. Samples were stained overnight with 1% uranyl acetate and then for 1 hour 
at 60
oC in Walton’s lead aspartate. They were then serially dehydrated with acetone and then 
embedded with Durcapan resin and polymerised. Individual islets were cut out of the resin, 
mounted and then imaged and sectioned using a Zeiss Sigma SEM fitted with a 3View (Gatan, CA, 
USA) at 2.25kv and 10Pa. The resultant images were analysed using the IMOD software (Kremer, 
Mastronarde et al. 1996) and 3D reconstructions were performed. 
Statistical Analyses All numerical data were presented as mean  SEM. Statistical analysis was 
performed using Microsoft Excel and GraphPad Prism. Data sets with just two groups were 
subjected to a two-tailed, un-paired Student’s t-test. Islets from at least 3 animals were used in each 
experiment. Significance is indicated in the figures as: * p<0.05, ** p<0.01, *** p<0.001.  
 
 
 
 
 
 
 
 
 
 
 
 
Page | 99  
 
5.3 Results 
Lepr
db
 is a long standing animal model for investigating T2D; which shares many 
pathophysiological sequences with human T2D (Hummel, Dickie et al. 1966; Berglund, Frankel et 
al. 1978; Yamazaki, Kato et al. 2009). The Lepr
db 
colony exhibited similar profiles of body weight 
(Figure 4.1) and average blood glucose (tracked by the mean GTT) as published work (Matsuda, 
Kido et al. 2008; Miyawaki, Inoue et al. 2008; Kaneko, Ueki et al. 2010). However, individual 
GTTs were varied between mice. In chapter 4, the morphological changes in pancreatic islets over 4 
stages of disease were characterised. This chapter focuses mainly on functional changes of the beta-
cells during the disease progression. 
Firstly, islet function was tested to determine whether insulin secretion changed over the 
stages of disease severity. Isolated islets were stimulated for 20 minutes with 15 mM glucose. 
Compared to WT, db/db islets showed a significant increase in insulin secretion at stage 1 (Figure 
5.1, n=24 WT, 25 db/db mice). At stage 2 insulin secretion was variable but the mean was not 
different from WT. Stage 3 showed a further decrease and secretion was significantly less than WT 
at stage 4.  
 
Figure 5.1: Glucose-induced islet insulin secretion at different stages of db/db disease. 
(A) Glucose-induced islet insulin secretion is increased at stage 1 and reduced for the later stages of disease  
(B) Glucose-induced islet insulin secretion is expressed as percentage of insulin content. 
(n=24 WT, 5db/db stage 1, 5 db/db stage 2, 5 db/db stage 3, 10 db/db stage 4). **,p<0.01; ***,p<0.001. 
 
The study then focused on the animals classified as stage 1, prediabetes and show that, as a 
group, they have significantly higher body weight than WT (Figure 5.2A, n=11 WT and HET, 19 
stage 1 db/db mice), no significant difference in the GTT (1g/kg, ip.) (Figure 5.2B) and a small, but 
significant increase in FBG (8.6 mM vs. 7.2 mM, p= 0.037) (Figure 5.2C). 
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Figure 5.2: Body weight and plasma glucose level of stage 1 db/db mice. 
(A) Body weight of db/db mice is significantly higher than the WT and HET. 
(B,C) Db/db mice have slightly higher FBG but no difference in the glucose response to the GTT compared 
with WT and HET; (n=11 WT and HET, 19 db/db stage 1). *,p<0.05; ***,p<0.001. 
Islet size and insulin content increase in prediabetes Islets isolated from WT and stage 1, 
prediabetic db/db animals showed changes in morphology; both the islet size (Figure 5.3 A,B,C, 
n=6 WT, 5 db/db mice) and insulin content increase (Figure 5.3D, n=23 WT, 7 db/db mice). The 
islet composition also changed, with an apparent selective up-regulation of beta-cell proliferation 
that leaded to a decrease in the relative percentage of alpha-cells (Figure 5.3E, n=16 WT, 7 db/db 
mice).  
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Figure 5.3: Islet morphology changes in stage 1 db/db mice. 
(A,B,C) Stage 1 db/db islets have larger size compared to WT (n=6 WT, 5 db/db stage 1). 
(D) Stage 1 db/db islets have higher islet insulin content compared to WT ( n=23 WT, 7 db/db mice). 
(E) Immunostaining shows a selective expansion in beta-cells compared to alpha-cells in stage 1 islets 
compared to WT ( n=16 WT, 7 db/db mice).  
Note: (C) and (D) are similar to Figure 4.3 C, D and reproduced here for emphasizing the changes in 
stage 1 db/db islets. **,p<0.01; ***,p<0.001. 
 Secretion from single beta-cells within an islet changes significantly across the stages of 
disease. The patterns of change in insulin secretion described in Figure 5.1 are consistent with 
current understanding of the progression of human T2D. What is unknown is the basis for the 
increased insulin secretion during the early, prediabetic phase and whether it is a reflection of an 
increase in islet size and beta-cell number or an increase in secretory output from individual beta-
cells? 
Insulin secretion during stage 1 shows an upregulation of exocytic fusion granules. To study 
secretory function of individual beta-cells within intact islets, a two-photon granule fusion assay 
that have been used in our previous work (Low, Mitchell et al. 2013) was employed to characterise 
individual fusion granules from beta-cells within stage1 db/db islets. I have previously shown that 
recording from the core of the islets, where almost all the cells are beta-cells (see Figure 5.3E), this 
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method detects granule fusion events that are the same size as insulin granules, that colocalise with 
insulin and in terms of fusion numbers, fully account for insulin secretion from the islets.  
Islets were stimulated with 15 mM glucose for 20 minutes and, as each granule fuses with 
the cell membrane, extracellular dye enters the granule and enables precise location of the fusion 
event in space and time (Figure 5.4A). The results showed that compared to WT there is an increase 
in granule fusion numbers during stage 1, prediabetes, directly demonstrating that functional 
changes are occurring in the beta-cells. Interestingly, recording under identical conditions from the 
islets of animals at stage 2 of the disease showed a drop in the numbers of insulin granule fusion 
events. These animals had overt diabetes, as measured with a GTT, and so a reduction in granule 
fusion was expected, as reported in my previous paper (Do, Low et al. 2014). However, the 
dramatic drop indicates that important changes to beta-cell function are occurring at the stage 1, 
stage 2 interface.  
 Further characterisation showed the increase in the numbers of fusing granules in 
prediabetes, stage 1, reflecting both an increase in the numbers of cells that respond to glucose and 
an increase in the numbers of fusing granules per cell (Figure 5.4 C and D, n = 9 WT, 3 stage 1 
db/db and 10 stage 2 db/db mice). Both of these parameters indicate that individual beta-cells have 
become more responsive to a glucose stimulus. In contrast, islets from stage 2 showed a reduction 
in both parameters. 
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Figure 5.4: Glucose induced insulin granule fusion is substantially altered in db/db islets. 
  (A,B) A two-photon granule-fusion assay identifies the sites of granule-fusion events (yellow circles) over a 
20 minute time period in response to 15 mM glucose. Compared to WT many more fusion events are seen in 
stage1 db/db islets, with greater spatial clustering of fusion. In contrast, stage 2 islets show a dramatic 
decrease in fusion event (n = 9 WT, 3 stage 1 db/db, 10 stage 2 db/db). 
 (C,D) Changes in granule exocytosis in terms of the numbers of responding cells and the responses per cell 
within the two-photon volume (n = 9 WT, 3 stage 1 db/db, 10 stage 2 db/db). *,p<0.05; **,p<0.01; 
***,p<0.001. 
The above data demonstrate that insulin granule fusion, the last step in the stimulus-
secretion cascade, does change in early disease. This could be due to selective changes in the 
exocytic machinery or it could be due to upstream changes, which might lead to alterations in the 
cytosolic calcium response which is triggered by glucose. To test this, I compared the glucose-
induced calcium responses between WT and db/db islets. The results show that stage 1 db/db islets 
have higher resting calcium than WT but no significant change in the peak calcium response 
(Figure 5.5A, n=12 WT, 9 db/db mice). This indicates that the increase in granule fusion, at stage 1 
disease, is less likely to be the result of any change upstream of the calcium signal and points to a 
specific up-regulation of the granule fusion process. Further evidence for changes in the processes 
of granule fusion comes from experiments where high potassium was used as a stimulus to directly 
depolarize the cells and therefore bypass any effects of glucose metabolism.  In this case, the high 
potassium induced insulin secretion is much larger from stage 1 islets compared to control (Figure 
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5.5B, n=16 WT, 10 db/db mice). This functional evidence is supported by quantitative polymerase 
chain reaction (qPCR) data that show up-regulation of mRNA for the SNAREs, SNAP25 and 
VAMP2, although syntaxin-1A does not change significantly (Figure 5.5C, n=3 WT, 5 db/db mice). 
 The next issue would be to explore the basis for the dramatic drop in glucose induced 
insulin granule fusion seen in stage 2 db/db islets (Figure 5.4). Using a high potassium stimulus I 
observed that insulin secretion was still greater than in control islets (Figure 5.5B) suggesting that 
the exocytic machinery of stage 2 db/db islets was functional, an observation supported by the 
continued up-regulation of the mRNA for the SNAREs as measured with qPCR (Figure 5.5C). The 
possibility of an upstream defect of stage 2 db/db islets is supported by a lower glucose-induced 
calcium response (Figure 5.5A) and a decreased mRNA expression of GLUT2 (SLC2A2, Figure 
5.5C). Collectively, these data indicate that the beta-cells at stage 2 are still secretory competent but 
now are defective in glucose sensing. 
 
 
 
 
Page | 105  
 
 
Figure 5.5: Characterisation of beta-cell changes in stage 1 and 2 db/db 
(A) Glucose-induced islet calcium responses are comparable between WT and db/db stage 1 islets but 
significantly drop in stage 2 db/db islets.(n=12 WT; 3 stage 1 db/db; 6 stage 2 db/db) 
(B)  Islet insulin secretion shows elevated basal responses (3 mM glucose) at stage 1 and 2. The 15 mM 
glucose responses are the same as in Figure 5.1 and reproduced here for comparison. Responses to 50 
mM KCl shows enhanced insulin secretion at stage 1 and 2 compared with WT. (n=16 WT;5 stage 1 
db/db; 5 stage 2 db/db) 
(C) qPCR shows elevations in SNARE mRNA expression at stage 1 and 2 but a reduction in GLUT2 
(SLC2A2) at stage 2. (n=3 WT; 3 stage 1 db/db; 2 stage 2 db/db) 
Granule fusion behaviour in stage 1 prediabetic islets The findings from stage 1, prediabetic 
islets show that there is a specific upregulation of beta-cell function but, as could be noticed, the 
pattern of granule fusion showed evidence for spatial clustering that was not seen in control animals 
(Figure 5.4A). To quantify this, the spatial coordinates of all fusion events were measured. Then, 
for each individual granule fusion event, I looked in a 4 µm
2
 area around that event and determined 
the frequency that 1 or more other fusion events occurred. In WT (and stage 2) I observed a steadily 
decreasing frequency that more and more fusion events would occur around each event (Figure 
5.6A, n=27 WT, 33 db/db islets; n=845 WT, 1409 db/db fusion granules). This suggested that, on 
this small scale, there was little evidence for clustering of insulin granule fusion. In contrast, at 
stage 1, the frequency to observe multiple events, even up to 10 events, remained high (Figure 
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5.6A, for comparison 4.62% of events had 7 or more fusion events within 4 µm
2
 in WT compared 
to 22.71% at stage 1). A closer study showed that repeated fusion occurred, (limited by our optical 
spatial resolution) within the same region of interest (Figure 5.6B). In many cases this led to a 
build-up of fused granules that is suggestive of compound exocytosis where granules fuse with each 
other (Figure 5.6C). To quantify this behaviour, I chose an arbitrary threshold of ≥7 granules, 
within a 4 μm2 area, as suggestive of compound exocytosis and <7 as suggestive of primary 
exocytosis. Both the total number of primary exocytic events and the proportion of compound 
exocytic events increased significantly at stage 1, prediabetic islets, and decreased to below the 
control in the islets from stage 2 animals (Figure 5.6D,E). 
  To prove that the db/db responses do include compound exocytosis a serial block-face 
electron microscopy was applied to islets that have been fixed after 15 mM glucose stimulation for 
7 minutes (Figure 5.6F). In these experiments I were readily able to identify chains of fused insulin 
granules that made one exit point at the cell membrane which, in the reconstructions, provide good 
evidence for granule-to-granule fusion. These live-cell imaging and electron microscopy results 
indicate that stage 1, prediabetic phenotype shows a general upregulation of insulin granule fusion 
that includes an increased prevalence of compound exocytosis. 
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Figure 5.6: Increase in compound exocytosis of stage 1 db/db beta-cells 
(A) Analysis of a 4 µm
2
 region around each exocytic event shows that the frequency of observing more 
events (≥7) becomes much rarer in WT and stage 2 but not stage 1 db/db islets.( n=27 WT, 9 stage 1 db/db 
and 24 stage 2 db/db islets).**,p<0.01 
(B) Evidence for multiple granule fusion events occurring within the same region of interest. 
(C) This is shown as an image series with the numbers (i, ii, iii) indicating the peaks of fluorescence as 
each granule fuses and the extracellular dye enters into the fused granule. 
(D,E) Histograms of primary exocytosis (<7 events within a 4 µm
2 
region) and compound exocytosis (≥7 
events within a 4 µm
2 
region) show increases at stage 1 and decreases at stage 2..( n=27 WT, 9 stage 1 
db/db and 24 stage 2 db/db islets).***,p<0.001 
(F) Serial block face electron micrographs through a typical example of multigranular compound 
exocytosis in a db/db islet stimulated with 15 mM glucose. 
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To test whether the increased response of individual beta-cells observed at 13-18 week-old 
stage 1 db/db is an intrinsic or acquired characteristic, cellular insulin secretion of younger age 
animals was examined. Using 5-6 week-old WT and db/db mice with comparable GTTs (AUC of 
the GTT= 916 ± 43 in WT and 1076 ± 108 mM.minutes in db/db, p=0.24), the data reveal that there 
was no significant change in islet size (Figure 5.7A,B, n=3 WT, 3 db/db mice) and islet insulin 
content (Figure 5.7E; n=4 WT, 4 db/db mice). For the islet cell composition, there is a slight but not 
yet significant decrease in proportion of alpha cells in db/db compared to WT (Figure 5.7C,D; n=3 
WT, 3 db/db mice). More importantly, the islet insulin secretion in response to glucose is similar 
between WT and db/db animals (Figure 5.7H, n=4 WT, 4 db/db mice) which is a reflection of 
comparable secretion of individual beta-cells assessed by the two-photon assay (Figure 5.7F,G; n=3 
WT, 3 db/db mice). These data, in general, indicate that structural and functional changes observed 
in db/db islets evolve during the course of disease rather than innate features of the mice. 
 
Figure 5.7: Islet structure and function are unchanged in 5-6 week-old db/db mice with normal 
GTTs. 
(A,B) 5-6 weeks old db/db islets have similar size compared with WT. (n=3 WT, 3 db/db mice) 
(C,D) Immunostaining shows slightly but not significantly higher proportion of alpha cells in db/db islets 
compared with WT (DAPI in blue, insulin in green, glucagon in red). (n=3 WT, 3 db/db mice) 
(E) Islet insulin content is comparable between WT and db/db animals. (n=3 WT, 3 db/db mice) 
(F,G) Glucose induced insulin granule fusion is unchanged in db/db beta-cells. (n=3 WT, 3 db/db mice) 
(H) Glucose stimulated insulin secretion is unaltered in db/db islets. (n=4 WT, 4 db/db mice) 
Page | 109  
 
 Lastly, given the switching in beta-cell behaviour between stage 1 and 2 db/db is mainly due 
to the loss of glucose sensing, I wonder whether this upstream defect plays a dominant role at more 
advanced stages of disease. Therefore, the secretory response was investigated in stage 4 db/db. 
Similarly, an even more extreme defect in glucose sensing was detected, evident by a severely 
impaired glucose but not potassium-induced intracellular calcium signal and insulin secretion 
(Figure 5.8A,B,C; n=17 WT, 7 stage 4 db/db) as well as a marked drop in GLUT2 mRNA 
expression (reduced by 94% compared with WT) (Figure 5.8D; n=3 WT, 3 db/db mice). 
 
Figure 5.8: The predominant defect of glucose sensing in stage 4 db/db islets 
(A,B) Fura-2 loaded islets show that while the calcium response in stage 4 islets is markedly reduced in 
response to 15 mM glucose, it maintains high in response to high potassium stimulation.( n=17 WT, 7 
stage 4 db/db) 
(C ) Stage 4 db/db islets show enhanced basal insulin secretion (measured at 3 mM glucose), a decrease 
response to 15 mM glucose but similar levels of insulin secretion in response to high potassium. ( n=17 
WT, 7 stage 4 db/db) 
(D) shows a significant reduction in mRNA expression of GLUT2 in stage 4 db/db islets compared to WT.  
(n=3 WT, 3 stage 4 db/db) 
 
 
Page | 110  
 
5.4 Discussion 
The major outcome from this work is the insight that changes in beta-cell function do occur 
in prediabetes, prior to the earliest stages of overt diabetes. At stage 1, prediabetes, the GTT is no 
different from WT but insulin secretion from isolated islets increases ~2 fold. Both islet size and 
insulin content are increased at stage 1 db/db but I show that insulin granule fusion also 
significantly increases which includes an exaggerated prevalence of compound exocytosis.  
My data clearly demonstrates that beta-cell function is affected in prediabetes. Furthermore, 
at stage 2 of the disease, a dramatic drop in glucose-induced granule exocytosis was noticed. Since 
the high potassium responses are still retained, the results indicate that this decline in function, just 
at the point of overt diabetes, is predominantly due to a reduction in glucose sensing.  
My results support a model where functional compensation of the beta-cell exocytic 
capacity is initiated during prediabetes and is maintained as the disease progresses. This 
compensation leads to enhanced glucose induced secretion in prediabetes but, at the point of overt 
disease, reduced glucose sensing leads to a collapse of the beta-cell’s ability to respond to glucose. 
This work lends support to therapies targeted towards re-establishing homeostatic glucose control 
during prediabetes and preventing the deleterious drop in glucose sensing that occurs at, and is 
likely the cause of, disease.   
Comparison of phenotypic characterisation of disease progression with humans These data 
from db/db mice are consistent with the mapping of progression of T2D in humans (Weir and 
Bonner-Weir 2004). In humans, compensatory increases in the insulin response occur in early 
disease (Gastaldelli, Ferrannini et al. 2004; Festa, Williams et al. 2006) and are associated with 
increased islet size and insulin content (Kloppel, Lohr et al. 1985; Butler, Janson et al. 2003), 
although it is unknown if beta-cell function is affected. Moving through disease progression a 
progressive loss of insulin content is seen in human disease (Ward, Bolgiano et al. 1984) and, as 
observed in the mouse, glucose induced insulin secretion was reduced (Deng, Vatamaniuk et al. 
2004; Del Guerra, Lupi et al. 2005). 
There is a variation in the factors that determine glucose homeostasis in normal human 
subjects. This means that to maintain glucose homeostasis, subjects with relatively poorer insulin 
sensitivity have a larger insulin secretory response (Bergman, Phillips et al. 1981). The product of 
insulin sensitivity and pancreatic responsivity is a constant, called the disposition index, with a 
hyperbolic relationship (Bergman, Phillips et al. 1981). In normal subjects the factors underlying 
this relationship are not likely to change. But there is evidence, from obese subjects with insulin 
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resistance, that insulin secretion can change dynamically, according to demand and responses to 
hyperglycemic clamp showed a significant increase in insulin secretion compared to controls 
(Polonsky, Given et al. 1988). In another study, a detailed plot of fasting glucose against oGTT-
induced insulin secretion, shows increasing insulin secretion up to a maximum at a blood glucose of 
5.6 mM, followed by a decline (Gastaldelli, Ferrannini et al. 2004). Together these data suggest 
insulin secretion increases in an attempt to overcome peripheral insulin resistance and that failure to 
do so might lead to disease. In support of this, longitudinal studies show that subjects who 
progressed to diabetes did not have compensatory increases in insulin secretion, in contrast those 
with increased secretion did not progress (Weyer, Bogardus et al. 1999; Festa, Williams et al. 
2006). Consistent with this human data, animal models of diabetes also show increased insulin 
secretion in early disease (Kaneko, Ueki et al. 2010; Mao, Dillon et al. 2014).  
Where my work is new is that it clearly demonstrates that during prediabetes, changes in 
insulin secretion arise due to direct modulation of beta-cell function. 
Beta-cell function in prediabetes and the early stages of disease The data reveal that in 
prediabetes both the glucose induced and high potassium induced insulin secretion are increased 
and demonstrate an increased number of granule fusion events in response to stimulation compared 
to WT, with no increase in the calcium response to glucose. These findings are consistent with a 
selective up regulation of the terminal stages of the stimulus-secretion pathway, downstream of 
calcium entry; a conclusion supported by the increase in mRNA for some of the SNARE proteins. 
An interesting observation is the increased prevalence of compound exocytosis, a process that is 
rarely observed in WT beta-cells stimulated with glucose. In WT, compound exocytosis is 
specifically upregulated under certain conditions, such as in response to GLP-1 stimulation (Kwan 
and Gaisano 2005). While it is possible that beta-cells in stage 1 disease have selective changes 
enhancing the pathways that normally regulate compound exocytosis, the results suggest that it is 
due to non-specific up regulation of the exocytic machinery. Given the critical importance of 
balanced expression of SNAREs in regulating granule fusion (Hugo, Dembla et al. 2013) it is 
possible that a slight imbalance might lead to compound exocytosis taking precedent over normal 
exocytosis.  
Moving on to considering stage 2 animals, a dramatic drop in number of granule fusion 
events was observed (Figure 5.4). This drop is coincident with the increase in AUC of the GTT 
(Figure 4.1D) and demonstrates very clearly that altered beta-cell function is strongly associated 
with loss of glucose homeostasis. The new findings are consistent with my previous chapter 
(chapter 3), where animals with overt disease and compromised GTTs were studied  (Do, Low et al. 
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2014). The results now show that at stage 2 the beta-cells are still competent to secrete and that a 
high potassium stimulus can elicit insulin secretion. The implication of an upstream defect is 
supported by the drop in GLUT2 mRNA levels, something that has, for a long time, been 
implicated in disease (Thorens, Wu et al. 1992; Chan, Luzuriaga et al. 2013). What is new in this 
study is that I specifically show that it is the appearance of the upstream glucose sensing defect that 
distinguishes prediabetes from overt disease. Similarly, the loss of GLUT2 is also the key 
contributor to the secretory dysfunction in severe diabetic islets (stage 4 db/db). However, it should 
be noted that there is evidence for high potassium to act on different granule pools (Yasuda, 
Shibasaki et al. 2010; Zhu, Xie et al. 2015) and therefore without further work I cannot conclude 
that exocytosis is normal in stage 2 beta-cells. 
The finding that the major beta-cell defect in early disease is glucose sensing is supported by 
work on isolated human islets from T2D subjects which shows a dramatic loss of glucose induced 
secretion but no appreciable change in arginine induced insulin secretion (Del Guerra, Lupi et al. 
2005). Furthermore, these data showing the effectiveness of high potassium as a stimulus for insulin 
secretion, at stage 2 and 4, is consistent with effectiveness of sulphonylureas, which target the 
potassium channel, in treating diabetes (UKPDS group 1998). 
Additionally, the 5-6 week-old animal data suggest that morphological and functional 
changes of the pancreatic beta-cells especially the hypersecretion in prediabetes develop over the 
course of disease presumably due to increased insulin resistance rather than inherited defect of the 
db/db animals. 
5.5 Conclusion  
My results demonstrate that beta-cell function is intimately associated with prediabetes and 
progression to diabetes and adds weight to clinical strategies for therapeutic intervention as early as 
possible. 
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CHAPTER 6: 
 
GENERAL DISCUSSION AND FUTURE DIRECTIONS 
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Although more and more studies are contributing towards the puzzle of beta-cell 
dysfunction in T2D, the full picture is far from complete. One of the missing pieces is whether there 
is any role for fusion pore dynamics of insulin-containing granules in the disease development. This 
idea was adapted from studies in other neuroendocrine cells and pushed forward by some 
researchers in the beta-cell field (Takahashi, Kishimoto et al. 2002; Tsuboi and Rutter 2003; Ma, 
Bindokas et al. 2004; MacDonald, Braun et al. 2006). However, the pathological relevance of 
fusion granule behaviour in diabetes remains controversial and most studies are limited to cell lines 
or single-cell experiments (Tsuboi and Rutter 2003; MacDonald and Rorsman 2007; Hanna, Pigeau 
et al. 2009). Using the db/db as a model of T2D, chapter 3 confirms the existence of different forms 
of fusion-granule behaviour, from complete fusion to “kiss-and-run” exocytosis in intact pancreatic 
islets of both diabetes and WT animals. However, my data indicate that the main contributor to the 
overt diabetic phenotype is the loss of granule fusion and the loss of responding beta-cells rather 
than differences in fusion granule behaviour (Do, Low et al. 2014).  
In the second part of the thesis I studied the progressive nature of T2D (Prentki and Nolan 
2006; Fonseca 2009). Using the AUC of the GTTs, each db/db mice was classified into stages of 
disease progression somewhat similar to what has been proposed in humans (Weir, Laybutt et al. 
2001; Weir and Bonner-Weir 2004; Prentki and Nolan 2006). Despite evidence for a compensating 
increase in beta-cell mass in young db/db mice (Dalbøge, Almholt et al. 2013), it remains obscure 
whether it is due to increase in beta-cell number, beta-cell size or cellular insulin content and to 
what extent that these factors contribute to the disease progression (Weir, Laybutt et al. 2001). The 
results indicate that islet size increases across all stages of db/db mice without an increase in a beta-
cell replication marker (Figure 4.4A,B). This is perhaps understandable in that I used relatively 
older animals, 13-18 week-old, and beta-cell replication in db/db islets has been reported to reduce 
significantly after 4 weeks of age (Guo, Dai et al. 2013).  
Moreover, it is noteworthy that, larger islet size in stage 1 db/db is mainly due to increased 
beta-cell number while the expansion in the islet size of later hyperglycemic stages db/db (stage 2-
4) is a function of both the beta-cell number and beta-cell size (Figure 4.3D). This result is in line 
with a study in pancreatectomised rats where chronic hyperglycemia leads to beta-cell hypertrophy 
(Jonas, Sharma et al. 1999). In addition, using immunofluorescent staining for insulin, I further 
showed that despite larger beta-cell size, cellular insulin stores progressively decrease in subsequent 
stages of disease (Figure 4.4C). 
In addition, recent studies suggested that during diabetes the beta-cells loss their mature 
identity and regress to an endocrine progenitor-like stage (Talchai, Xuan et al. 2012; Wang, York et 
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al. 2014). However, surprisingly, I observed only a moderate increase in the proportion of 
dedifferentiated beta-cells in all stages of db/db including pre-diabetes. For future experiments, I 
would like to develop a selective probe for live-cell imaging of dedifferentiation which would 
enable me to examine the secretory capacity of these islet progenitor-like cells. 
Given that there are morphological changes, at both the islet and beta-cell levels in all stages 
of disease, I next characterised the functional changes of pancreatic beta-cells over the disease time-
course; experiments that are not possible in humans. The results demonstrated that changes in the 
numbers of fusing granules, at each disease stage, mirrored that of islet secretion (Figure 6.1). 
Notably, it is not the case that progression to disease is tracked by a steady decline in insulin 
secretion. Instead, prior to, and including the first clinical manifestations of disease, there is 
evidence for increased insulin secretion. Specifically, stage 1 db/db mice showed a distinct 
upregulation in the number of fusion granules as well as the prevalence of compound exocytosis 
compared to WT and later stages. Thereafter, the glucose induced insulin granule fusion and islet 
insulin secretion decrease progressively across the disease course (stage 2-4). It is also worth noting 
that despite a drop in cellular insulin secretion at stage 2, islet insulin secretion remains comparable 
to WT, probably due to larger islet sizes (Figure 6.1). 
Importantly, the islet hypersecretion was not observed at 5-6 week-old db/db mice with 
similar GTTs, indicating that secretion from db/db is initially normal but then changes as the 
animals progress to stage 1 disease (Figure 6.1). The results highlight the plasticity of the secretory 
capacity of individual pancreatic beta-cells in response to increased insulin demand. These data are 
also consistent with evidence from obesity and pregnancy models (Sorenson and Brelje 1997; Irles, 
Neco et al. 2015). However, the mechanism of beta-cell hyperfunction in the context of normal 
glycemia of stage 1 db/db is not yet clear. It may include, but is not limited to, the upregulation of 
the exocytic SNARE proteins in the context of an undamaged upstream signaling. 
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Figure 6.1: Changes in islet and beta-cell secretion during the disease time-course of db/db 
mice 
(A) In response to 15mM glucose, there is no difference in the number of fusion events between 5-6 week-
old WT and db/db. Whereas, at 13-18 week, compared to WT, there is an upregulation in the number of 
fusion events in stage 1 db/db islets and a progressive loss across stage 2-4. 
(B) Similar pattern of changes was observed in the islet insulin secretion levels.  
Note: this figure is reproduced from figure 5.1, 5.4A and 5.7F for comparison. 
 
In addition, these data indicate that the secretory deficit in later stages of disease is mainly 
due to upstream defect centered on the glucose transporter 2 (GLUT2), which is consistent with 
previous reports (Thorens, Wu et al. 1992; Chan, Luzuriaga et al. 2013). The findings give an 
explanation for the effectiveness of sulfonylurea as a therapy for T2D by bypassing the glucose 
uptake and metabolism steps (Proks, Reimann et al. 2002; Del Guerra, Lupi et al. 2005). The fact 
that the loss of GLUT2 was identified as a major defect in frank diabetes, by no means, excludes 
other deficits of the beta-cells such as mitochondrial dysfunction, endoplasmic reticulum stress, 
oxidative stress or islet inflammation which undeniably act as aggravated factors of the vicious 
circle (Del Guerra, Lupi et al. 2005; Prentki and Nolan 2006; Chan, Luzuriaga et al. 2013). But my 
data do highlight that one of the major, and early defects that occurs concurrently with detected 
hyperglycemia is the loss of beta-cell sensing for glucose. 
  The main drawback of this thesis is the use of a single-gene mouse-model to investigate a 
polygenic disease of human. Therefore, future experiments are required to verify these findings in 
human T2D. Moreover, despite the substantial reduction of GLUT2 in overt diabetic db/db islets, it 
would be inadequate to mention upstream defect without assessing the possibly involved role of the 
glucose metabolism step which will be examined in the future. 
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  Finally, putting all of the observations together in the form of a spider plot, it is apparent 
that stage 1, prediabetes, is associated with beta-cell expansion leading to increased islet size and 
insulin content, alongside increased beta-cell function (Figure 6.2). Adding stage 2 data to the 
spider graph shows that although beta-cell expansion is still present the phenotype arises largely as 
a result of the large drop in cellular secretion which, in turn, is predominantly due to loss of glucose 
sensing. It is not surprising that all factors including insulin content as well as glucose induced 
intracellular calcium signal and granule fusion are severely compromised in the last stage of disease 
(stage 4) (Figure 6.2). 
 
Figure 6.2: Spider graph represents changes in the insulin content, islet and cellular insulin 
secretion across all stages of the disease. 
The width of the lines reflects the standard error of the mean and each line is centred around the mean for 
each of the parameters. Note, for clarity of representation, the AUC is inverted and shown as a fraction of 
5000 mM.minutes. 
Overall my data demonstrate the decisive role played by a decrease in the number of insulin-
granule fusion events rather than the post-fusion granule-behaviour in the disease development. I 
show that single beta-cells do change their behaviour in prediabetes and over all the stages of T2D. 
Future experiments on islets from prediabetic humans would provide invaluable insights into 
disease pathogenesis and provide further evidence to support earlier intervention. 
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